



(12) **DEMANDE DE BREVET CANADIEN**
CANADIAN PATENT APPLICATION

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2019/04/30
(87) Date publication PCT/PCT Publication Date: 2019/11/07
(85) Entrée phase nationale/National Entry: 2020/10/26
(86) N° demande PCT/PCT Application No.: US 2019/030068
(87) N° publication PCT/PCT Publication No.: 2019/213174
(30) Priorités/Priorities: 2018/04/30 (US62/664,841);
2018/09/27 (US62/737,647); 2018/11/08 (US62/757,714);
2018/12/10 (US62/777,697); 2019/02/26 (US62/810,790)

(51) Cl.Int./Int.Cl. *A61K 31/662* (2006.01),
A61K 31/7064 (2006.01), *A61P 35/00* (2006.01)

(71) Demandeur/Applicant:
ORIC PHARMACEUTICALS, INC., US

(72) Inventeurs/Inventors:
DU, XIAOHUI, US;
EKSTEROWICZ, JOHN, US;
FANTIN, VALERIA R., US;
SUN, DAQING, US;
YE, QIUPING, US;
MOORE, JARED, US;
...

(74) Agent: GOWLING WLG (CANADA) LLP

(54) Titre : INHIBITEURS DE CD73

(54) Title: CD73 INHIBITORS

(57) **Abrégé/Abstract:**

Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

(72) **Inventeurs(suite)/Inventors(continued)**: ZAVOROTINSKAYA, TATIANA, US; BLANK, BRIAN R., US; REW, YOSUP, US; WU, KEJIA, US; ZHU, LIUSHENG, US; PHAM, JOHNNY, US; KAWAI, HIROYUKI, US

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

07 November 2019 (07.11.2019)



(10) International Publication Number

WO 2019/213174 A1

(51) International Patent Classification:

A61K 31/662 (2006.01) *A61K 31/12* (2006.01)*C07F 9/6561* (2006.01) *A61K 31/10* (2006.01)*A61K 45/06* (2006.01) *A61P 25/28* (2006.01)

KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2019/030068

(22) International Filing Date:

30 April 2019 (30.04.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/664,841 30 April 2018 (30.04.2018) US

62/737,647 27 September 2018 (27.09.2018) US

62/757,714 08 November 2018 (08.11.2018) US

62/777,697 10 December 2018 (10.12.2018) US

62/810,790 26 February 2019 (26.02.2019) US

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))

(71) Applicant: **ORIC PHARMACEUTICALS, INC.**
[US/US]; 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US).

(72) Inventors: **DU, Xiaohui**; 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US). **EKSTEROWICZ, John**; 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US). **FANTIN, Valeria, R.**; 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US). **SUN, Daqing**; 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US). **YE, Qiuping**; 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US). **MOORE, Jared**; 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US). **ZAVOROTINSKAYA, Tatiana**; 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US). **BLANK, Brian, R.**; 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US). **REW, Yosup**; 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US). **WU, Kejia**; 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US). **ZHU, Liusheng**; 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US). **PHAM, Johnny**; 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US). **KAWAI, Hiroyuki**; 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US).

(74) Agent: **SMITH, Deborah, M.**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,

(54) Title: CD73 INHIBITORS

(57) Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

**WO 2019/213174 A1**

CD73 INHIBITORS

CROSS REFERENCE

[0001] This application claims the benefit of U.S. Application Ser. No. 62/664,841 filed April 30, 2018, U.S. Application Ser. No. 62/737,647 filed September 27, 2018, U.S. Application Ser. No. 62/757,714 filed November 8, 2018, U.S. Application Ser. No. 62/777,697 filed December 10, 2018, and U.S. Application Ser. No. 62/810,790 filed February 26, 2019, which are hereby incorporated by reference in their entirety.


BACKGROUND

[0002] A need exists in the art for an effective treatment of cancer, infections, and neurodegenerative diseases.

BRIEF SUMMARY OF THE INVENTION


[0003] Provided herein are compounds of Formulas (II) and (IV) or pharmaceutically acceptable salts, solvates, stereoisomers, or isotopic variants thereof, and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as CD73 inhibitors. Furthermore, the subject compounds and compositions are useful for the treatment of cancers, infections, and neurodegenerative diseases.

[0004] Provided herein are compounds having the structure of Formula (II), or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof:



Formula (II);

wherein:



Ring A is

Q^1 is N and Q^2 is CW or Q^1 is N and Q^2 is N;

Q^3 and Q^4 are independently N or CW; provided that at least one of Q^3 or Q^4 is N;

each W is independently hydrogen, halogen, -CN, -OR^b, NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

A is -O-;

X is -S- or -O-;

R¹ and R² are independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆

alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a}, or R¹ and R² are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{1b};

each R^{1a} and R^{1b} is independently oxo (when feasible) halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

R³ is hydrogen, halogen, -CN, -OR^b, -SR^b, -NR^cR^d, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{3a};

each R^{3a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁴ and R⁷ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁵ and R⁶ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁸ is hydrogen, halogen, -OR^b, -NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

R⁹ and R¹⁰ are independently hydrogen, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

R¹¹ is halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -OC(=O)NR¹⁵R¹⁶, -NR¹³C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, -NR¹³C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a};

R¹² is hydrogen, halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -OC(=O)NR¹⁵R¹⁶, -NR¹³C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, -NR¹³C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{12a};

or R¹¹ and R¹² are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b};

each R^{11a} , R^{11b} , and R^{12a} is independently oxo (when feasible), halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} ;

each R^{11c} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

each R^{13} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a} ;

each R^{14} is independently C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{14a} ;

each R^{15} and R^{16} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{15a} ;

or R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b} ;

each R^{13a} , R^{14a} , R^{15a} , and R^{15b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-CN$, $-OR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, or C_2 - C_6 alkynyl;

R^{21} and R^{22} are independently hydrogen, C_1 - C_{20} alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), C_1 - C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a} ;

or R^{21} and R^{22} are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b} ;

each R^{21a} and R^{21b} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);


each R^a is independently C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

each R^b is independently hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; and

each R^c and R^d is independently hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;


or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.

[0005] Also provided herein are compounds having the structure of Formula (IV), or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof:



Formula (IV);

wherein:



Ring A is

Q^2 is N or CW;

Q^3 is N and Q^4 is CW;

or Q^3 is CW and Q^4 is N;

each W is independently hydrogen, halogen, -CN, -OR^b, NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

A is -O- or -CH₂-;

X is -O-, -S-, -S(=O)₂-, -NR¹⁷-, or -C(R¹⁸)₂-;

R¹ and R² are independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,

cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆

alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl,

heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a};

or R¹ and R² are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{1b};

each R^{1a} and R^{1b} is independently oxo (when feasible) halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -

S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -

C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆

fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆

alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

R³ is hydrogen, halogen, -CN, -OR^b, -SR^b, -NR^cR^d, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆

haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆

alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein

each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently

optionally substituted with one, two, or three R^{3a};

each R^{3a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -

C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl,

aryl, or heteroaryl;

R⁴ and R⁷ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆

alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁵ and R⁶ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆

alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁸ is hydrogen, halogen, -OR^b, -NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

R⁹ and R¹⁰ are independently hydrogen, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

R¹¹ is hydrogen, halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -

S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -

OC(=O)NR¹⁵R¹⁶, -NR¹³C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, -NR¹³C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl,

C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a};

R¹² is hydrogen, halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -OC(=O)NR¹⁵R¹⁶, -NR¹³C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, -NR¹³C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{12a};

or R¹¹ and R¹² are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b};

each R^{11a}, R^{11b}, and R^{12a} is independently oxo (when feasible), halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -OC(=O)NR¹⁵R¹⁶, -NR¹³C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, -NR¹³C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c};

each R^{11c} is independently oxo (when feasible), halogen, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

each R¹³ is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a};

each R¹⁴ is independently C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{14a};

each R¹⁵ and R¹⁶ is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{15a};

or R¹⁵ and R¹⁶ are taken together with the nitrogen atom to which they are attached to form a

heterocycloalkyl optionally substituted with one, two, or three R^{15b};

each R^{13a}, R^{14a}, R^{15a}, and R^{15b} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NHS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -CN, -OR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl;

R¹⁷ is hydrogen, -CN, -OR^b, -S(=O)₂R^a, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

each R¹⁸ is independently hydrogen, halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NHS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

R²¹ and R²² are independently hydrogen, C₁-C₂₀ alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a};

or R²¹ and R²² are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b};

each R^{21a} and R^{21b} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NHS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

each R^a is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

each R^b is independently hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl,

heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl; and each R^c and R^d is independently hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl; or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.

[0006] Also disclosed herein are pharmaceutical compositions comprising a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, and a pharmaceutically acceptable excipient.

[0007] Also disclosed herein are methods of inhibiting CD73 comprising contacting CD73 with a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof.

[0008] Also disclosed herein are methods of treating cancer in a subject, comprising administering to the subject a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof or administering to the subject a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, and a pharmaceutically acceptable excipient.

[0009] Also disclosed herein are methods of treating an infection in a subject, comprising administering to the subject a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof or administering to the subject a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, and a pharmaceutically acceptable excipient.

[0010] Also disclosed herein are methods of treating a neurodegenerative disease in a subject, comprising administering to the subject a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof or administering to the subject a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, and a pharmaceutically acceptable excipient.

INCORPORATION BY REFERENCE

[0011] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference for the specific purposes identified herein.

DETAILED DESCRIPTION OF THE INVENTION

[0012] CD73 is a glycosylphosphatidylinositol (GPI) anchored cell surface protein that catalyzes the hydrolysis of AMP to adenosine, and works in concert with CD39, which converts ATP into AMP. The resulting adenosine functions as a signaling molecule that activates the P1 receptors expressed on the cell

surface in many different tissues. Four G protein-coupled P1 or adenosine receptors have been cloned and designated as A1, A2A, A2B, and A3. Adenosine impacts a wide range of physiological processes including neural function, vascular perfusion, and immune responses. In doing so, this metabolite regulates CNS, cardiovascular, and immune system functions, to name a few.

[0013] Increasing evidence suggests that interactions between tumor cells and their microenvironment are essential for tumorigenesis. The purinergic signaling pathway in which CD73 plays a critical role, has emerged as an important player in cancer progression. It has become clear in recent years that adenosine is one of the most important immunosuppressive regulatory molecules in the tumor microenvironment, and contributes to immune escape and tumor progression.

[0014] CD73 is a key protein molecule in cancer development. CD73 has been found to be overexpressed in many cancer cell lines and tumor types including, for example, breast cancer, colorectal cancer, ovarian cancer, gastric cancer, gallbladder cancer, and cancers associated with poor prognosis.

[0015] The expression of CD73 in tumors is regulated by a variety of mechanisms. CD73 expression is negatively regulated by estrogen receptor (ER) in breast cancer. Thus, CD73 is highly expressed in ER negative breast cancer patients. The hypoxia-inducible factor-1 α (HIF-1 α) has also been shown to regulate CD73 transcription. Additionally, inflammatory factors such as IFN- γ affect CD73 levels. CD73 expression is also epigenetically regulated by CpG island methylation in cell lines and clinical tumor samples.

[0016] In addition to being a prognostic biomarker in cancer patients, overexpression of CD73 has also been found to be functionally linked to therapy resistance. Elevated levels of CD73 were initially linked to resistance to a variety of chemotherapeutic agents including vincristine and doxorubicin.

[0017] CD73 has also been shown to be involved in immunotherapy resistance. This ectonucleotidase participates in the process of tumor immune escape by inhibiting the activation, clonal expansion, and homing of tumor-specific T cells (in particular, T helper and cytotoxic T cells); impairing tumor cell killing by cytolytic effector T lymphocytes; driving, via pericellular generation of adenosine, the suppressive capabilities of Treg and Th17 cells; enhancing the conversion of type 1 macrophages into tumor-promoting type 2 macrophages; and promoting the accumulation of MDSCs.

[0018] Small molecular inhibitors and monoclonal antibodies targeting CD73 have shown anti-tumor activity in a variety of immune-competent but not in immune-deficient mouse tumor models. Overall, these studies suggest that anti-CD73 therapy activity is dependent on its ability to elicit immune responses in vivo.

[0019] Antibodies which block PD-1, PD-L1, and CTLA-4 have shown impressive objective response in cancer patients. Recent data demonstrates that anti-CD73 mAb significantly enhances the activity of both anti-CTLA-4 and anti-PD-1 mAbs in several mouse tumor models. In addition to checkpoint blockade, CD73-mediated production of adenosine could contribute to resistance to additional immunotherapy modalities including CAR-T cells and cancer vaccines.

[0020] Interfering with CD73 activity represents a strategy to re-sensitize tumors to therapy. Based on the link between CD73 and therapy resistance, combining anti-CD73 treatment with chemotherapy or immunotherapy is an effective approach to enhance their activity in cancer patients with high CD73 levels.

In some instances, CD73 expression serves as a biomarker to identify patients that could benefit from anti-CD73 combination therapy.

[0021] In some instances, the CD39/CD73 couple turns ATP-driven pro-inflammatory cell activity toward an adenosine-mediated anti-inflammatory state. A number of studies have shown changes in the activity of the CD39/CD73 axis during infections induced by a variety of microorganisms. An increase in CD73 expression has also been observed in the brain of mice infected with *Toxoplasma gondii*, which promotes the parasite life cycle through the production of adenosine. Thus, the pharmacological blockade of CD73 is a promising therapeutic approach to treat human toxoplasmosis.

[0022] Enhanced expression and activity of CD39 and CD73 have been observed in endothelial cells infected with cytomegalovirus (CMV). The increase in local adenosine production, associated with the upregulation of ecto-nucleotidases, generates an immunosuppressive and antithrombotic microenvironment, which facilitates viral entry into target cells.

[0023] In some instances, inhibitors of CD73, by driving a decrease on adenosine production, have applications as antiviral agents. The elevated expression/activity of CD39 and CD73 on lymphocytes of individuals infected with human immunodeficiency virus (HIV) indicates a role for ecto-nucleotidases in the immune dysfunction associated with this disease. In fact, an increased proportion of Tregs expressing CD39, as well as a positive correlation between CD39 expression on Tregs and disease progression has been observed in different cohorts of HIV-infected patients. It has also been shown that HIV-positive patients had a higher number of CD39+ Treg, and that their Teff exhibited an increased sensitivity in vitro to the suppressive effect of adenosine, which was related to the elevated expression of immunosuppressive A2A receptors.

[0024] In the central nervous system, adenosine plays a critical role in controlling a multitude of neural functions. Through the activation of P1 receptors, adenosine is involved in diverse physiological and pathological processes such as regulation of sleep, general arousal state and activity, local neuronal excitability, and coupling of the cerebral blood flow to the energy demand. In some instances, manipulation of adenosine production via CD73 inhibitors is useful for treating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease, and psychiatric disorders such as schizophrenia and autism.

Definitions

[0025] As used herein and in the appended claims, the singular forms "a," "and," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an agent" includes a plurality of such agents, and reference to "the cell" includes reference to one or more cells (or to a plurality of cells) and equivalents thereof known to those skilled in the art, and so forth. When ranges are used herein for physical properties, such as molecular weight, or chemical properties, such as chemical formulae, all combinations and subcombinations of ranges and specific embodiments therein are intended to be included. The term "about" when referring to a number or a numerical range means that the number or numerical range referred to is an approximation within experimental variability (or within statistical experimental

error), and thus the number or numerical range, in some instances, will vary between 1% and 15% of the stated number or numerical range. The term “comprising” (and related terms such as “comprise” or “comprises” or “having” or “including”) is not intended to exclude that in other certain embodiments, for example, an embodiment of any composition of matter, composition, method, or process, or the like, described herein, “consist of” or “consist essentially of” the described features.

[0026] As used in the specification and appended claims, unless specified to the contrary, the following terms have the meaning indicated below.

[0027] “Alkyl” refers to an optionally substituted straight-chain, or optionally substituted branched-chain saturated hydrocarbon monoradical having from one to about ten carbon atoms, or from one to six carbon atoms. Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, tert-amyl and hexyl, and longer alkyl groups, such as heptyl, octyl, and the like.

Whenever it appears herein, a numerical range such as “C₁-C₆ alkyl” means that the alkyl group consists of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated. In some embodiments, the alkyl is a C₁-C₁₀ alkyl, a C₁-C₉ alkyl, a C₁-C₈ alkyl, a C₁-C₇ alkyl, a C₁-C₆ alkyl, a C₁-C₅ alkyl, a C₁-C₄ alkyl, a C₁-C₃ alkyl, a C₁-C₂ alkyl, or a C₁ alkyl. Unless stated otherwise specifically in the specification, an alkyl group is optionally substituted for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the alkyl is optionally substituted with oxo, halogen, -CN, -CF₃, -OH, -OMe, -NH₂, or -NO₂. In some embodiments, the alkyl is optionally substituted with oxo, halogen, -CN, -CF₃, -OH, or -OMe. In some embodiments, the alkyl is optionally substituted with halogen.

[0028] “Alkenyl” refers to an optionally substituted straight-chain, or optionally substituted branched-chain hydrocarbon monoradical having one or more carbon-carbon double-bonds and having from two to about ten carbon atoms, more preferably two to about six carbon atoms. The group may be in either the *cis* or *trans* conformation about the double bond(s), and should be understood to include both isomers. Examples include, but are not limited to ethenyl (-CH=CH₂), 1-propenyl (-CH₂CH=CH₂), isopropenyl [-C(CH₃)=CH₂], butenyl, 1,3-butadienyl and the like. Whenever it appears herein, a numerical range such as “C₂-C₆ alkenyl” means that the alkenyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkenyl” where no numerical range is designated. In some embodiments, the alkenyl is a C₂-C₁₀ alkenyl, a C₂-C₉ alkenyl, a C₂-C₈ alkenyl, a C₂-C₇ alkenyl, a C₂-C₆ alkenyl, a C₂-C₅ alkenyl, a C₂-C₄ alkenyl, a C₂-C₃ alkenyl, or a C₂ alkenyl. Unless stated otherwise specifically in the specification, an alkenyl group is optionally substituted for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, an alkenyl is optionally

substituted with oxo, halogen, -CN, -CF₃, -OH, -OMe, -NH₂, or -NO₂. In some embodiments, an alkenyl is optionally substituted with oxo, halogen, -CN, -CF₃, -OH, or -OMe. In some embodiments, the alkenyl is optionally substituted with halogen.

[0029] “Alkynyl” refers to an optionally substituted straight-chain or optionally substituted branched-chain hydrocarbon monoradical having one or more carbon-carbon triple-bonds and having from two to about ten carbon atoms, more preferably from two to about six carbon atoms. Examples include, but are not limited to ethynyl, 2-propynyl, 2-butylnyl, 1,3-butadiynyl and the like. Whenever it appears herein, a numerical range such as “C₂-C₆ alkynyl” means that the alkynyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkynyl” where no numerical range is designated. In some embodiments, the alkynyl is a C₂-C₁₀ alkynyl, a C₂-C₉ alkynyl, a C₂-C₈ alkynyl, a C₂-C₇ alkynyl, a C₂-C₆ alkynyl, a C₂-C₅ alkynyl, a C₂-C₄ alkynyl, a C₂-C₃ alkynyl, or a C₂ alkynyl. Unless stated otherwise specifically in the specification, an alkynyl group is optionally substituted for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, an alkynyl is optionally substituted with oxo, halogen, -CN, -CF₃, -OH, -OMe, -NH₂, or -NO₂. In some embodiments, an alkynyl is optionally substituted with oxo, halogen, -CN, -CF₃, -OH, or -OMe. In some embodiments, the alkynyl is optionally substituted with halogen.

[0030] “Alkylene” refers to a straight or branched divalent hydrocarbon chain. Unless stated otherwise specifically in the specification, an alkylene group may be optionally substituted for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, an alkylene is optionally substituted with oxo, halogen, -CN, -CF₃, -OH, -OMe, -NH₂, or -NO₂. In some embodiments, an alkylene is optionally substituted with oxo, halogen, -CN, -CF₃, -OH, or -OMe. In some embodiments, the alkylene is optionally substituted with halogen.

[0031] “Alkoxy” refers to a radical of the formula -OR_a where R_a is an alkyl radical as defined. Unless stated otherwise specifically in the specification, an alkoxy group may be optionally substituted for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, an alkoxy is optionally substituted with oxo, halogen, -CN, -CF₃, -OH, -OMe, -NH₂, or -NO₂. In some embodiments, an alkoxy is optionally substituted with oxo, halogen, -CN, -CF₃, -OH, or -OMe. In some embodiments, the alkoxy is optionally substituted with halogen.

[0032] “Aryl” refers to a radical derived from a hydrocarbon ring system comprising hydrogen, 6 to 30 carbon atoms and at least one aromatic ring. The aryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused (when fused with a cycloalkyl or heterocycloalkyl ring, the aryl is bonded through an aromatic ring atom) or bridged ring systems. In some embodiments, the aryl is a 6- to 10-membered aryl. In some embodiments, the aryl is a 6-membered aryl. Aryl radicals include, but are not limited to, aryl radicals derived from the hydrocarbon ring systems of anthrylene, naphthylene, phenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. In some

embodiments, the aryl is phenyl. Unless stated otherwise specifically in the specification, an aryl may be optionally substituted for example, with halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, an aryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF₃, -OH, -OMe, -NH₂, or -NO₂. In some embodiments, an aryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF₃, -OH, or -OMe. In some embodiments, the aryl is optionally substituted with halogen.

[0033] “Cycloalkyl” refers to a stable, partially or fully saturated, monocyclic or polycyclic carbocyclic ring, which may include fused (when fused with an aryl or a heteroaryl ring, the cycloalkyl is bonded through a non-aromatic ring atom) or bridged ring systems. Representative cycloalkyls include, but are not limited to, cycloalkyls having from three to fifteen carbon atoms (C₃-C₁₅ cycloalkyl), from three to ten carbon atoms (C₃-C₁₀ cycloalkyl), from three to eight carbon atoms (C₃-C₈ cycloalkyl), from three to six carbon atoms (C₃-C₆ cycloalkyl), from three to five carbon atoms (C₃-C₅ cycloalkyl), or three to four carbon atoms (C₃-C₄ cycloalkyl). In some embodiments, the cycloalkyl is a 3- to 6-membered cycloalkyl. In some embodiments, the cycloalkyl is a 5- to 6-membered cycloalkyl. Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyls or carbocycles include, for example, adamantyl, norbornyl, decalyl, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, cis-decalin, trans-decalin, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, and bicyclo[3.3.2]decane, and 7,7-dimethyl-bicyclo[2.2.1]heptanyl. Partially saturated cycloalkyls include, for example cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Unless stated otherwise specifically in the specification, a cycloalkyl is optionally substituted for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, a cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF₃, -OH, -OMe, -NH₂, or -NO₂. In some embodiments, a cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF₃, -OH, or -OMe. In some embodiments, the cycloalkyl is optionally substituted with halogen.

[0034] “Halo” or “halogen” refers to bromo, chloro, fluoro or iodo. In some embodiments, halogen is fluoro or chloro. In some embodiments, halogen is fluoro.

[0035] “Haloalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like.

[0036] “Heterocycloalkyl” refers to a stable 3- to 24-membered partially or fully saturated ring radical comprising 2 to 23 carbon atoms and from one to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous and sulfur. Unless stated otherwise specifically in the specification, the heterocycloalkyl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused (when fused with an aryl or a heteroaryl ring, the heterocycloalkyl is bonded through a non-aromatic ring atom) or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocycloalkyl

radical may be optionally oxidized; the nitrogen atom may be optionally quaternized. In some embodiments, the heterocycloalkyl is a 3- to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 5- to 6-membered heterocycloalkyl. Examples of such heterocycloalkyl radicals include, but are not limited to, aziridinyl, azetidiny, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazoliny, imidazolidiny, isothiazolidiny, isoxazolidiny, morpholiny, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidiny, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidiny, quinuclidiny, thiazolidiny, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholiny, thiamorpholiny, 1-oxo-thiomorpholiny, 1,1-dioxo-thiomorpholiny, 1,3-dihydroisobenzofuran-1-yl, 3-oxo-1,3-dihydroisobenzofuran-1-yl, methyl-2-oxo-1,3-dioxol-4-yl, and 2-oxo-1,3-dioxol-4-yl. The term heterocycloalkyl also includes all ring forms of the carbohydrates, including but not limited to the monosaccharides, the disaccharides and the oligosaccharides. Unless otherwise noted, heterocycloalkyls have from 2 to 10 carbons in the ring. It is understood that when referring to the number of carbon atoms in a heterocycloalkyl, the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (including the heteroatoms) that make up the heterocycloalkyl (i.e. skeletal atoms of the heterocycloalkyl ring). Unless stated otherwise specifically in the specification, a heterocycloalkyl is optionally substituted for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, a heterocycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF₃, -OH, -OMe, -NH₂, or -NO₂. In some embodiments, a heterocycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF₃, -OH, or -OMe. In some embodiments, the heterocycloalkyl is optionally substituted with halogen.

[0037] “Heteroalkyl” refers to an alkyl group in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, or combinations thereof. A heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl. In one aspect, a heteroalkyl is a C₁-C₆ heteroalkyl wherein the heteroalkyl is comprised of 1 to 6 carbon atoms and one or more atoms other than carbon, e.g., oxygen, nitrogen (e.g. -NH-, -N(alkyl)-), sulfur, or combinations thereof wherein the heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl. Examples of such heteroalkyl are, for example, -CH₂OCH₃, -CH₂CH₂OCH₃, or -CH(CH₃)OCH₃. Unless stated otherwise specifically in the specification, a heteroalkyl is optionally substituted for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, a heteroalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF₃, -OH, -OMe, -NH₂, or -NO₂. In some embodiments, a heteroalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF₃, -OH, or -OMe. In some embodiments, the heteroalkyl is optionally substituted with halogen.

[0038] “Heteroaryl” refers to a 5- to 14-membered ring system radical comprising hydrogen atoms, one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous and sulfur, and at least one aromatic ring. The heteroaryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused (when fused with a cycloalkyl or

heterocycloalkyl ring, the heteroaryl is bonded through an aromatic ring atom) or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized. In some embodiments, the heteroaryl is a 5- to 10-membered heteroaryl. In some embodiments, the heteroaryl is a 5- to 6-membered heteroaryl. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothieryl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolyl, isoindolyl, isoquinolyl, indolizyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolyl, quinuclidinyl, isoquinolyl, tetrahydroquinolyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl). Unless stated otherwise specifically in the specification, a heteroaryl is optionally substituted for example, with halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, a heteroaryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF₃, -OH, -OMe, -NH₂, or -NO₂. In some embodiments, a heteroaryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF₃, -OH, or -OMe. In some embodiments, the heteroaryl is optionally substituted with halogen.

[0039] “Hydroxyalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more -OH e.g., hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, dihydroxymethyl, dihydroxyethyl, dihydroxypropyl, dihydroxybutyl, dihydroxypentyl, and the like.

[0040] “Oxo” refers to =O.

[0041] The term “optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, “optionally substituted alkyl” means either “alkyl” or “substituted alkyl” as defined above. Further, an optionally substituted group may be un-substituted (e.g., -CH₂CH₃), fully substituted (e.g., -CF₂CF₃), mono-substituted (e.g., -CH₂CH₂F) or substituted at a level anywhere in-between fully substituted and mono-substituted (e.g., -CH₂CHF₂, -CH₂CF₃, -CF₂CH₃, -CFHCHF₂, etc.). It will be understood by those skilled in the art with respect to any group containing one or more substituents that such groups are not intended to introduce any substitution or substitution patterns (e.g., substituted alkyl includes optionally substituted cycloalkyl groups, which in turn are defined as including optionally substituted alkyl groups, potentially ad infinitum) that are sterically impractical and/or synthetically non-feasible. Thus, any substituents described should generally be understood as having a maximum molecular weight of about 1,000 daltons, and more typically, up to about 500 daltons.


[0042] The terms “inhibit,” “block,” “suppress,” and grammatical variants thereof are used interchangeably herein and refer to any statistically significant decrease in biological activity, including full blocking of the activity. In some embodiments, “inhibition” refers to a decrease of about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or about 100% in biological activity. Accordingly, when the terms “inhibition” or “suppression” are applied to describe, e.g., an effect on the enzymatic activity of CD73, the term refers to the ability of a compound disclosed herein to statistically significantly decrease the 5'-nucleotidase activity of CD73 (catabolizing the hydrolysis of adenosine monophosphate, AMP, to adenosine), relative to the CD73-mediated 5'-nucleotidase activity in an untreated (control) cell. In some instances, the cell which expresses CD73 is a naturally occurring cell or cell line (e.g., a cancer cell) or is recombinantly produced by introducing a nucleic acid encoding CD73 into a host cell. In some aspects, compounds disclosed herein statistically significantly decrease the 5'-nucleotidase activity of a soluble form of CD73 in a biological fluid. In one aspect, the compound disclosed herein inhibit CD73-mediated 5'-nucleotidase activity by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or about 100%, as determined, for example, by the methods described in the Examples and/or methods known in the art.

[0043] As used herein, “treatment” or “treating,” or “palliating” or “ameliorating” are used interchangeably. These terms refer to an approach for obtaining beneficial or desired results including but not limited to therapeutic benefit and/or a prophylactic benefit. By “therapeutic benefit” is meant eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient is still afflicted with the underlying disorder. For prophylactic benefit, the compositions are, in some embodiments, administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease has not been made.

Compounds


[0044] Described herein are compounds that are CD73 inhibitors. These compounds, and compositions comprising these compounds, are useful for the treatment of cancer, infections, and neurodegenerative diseases.

[0045] In some embodiments provided herein is a compound having the structure of Formula (I), or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof:



Formula (I);

wherein:



Ring A is

Q^1 and Q^2 are independently N or CW;

Q^3 and Q^4 are independently N or CW; provided that at least one of Q^3 or Q^4 is N;

each W is independently hydrogen, halogen, -CN, -OR^b, NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

A is -O- or -CH₂-;

X is -S(=O)₂-;

R¹ and R² are independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a}; or R¹ and R² are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{1b};

each R^{1a} and R^{1b} is independently oxo (when feasible) halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

R³ is hydrogen, halogen, -CN, -OR^b, -SR^b, -NR^cR^d, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{3a};

each R^{3a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁴ and R⁷ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁵ and R⁶ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁸ is hydrogen, halogen, -OR^b, -NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

R⁹ and R¹⁰ are independently hydrogen, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

R¹¹ is halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -

$\text{OC(=O)NR}^{15}\text{R}^{16}$, $-\text{NR}^{13}\text{C(=O)NR}^{15}\text{R}^{16}$, $-\text{NR}^{13}\text{C(=O)R}^{14}$, $-\text{NR}^{13}\text{C(=O)OR}^{13}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} ;

R^{12} is hydrogen, halogen, $-\text{CN}$, $-\text{OR}^{13}$, $-\text{SR}^{13}$, $-\text{S(=O)R}^{14}$, $-\text{NO}_2$, $-\text{NR}^{15}\text{R}^{16}$, $-\text{S(=O)}_2\text{R}^{14}$, $-\text{NR}^{13}\text{S(=O)}_2\text{R}^{14}$, $-\text{S(=O)}_2\text{NR}^{15}\text{R}^{16}$, $-\text{C(=O)R}^{14}$, $-\text{OC(=O)R}^{14}$, $-\text{C(=O)OR}^{13}$, $-\text{OC(=O)OR}^{13}$, $-\text{C(=O)NR}^{15}\text{R}^{16}$, $-\text{OC(=O)NR}^{15}\text{R}^{16}$, $-\text{NR}^{13}\text{C(=O)NR}^{15}\text{R}^{16}$, $-\text{NR}^{13}\text{C(=O)R}^{14}$, $-\text{NR}^{13}\text{C(=O)OR}^{13}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{12a} ;

or R^{11} and R^{12} are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b} ;

each R^{11a} , R^{11b} , and R^{12a} is independently oxo (when feasible), halogen, $-\text{CN}$, $-\text{OR}^{13}$, $-\text{SR}^{13}$, $-\text{S(=O)R}^{14}$, $-\text{NO}_2$, $-\text{NR}^{15}\text{R}^{16}$, $-\text{S(=O)}_2\text{R}^{14}$, $-\text{NR}^{13}\text{S(=O)}_2\text{R}^{14}$, $-\text{S(=O)}_2\text{NR}^{15}\text{R}^{16}$, $-\text{C(=O)R}^{14}$, $-\text{OC(=O)R}^{14}$, $-\text{C(=O)OR}^{13}$, $-\text{OC(=O)OR}^{13}$, $-\text{C(=O)NR}^{15}\text{R}^{16}$, $-\text{OC(=O)NR}^{15}\text{R}^{16}$, $-\text{NR}^{13}\text{C(=O)NR}^{15}\text{R}^{16}$, $-\text{NR}^{13}\text{C(=O)R}^{14}$, $-\text{NR}^{13}\text{C(=O)OR}^{13}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} ;

each R^{11c} is independently oxo (when feasible), halogen, $-\text{CN}$, $-\text{OR}^b$, $-\text{SR}^b$, $-\text{S(=O)R}^a$, $-\text{NO}_2$, $-\text{NR}^c\text{R}^d$, $-\text{S(=O)}_2\text{R}^a$, $-\text{NR}^b\text{S(=O)}_2\text{R}^a$, $-\text{S(=O)}_2\text{NR}^c\text{R}^d$, $-\text{C(=O)R}^a$, $-\text{OC(=O)R}^a$, $-\text{C(=O)OR}^b$, $-\text{OC(=O)OR}^b$, $-\text{C(=O)NR}^c\text{R}^d$, $-\text{OC(=O)NR}^c\text{R}^d$, $-\text{NR}^b\text{C(=O)NR}^c\text{R}^d$, $-\text{NR}^b\text{C(=O)R}^a$, $-\text{NR}^b\text{C(=O)OR}^b$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, $\text{C}_1\text{-C}_6$ alkyl(aryl), $\text{C}_1\text{-C}_6$ alkyl(heteroaryl), $\text{C}_1\text{-C}_6$ alkyl(cycloalkyl), or $\text{C}_1\text{-C}_6$ alkyl(heterocycloalkyl);

each R^{13} is independently hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a} ;

each R^{14} is independently $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{14a} ;

each R^{15} and R^{16} is independently hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{15a} ;

or R¹⁵ and R¹⁶ are taken together with the nitrogen atom to which they are attached to form a

heterocycloalkyl optionally substituted with one, two, or three R^{15b};

each R^{13a}, R^{14a}, R^{15a}, and R^{15b} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NHS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -CN, -OR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl;

R²¹ and R²² are independently hydrogen, C₁-C₂₀ alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a};

or R²¹ and R²² are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b};

each R^{21a} and R^{21b} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NHS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);


each R^a is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

each R^b is independently hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl; and

each R^c and R^d is independently hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;


or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.

[0046] In some embodiments provided herein is a compound having the structure of Formula (I), or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof:



Formula (I);

wherein:



Ring A is ;

Q^1 and Q^2 are independently N or CW;

Q^3 and Q^4 are independently N or CW; provided that at least one of Q^3 or Q^4 is N;

each W is independently hydrogen, halogen, -CN, -OR^b, NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

A is -O- or -CH₂-;

X is -S(=O)₂-;

R¹ and R² are independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,

cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆

alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl,

heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a};

or R¹ and R² are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{1b};

each R^{1a} and R^{1b} is independently oxo (when feasible) halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -

S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -

C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆

fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆

alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

R³ is hydrogen, halogen, -CN, -OR^b, -SR^b, -NR^cR^d, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆

haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆

alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein

each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently

optionally substituted with one, two, or three R^{3a};

each R^{3a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -

C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl,

aryl, or heteroaryl;

R^4 and R^7 are independently hydrogen, halogen, $-OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^5 and R^6 are independently hydrogen, halogen, $-OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^8 is hydrogen, halogen, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

R^9 and R^{10} are independently hydrogen, halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

R^{11} is halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} ,

R^{12} is hydrogen, halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{12a} ,

or R^{11} and R^{12} are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b} ,

each R^{11a} , R^{11b} , and R^{12a} is independently oxo (when feasible), halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} ,

each R^{11c} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

each R^{13} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a} ;

each R^{14} is independently C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{14a} ;

each R^{15} and R^{16} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{15a} ;

or R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b} ;

each R^{13a} , R^{14a} , R^{15a} , and R^{15b} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NHS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

R^{21} and R^{22} are independently hydrogen, C_1 - C_{20} alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), C_1 - C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a} ;

or R^{21} and R^{22} are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b} ;

each R^{21a} and R^{21b} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NHS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);


each R^a is independently C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

each R^b is independently hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; and

each R^c and R^d is independently hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl,

cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;
or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.

[0047] In some embodiments provided herein is a compound having the structure of Formula (I), or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof:



Formula (I);

wherein:



Ring A is

Q¹ and Q² are independently N or CW;

Q³ and Q⁴ are independently N or CW; provided that at least one of Q³ or Q⁴ is N;

each W is independently hydrogen, halogen, -CN, -OR^b, NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

A is -O- or -CH₂-;

X is -S(=O)₂-;

R¹ and R² are independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a}, or R¹ and R² are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{1b};

each R^{1a} and R^{1b} is independently oxo (when feasible) halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);
R³ is hydrogen, halogen, -CN, -OR^b, -SR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

R^4 and R^7 are independently hydrogen, halogen, $-OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^5 and R^6 are independently hydrogen, halogen, $-OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^8 is hydrogen, halogen, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

R^9 and R^{10} are independently hydrogen, halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

R^{11} is halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} ,

R^{12} is hydrogen, halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{12a} ,

or R^{11} and R^{12} are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b} ,

each R^{11a} , R^{11b} , and R^{12a} is independently oxo (when feasible), halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} ,

each R^{11c} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

each R^{13} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a} ;

each R^{14} is independently C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{14a} ;

each R^{15} and R^{16} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{15a} ;

or R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b} ;

each R^{13a} , R^{14a} , R^{15a} , and R^{15b} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NHS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

R^{21} and R^{22} are independently hydrogen, C_1 - C_{20} alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), C_1 - C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a} ;

or R^{21} and R^{22} are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b} ;


each R^{21a} and R^{21b} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NHS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

each R^a is independently C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

each R^b is independently hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; and

each R^c and R^d is independently hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl,

cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;
 or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;
 provided that the compound is not:



[0048] In some embodiments of a compound of Formula (I), Q¹ is N and Q² is CW. In some embodiments of a compound of Formula (I), Q¹ is CW and Q² is N. In some embodiments of a compound of Formula (I), Q¹ is N and Q² is N. In some embodiments of a compound of Formula (I), Q¹ is CW and Q² is CW. In some embodiments of a compound of Formula (I), Q¹ is N and Q² is N or Q¹ is N and Q² is CW.

[0049] In some embodiments of a compound of Formula (I), Q³ is N and Q⁴ is CW. In some embodiments of a compound of Formula (I), Q⁴ is N and Q³ is CW. In some embodiments of a compound of Formula (I), Q³ is N and Q⁴ is N.

[0050] In some embodiments of a compound of Formula (I), each W is independently hydrogen, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl. In some embodiments of a compound of Formula (I), each W is independently hydrogen, halogen, or C₁-C₆ alkyl. In some embodiments of a compound of Formula (I), each W is hydrogen.

[0051] In some embodiments of a compound of Formula (I), R³ is halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, alkynyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R^{3a}. In some embodiments of a compound of Formula (I), R³ is halogen, C₁-C₆ alkyl, C₂-C₆ alkynyl, C₁-C₆ hydroxyalkyl, or C₁-C₆ heteroalkyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{3a}.

[0052] In some embodiments of a compound of Formula (I), R³ is halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (I), R³ is halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (I), R³ is halogen, or C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl. In some embodiments of a compound of Formula (I), R³ is halogen.

[0053] In some embodiments of a compound of Formula (I), each R^{3a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (I), each R^{3a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, cycloalkyl,

or heterocycloalkyl. In some embodiments of a compound of Formula (I), each R^{3a} is independently oxo (when feasible) halogen, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (I), each R^{3a} is independently oxo (when feasible) halogen, C_1 - C_6 alkyl, or C_1 - C_6 fluoroalkyl. In some embodiments of a compound of Formula (I), each R^{3a} is independently halogen or C_1 - C_6 alkyl. In some embodiments of a compound of Formula (I), each R^{3a} is independently halogen, $-OR^b$, C_1 - C_6 alkyl, or cycloalkyl.

[0054] In some embodiments of a compound of Formula (I), R^1 is C_1 - C_6 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a} . In some embodiments of a compound of Formula (I), R^1 is C_1 - C_6 alkyl, cycloalkyl, heterocycloalkyl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a} . In some embodiments of a compound of Formula (I), R^1 is cycloalkyl or C_1 - C_6 alkyl(cycloalkyl); wherein each alkyl and cycloalkyl is independently optionally substituted with one, two, or three R^{1a} . In some embodiments of a compound of Formula (I), R^1 is cycloalkyl optionally substituted with one, two, or three R^{1a} .

[0055] In some embodiments of a compound of Formula (I), each R^{1a} is independently oxo (when feasible) halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (I), each R^{1a} is independently oxo (when feasible) halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (I), each R^{1a} is independently oxo (when feasible) halogen, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (I), each R^{1a} is independently oxo (when feasible) halogen, C_1 - C_6 alkyl, or C_1 - C_6 fluoroalkyl. In some embodiments of a compound of Formula (I), each R^{1a} is independently halogen or C_1 - C_6 alkyl.

[0056] In some embodiments of a compound of Formula (I), R^2 is hydrogen or C_1 - C_6 alkyl. In some embodiments of a compound of Formula (I), R^2 is hydrogen. In some embodiments of a compound of Formula (I), R^1 and R^2 are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{1b} .

[0057] In some embodiments of a compound of Formula (I), each R^{1b} is independently oxo (when feasible) halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (I), each R^{1b} is independently oxo (when feasible) halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (I), each R^{1b} is independently oxo (when feasible) halogen, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (I), each R^{1b} is independently oxo (when feasible) halogen, C_1 - C_6

alkyl, or C₁-C₆ fluoroalkyl. In some embodiments of a compound of Formula (I), each R^{1b} is independently halogen or C₁-C₆ alkyl.

[0058] In some embodiments of a compound of Formula (I), R⁸ is hydrogen or C₁-C₆ alkyl. In some embodiments of a compound of Formula (I), R⁸ is hydrogen.

[0059] In some embodiments of a compound of Formula (I), R⁹ and R¹⁰ are independently hydrogen or C₁-C₆ alkyl. In some embodiments of a compound of Formula (I), R⁹ and R¹⁰ are hydrogen.

[0060] In some embodiments of a compound of Formula (I), A is -O-. In some embodiments of a compound of Formula (I), A is -CH₂-.

[0061] In some embodiments of a compound of Formula (I), R⁵ and R⁶ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, or C₁-C₆ haloalkyl. In some embodiments of a compound of Formula (I), R⁵ and R⁶ are independently hydrogen, halogen, -OR^b, or C₁-C₆ alkyl. In some embodiments of a compound of Formula (I), R⁵ and R⁶ are hydrogen.

[0062] In some embodiments of a compound of Formula (I), R⁴ and R⁷ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, or C₁-C₆ haloalkyl. In some embodiments of a compound of Formula (I), R⁴ and R⁷ are independently hydrogen, halogen, -OR^b, or C₁-C₆ alkyl. In some embodiments of a compound of Formula (I), R⁴ and R⁷ are independently hydrogen, halogen, or -OR^b. In some embodiments of a compound of Formula (I), R⁴ and R⁷ are independently hydrogen, halogen, or -OH. In some embodiments of a compound of Formula (I), R⁴ and R⁷ are independently halogen or -OH. In some embodiments of a compound of Formula (I), R⁴ and R⁷ are independently hydrogen or -OH. In some embodiments of a compound of Formula (I), R⁴ and R⁷ are -OH.

[0063] In some embodiments of a compound of Formula (I), R⁵ and R⁶ are hydrogen and R⁴ and R⁷ are -OH. In some embodiments of a compound of Formula (I), R⁵ and R⁶ are hydrogen and R⁴ and R⁷ are independently halogen or -OH. In some embodiments of a compound of Formula (I), R⁵ and R⁶ are hydrogen and R⁴ and R⁷ are independently hydrogen or -OH.

[0064] In some embodiments of a compound of Formula (I), R²¹ and R²² are independently hydrogen, C₁-C₂₀ alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a}. In some embodiments of a compound of Formula (I), R²¹ and R²² are independently hydrogen, C₁-C₂₀ alkyl or aryl; wherein each alkyl and aryl is independently optionally substituted with one, two, or three R^{21a}. In some embodiments of a compound of Formula (I), R²¹ and R²² are independently hydrogen, C₁-C₂₀ alkyl optionally substituted with one, two, or three R^{21a}. In some embodiments of a compound of Formula (I), R²¹ and R²² are hydrogen.

[0065] In some embodiments of a compound of Formula (I), each R^{21a} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, or C₁-C₆ alkyl. In some embodiments of a compound of Formula (I), each R^{21a} is independently -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, or -

$\text{OC(=O)NR}^{\text{c}}\text{R}^{\text{d}}$. In some embodiments of a compound of Formula (I), each $\text{R}^{21\text{a}}$ is independently $-\text{C(=O)OR}^{\text{b}}$ or $-\text{OC(=O)OR}^{\text{b}}$.

[0066] In some embodiments of a compound of Formula (I), R^{21} and R^{22} are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three $\text{R}^{21\text{b}}$.

[0067] In some embodiments of a compound of Formula (I), each $\text{R}^{21\text{b}}$ is independently oxo (when feasible), halogen, $-\text{CN}$, $-\text{OR}^{\text{b}}$, $-\text{NR}^{\text{c}}\text{R}^{\text{d}}$, $-\text{C(=O)R}^{\text{a}}$, $-\text{OC(=O)R}^{\text{a}}$, $-\text{C(=O)OR}^{\text{b}}$, $-\text{OC(=O)OR}^{\text{b}}$, $-\text{OC(=O)NR}^{\text{c}}\text{R}^{\text{d}}$, $-\text{NR}^{\text{b}}\text{C(=O)NR}^{\text{c}}\text{R}^{\text{d}}$, $-\text{NR}^{\text{b}}\text{C(=O)R}^{\text{a}}$, $-\text{NR}^{\text{b}}\text{C(=O)OR}^{\text{b}}$, $\text{C}_1\text{-C}_6$ alkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (I), each $\text{R}^{21\text{b}}$ is independently halogen, $-\text{CN}$, $-\text{OR}^{\text{b}}$, $-\text{NR}^{\text{c}}\text{R}^{\text{d}}$, $\text{C}_1\text{-C}_6$ alkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (I), each $\text{R}^{21\text{b}}$ is independently halogen or $\text{C}_1\text{-C}_6$ alkyl.

[0068] In some embodiments of a compound of Formula (I), R^{12} is hydrogen, halogen, $-\text{CN}$, $-\text{OR}^{13}$, $-\text{NR}^{15}\text{R}^{16}$, $-\text{C(=O)R}^{14}$, $-\text{C(=O)OR}^{13}$, $-\text{C(=O)NR}^{15}\text{R}^{16}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (I), R^{12} is halogen, $-\text{CN}$, $-\text{OR}^{13}$, $-\text{NR}^{15}\text{R}^{16}$, $-\text{C(=O)R}^{14}$, $-\text{C(=O)OR}^{13}$, $-\text{C(=O)NR}^{15}\text{R}^{16}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (I), R^{12} is hydrogen, halogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, or $\text{C}_1\text{-C}_6$ hydroxyalkyl. In some embodiments of a compound of Formula (I), R^{12} is $\text{C}_1\text{-C}_6$ alkyl. In some embodiments of a compound of Formula (I), R^{12} is $\text{C}_1\text{-C}_6$ hydroxyalkyl. In some embodiments of a compound of Formula (I), R^{12} is hydrogen. In some embodiments of a compound of Formula (I), R^{12} is not hydrogen.

[0069] In some embodiments of a compound of Formula (I), each $\text{R}^{12\text{a}}$ is independently halogen, $-\text{CN}$, $-\text{OR}^{13}$, $-\text{NR}^{15}\text{R}^{16}$, $-\text{S(=O)}_2\text{R}^{14}$, $-\text{NR}^{14}\text{S(=O)}_2\text{R}^{14}$, $-\text{S(=O)}_2\text{NR}^{15}\text{R}^{16}$, $-\text{C(=O)R}^{14}$, $-\text{OC(=O)R}^{14}$, $-\text{C(=O)OR}^{13}$, $-\text{C(=O)NR}^{15}\text{R}^{16}$, $-\text{NR}^{13}\text{C(=O)R}^{14}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three $\text{R}^{11\text{c}}$.

[0070] In some embodiments of a compound of Formula (I), each $\text{R}^{12\text{a}}$ is independently halogen, $-\text{CN}$, $-\text{OR}^{13}$, $-\text{NR}^{15}\text{R}^{16}$, $-\text{S(=O)}_2\text{R}^{14}$, $-\text{NR}^{14}\text{S(=O)}_2\text{R}^{14}$, $-\text{S(=O)}_2\text{NR}^{15}\text{R}^{16}$, $-\text{C(=O)R}^{14}$, $-\text{OC(=O)R}^{14}$, $-\text{C(=O)OR}^{13}$, $-\text{C(=O)NR}^{15}\text{R}^{16}$, $-\text{NR}^{13}\text{C(=O)R}^{14}$, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three $\text{R}^{11\text{c}}$.

[0071] In some embodiments of a compound of Formula (I), each $\text{R}^{12\text{a}}$ is independently $-\text{OR}^{13}$, $-\text{S(=O)}_2\text{R}^{14}$, $-\text{NR}^{13}\text{C(=O)R}^{14}$, cycloalkyl, aryl, or heteroaryl; wherein each cycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three $\text{R}^{11\text{c}}$.

[0072] In some embodiments of a compound of Formula (I), R^{11} is halogen, $-\text{CN}$, $-\text{OR}^{13}$, $-\text{NR}^{15}\text{R}^{16}$, $-\text{S(=O)}_2\text{R}^{14}$, $-\text{C(=O)R}^{14}$, $-\text{C(=O)OR}^{13}$, $-\text{C(=O)NR}^{15}\text{R}^{16}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three $\text{R}^{11\text{a}}$. In some embodiments of a compound of Formula (I), R^{11} is halogen, $-\text{CN}$, $-\text{S(=O)}_2\text{R}^{14}$, $-\text{C(=O)R}^{14}$, $-\text{C(=O)OR}^{13}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, cycloalkyl, heterocycloalkyl, aryl, or

heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} . In some embodiments of a compound of Formula (I), R^{11} is $-\text{CN}$, $-\text{S}(=\text{O})_2\text{R}^{14}$, $-\text{C}(=\text{O})\text{OR}^{13}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, or heteroaryl; wherein each alkyl and heteroaryl is independently optionally substituted with one, two, or three R^{11a} . In some embodiments of a compound of Formula (I), R^{11} is $\text{C}_1\text{-C}_6$ alkyl optionally substituted with one, two, or three R^{11a} . In some embodiments of a compound of Formula (I), R^{11} is $\text{C}_1\text{-C}_6$ alkyl substituted with one R^{11a} . In some embodiments of a compound of Formula (I), R^{11} is $\text{C}_1\text{-C}_6$ hydroxyalkyl.

[0073] In some embodiments of a compound of Formula (I), each R^{11a} is independently halogen, $-\text{CN}$, $-\text{OR}^{13}$, $-\text{NR}^{15}\text{R}^{16}$, $-\text{S}(=\text{O})_2\text{R}^{14}$, $-\text{NR}^{14}\text{S}(=\text{O})_2\text{R}^{14}$, $-\text{S}(=\text{O})_2\text{NR}^{15}\text{R}^{16}$, $-\text{C}(=\text{O})\text{R}^{14}$, $-\text{OC}(=\text{O})\text{R}^{14}$, $-\text{C}(=\text{O})\text{OR}^{13}$, $-\text{C}(=\text{O})\text{NR}^{15}\text{R}^{16}$, $-\text{NR}^{13}\text{C}(=\text{O})\text{R}^{14}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (I), each R^{11a} is independently halogen, $-\text{CN}$, $-\text{OR}^{13}$, $-\text{NR}^{15}\text{R}^{16}$, $-\text{S}(=\text{O})_2\text{R}^{14}$, $-\text{NR}^{14}\text{S}(=\text{O})_2\text{R}^{14}$, $-\text{S}(=\text{O})_2\text{NR}^{15}\text{R}^{16}$, $-\text{C}(=\text{O})\text{R}^{14}$, $-\text{OC}(=\text{O})\text{R}^{14}$, $-\text{C}(=\text{O})\text{OR}^{13}$, $-\text{C}(=\text{O})\text{NR}^{15}\text{R}^{16}$, $-\text{NR}^{13}\text{C}(=\text{O})\text{R}^{14}$, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (I), each R^{11a} is independently $-\text{OR}^{13}$, $-\text{S}(=\text{O})_2\text{R}^{14}$, $-\text{NR}^{13}\text{C}(=\text{O})\text{R}^{14}$, cycloalkyl, aryl, or heteroaryl; wherein each cycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (I), each R^{11a} is independently aryl optionally substituted with one, two, or three R^{11c} .

[0074] In some embodiments of a compound of Formula (I), each R^{11a} is independently $-\text{OR}^{13}$. In some embodiments of a compound of Formula (I), each R^{11a} is independently $-\text{S}(=\text{O})_2\text{R}^{14}$. In some embodiments of a compound of Formula (I), each R^{11a} is independently cycloalkyl optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (I), each R^{11a} is independently $-\text{NR}^{13}\text{C}(=\text{O})\text{R}^{14}$.

[0075] In some embodiments of a compound of Formula (I), each R^{11c} is independently oxo (when feasible), halogen, $-\text{CN}$, $-\text{OR}^b$, $-\text{NR}^c\text{R}^d$, $-\text{C}(=\text{O})\text{R}^a$, $-\text{C}(=\text{O})\text{OR}^b$, $-\text{C}(=\text{O})\text{NR}^c\text{R}^d$, $\text{C}_1\text{-C}_6$ alkyl, or $\text{C}_1\text{-C}_6$ haloalkyl. In some embodiments of a compound of Formula (I), each R^{11c} is independently halogen, $-\text{CN}$, $-\text{OR}^b$, $-\text{NR}^c\text{R}^d$, $\text{C}_1\text{-C}_6$ alkyl, or $\text{C}_1\text{-C}_6$ haloalkyl. In some embodiments of a compound of Formula (I), each R^{11c} is independently halogen, $\text{C}_1\text{-C}_6$ alkyl, or $\text{C}_1\text{-C}_6$ haloalkyl.

[0076] In some embodiments of a compound of Formula (I), R^{11} and R^{12} are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b} . In some embodiments of a compound of Formula (I), R^{11} and R^{12} are taken together to form a cycloalkyl optionally substituted with one, two, or three R^{11b} . In some embodiments of a compound of Formula (I), R^{11} and R^{12} are taken together to form a heterocycloalkyl optionally substituted with one, two, or three R^{11b} .

[0077] In some embodiments of a compound of Formula (I), each R^{11b} is independently oxo (when feasible), halogen, $-\text{CN}$, $-\text{OR}^b$, $-\text{NR}^c\text{R}^d$, $-\text{C}(=\text{O})\text{R}^a$, $-\text{C}(=\text{O})\text{OR}^b$, $-\text{C}(=\text{O})\text{NR}^c\text{R}^d$, $\text{C}_1\text{-C}_6$ alkyl, or $\text{C}_1\text{-C}_6$ haloalkyl. In some embodiments of a compound of Formula (I), each R^{11b} is independently oxo (when

feasible), halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl. In some embodiments of a compound of Formula (I), each R^{11b} is independently oxo (when feasible), halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.

[0078] In some embodiments of a compound of Formula (I), each R¹³ is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ heteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R^{13a}. In some embodiments of a compound of Formula (I), each R¹³ is independently hydrogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{13a}. In some embodiments of a compound of Formula (I), each R¹³ is independently hydrogen or C₁-C₆ alkyl.

[0079] In some embodiments of a compound of Formula (I), each R^{13a} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (I), each R^{13a} is independently halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (I), each R^{13a} is independently halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.

[0080] In some embodiments of a compound of Formula (I), each R¹⁴ is independently C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ heteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R^{14a}. In some embodiments of a compound of Formula (I), each R¹⁴ is independently C₁-C₆ alkyl, or C₁-C₆ haloalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{14a}. In some embodiments of a compound of Formula (I), each R¹⁴ is independently C₁-C₆ alkyl.

[0081] In some embodiments of a compound of Formula (I), each R^{14a} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (I), each R^{14a} is independently halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (I), each R^{14a} is independently halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.

[0082] In some embodiments of a compound of Formula (I), each R¹⁵ and R¹⁶ is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ heteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R^{15a}. In some embodiments of a compound of Formula (I), each R¹⁵ and R¹⁶ is independently hydrogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{15a}. In some embodiments of a compound of Formula (I), each R¹⁵ and R¹⁶ is independently hydrogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{15a}. In some embodiments of a compound of Formula (I), each R¹⁵ and R¹⁶ is independently hydrogen or C₁-C₆ alkyl.


[0083] In some embodiments of a compound of Formula (I), each R^{15a} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl,

cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (I), each R^{15a} is independently halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (I), each R^{15a} is independently halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.

In some embodiments of a compound of Formula (I), R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b} . In some embodiments of a compound of Formula (I), R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl.


[0084] In some embodiments of a compound of Formula (I), each R^{15b} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (I), each R^{15b} is independently halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (I), each R^{15b} is independently halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.

[0085] In some embodiments provided herein is a compound having the structure of Formula (II), or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof:



Formula (II);

wherein:



Ring A is

Q^1 is N and Q^2 is CW or Q^1 is N and Q^2 is N;

Q^3 and Q^4 are independently N or CW; provided that at least one of Q^3 or Q^4 is N;

each W is independently hydrogen, halogen, -CN, -OR^b, NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

A is -O-;

X is -S- or -O-;

R^1 and R^2 are independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a} ;

or R^1 and R^2 are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{1b} ;

each R^{1a} and R^{1b} is independently oxo (when feasible) halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

R^3 is hydrogen, halogen, -CN, -OR^b, -SR^b, -NR^cR^d, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{3a} ;

each R^{3a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^4 and R^7 are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^5 and R^6 are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^8 is hydrogen, halogen, -OR^b, -NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

R^9 and R^{10} are independently hydrogen, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

R^{11} is halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -OC(=O)NR¹⁵R¹⁶, -NR¹³C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, -NR¹³C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} ;

R^{12} is hydrogen, halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -OC(=O)NR¹⁵R¹⁶, -NR¹³C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, -NR¹³C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{12a} ;

or R^{11} and R^{12} are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b} ;

each R^{11a} , R^{11b} , and R^{12a} is independently oxo (when feasible), halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -

OC(=O)OR^{13} , $-\text{C(=O)NR}^{15}\text{R}^{16}$, $-\text{OC(=O)NR}^{15}\text{R}^{16}$, $-\text{NR}^{13}\text{C(=O)NR}^{15}\text{R}^{16}$, $-\text{NR}^{13}\text{C(=O)R}^{14}$, $-\text{NR}^{13}\text{C(=O)OR}^{13}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} ;

each R^{11c} is independently oxo (when feasible), halogen, $-\text{CN}$, $-\text{OR}^b$, $-\text{SR}^b$, $-\text{S(=O)R}^a$, $-\text{NO}_2$, $-\text{NR}^c\text{R}^d$, $-\text{S(=O)}_2\text{R}^a$, $-\text{NR}^b\text{S(=O)}_2\text{R}^a$, $-\text{S(=O)}_2\text{NR}^c\text{R}^d$, $-\text{C(=O)R}^a$, $-\text{OC(=O)R}^a$, $-\text{C(=O)OR}^b$, $-\text{OC(=O)OR}^b$, $-\text{C(=O)NR}^c\text{R}^d$, $-\text{OC(=O)NR}^c\text{R}^d$, $-\text{NR}^b\text{C(=O)NR}^c\text{R}^d$, $-\text{NR}^b\text{C(=O)R}^a$, $-\text{NR}^b\text{C(=O)OR}^b$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, $\text{C}_1\text{-C}_6$ alkyl(aryl), $\text{C}_1\text{-C}_6$ alkyl(heteroaryl), $\text{C}_1\text{-C}_6$ alkyl(cycloalkyl), or $\text{C}_1\text{-C}_6$ alkyl(heterocycloalkyl);

each R^{13} is independently hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a} ;

each R^{14} is independently $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{14a} ;

each R^{15} and R^{16} is independently hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{15a} ;

or R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b} ;

each R^{13a} , R^{14a} , R^{15a} , and R^{15b} is independently oxo (when feasible), halogen, $-\text{CN}$, $-\text{OR}^b$, $-\text{SR}^b$, $-\text{S(=O)R}^a$, $-\text{NO}_2$, $-\text{NR}^c\text{R}^d$, $-\text{S(=O)}_2\text{R}^a$, $-\text{NR}^b\text{S(=O)}_2\text{R}^a$, $-\text{S(=O)}_2\text{NR}^c\text{R}^d$, $-\text{C(=O)R}^a$, $-\text{OC(=O)R}^a$, $-\text{C(=O)OR}^b$, $-\text{OC(=O)OR}^b$, $-\text{C(=O)NR}^c\text{R}^d$, $-\text{OC(=O)NR}^c\text{R}^d$, $-\text{NR}^b\text{C(=O)NR}^c\text{R}^d$, $-\text{NR}^b\text{C(=O)R}^a$, $-\text{NR}^b\text{C(=O)OR}^b$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, $\text{C}_1\text{-C}_6$ alkyl(aryl), $\text{C}_1\text{-C}_6$ alkyl(heteroaryl), $\text{C}_1\text{-C}_6$ alkyl(cycloalkyl), or $\text{C}_1\text{-C}_6$ alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-\text{CN}$, $-\text{OR}^b$, $-\text{S(=O)R}^a$, $-\text{NO}_2$, $-\text{NR}^c\text{R}^d$, $-\text{S(=O)}_2\text{R}^a$, $-\text{S(=O)}_2\text{NR}^c\text{R}^d$, $-\text{C(=O)R}^a$, $-\text{C(=O)OR}^b$, $-\text{C(=O)NR}^c\text{R}^d$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_2\text{-C}_6$ alkenyl, or $\text{C}_2\text{-C}_6$ alkynyl;

R^{21} and R^{22} are independently hydrogen, $\text{C}_1\text{-C}_{20}$ alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, $\text{C}_1\text{-C}_6$ alkyl(aryl), $\text{C}_1\text{-C}_6$ alkyl(heteroaryl), $\text{C}_1\text{-C}_6$ alkyl(cycloalkyl), $\text{C}_1\text{-C}_6$ alkyl(heterocycloalkyl); wherein

each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a} ;

or R^{21} and R^{22} are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b} ;

each R^{21a} and R^{21b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);


each R^a is independently C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

each R^b is independently hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; and

each R^c and R^d is independently hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;


or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.

[0086] In some embodiments provided herein is a compound having the structure of Formula (II), or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof:



Formula (II);

wherein:



Q^1 is N and Q^2 is CW or Q^1 is N and Q^2 is N;

Q^3 and Q^4 are independently N or CW; provided that at least one of Q^3 or Q^4 is N;

each W is independently hydrogen, halogen, -CN, -OR^b, NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

A is -O-;

X is -S- or -O-;

R¹ and R² are independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a}, or R¹ and R² are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{1b};

each R^{1a} and R^{1b} is independently oxo (when feasible) halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

R³ is hydrogen, halogen, -CN, -OR^b, -SR^b, -NR^cR^d, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{3a};

each R^{3a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁴ and R⁷ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁵ and R⁶ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁸ is hydrogen, halogen, -OR^b, -NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

R⁹ and R¹⁰ are independently hydrogen, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

R¹¹ is halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -OC(=O)NR¹⁵R¹⁶, -NR¹³C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, -NR¹³C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a};

R¹² is hydrogen, halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -

OC(=O)NR¹⁵R¹⁶, -NR¹³C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, -NR¹³C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{12a},

or R¹¹ and R¹² are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b},

each R^{11a}, R^{11b}, and R^{12a} is independently oxo (when feasible), halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -OC(=O)NR¹⁵R¹⁶, -NR¹³C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, -NR¹³C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c},

each R^{11c} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

each R¹³ is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a},

each R¹⁴ is independently C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{14a},

each R¹⁵ and R¹⁶ is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{15a},

or R¹⁵ and R¹⁶ are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b},

each R^{13a}, R^{14a}, R^{15a}, and R^{15b} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

R^{21} and R^{22} are independently hydrogen, C_1 - C_{20} alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), C_1 - C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a} ;

or R^{21} and R^{22} are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b} ;

each R^{21a} and R^{21b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);


each R^a is independently C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

each R^b is independently hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; and

each R^c and R^d is independently hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;


or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.

[0087] In some embodiments provided herein is a compound having the structure of Formula (II), or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof:



Formula (II);

wherein:



Ring A is

Q^1 is N and Q^2 is CW or Q^1 is N and Q^2 is N;

Q^3 and Q^4 are independently N or CW; provided that at least one of Q^3 or Q^4 is N;

each W is independently hydrogen, halogen, -CN, -OR^b, NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

A is -O-;

X is -S- or -O-;

R¹ and R² are independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a}, or R¹ and R² are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{1b};

each R^{1a} and R^{1b} is independently oxo (when feasible) halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

R³ is hydrogen, halogen, -CN, -OR^b, -SR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

R⁴ and R⁷ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁵ and R⁶ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁸ is hydrogen, halogen, -OR^b, -NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

R⁹ and R¹⁰ are independently hydrogen, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

R¹¹ is halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -OC(=O)NR¹⁵R¹⁶, -NR¹³C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, -NR¹³C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a};

R¹² is hydrogen, halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -OC(=O)NR¹⁵R¹⁶, -NR¹³C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, -NR¹³C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl,

C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{12a};

or R¹¹ and R¹² are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b};

each R^{11a}, R^{11b}, and R^{12a} is independently oxo (when feasible), halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -OC(=O)NR¹⁵R¹⁶, -NR¹³C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, -NR¹³C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c};

each R^{11c} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

each R¹³ is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a};

each R¹⁴ is independently C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{14a};

each R¹⁵ and R¹⁶ is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{15a};

or R¹⁵ and R¹⁶ are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b};

each R^{13a}, R^{14a}, R^{15a}, and R^{15b} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

R^{21} and R^{22} are independently hydrogen, C_1 - C_{20} alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), C_1 - C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a} ;

or R^{21} and R^{22} are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b} ;

each R^{21a} and R^{21b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);


each R^a is independently C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

each R^b is independently hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; and


each R^c and R^d is independently hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

provided that the compound is not:




[0088] In some embodiments provided herein is a compound having the structure of Formula (II), or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof:



Formula (II);

wherein:



Ring A is

Q^1 is N and Q^2 is CW or Q^1 is N and Q^2 is N;

Q^3 and Q^4 are independently N or CW; provided that at least one of Q^3 or Q^4 is N;

each W is independently hydrogen, halogen, or C_1 - C_6 alkyl;

A is -O-;

X is -O-;

R^1 and R^2 are independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, cycloalkyl, heterocycloalkyl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a} ;

each R^{1a} is independently oxo (when feasible) halogen, -CN, -OR^b, C_1 - C_6 alkyl, or C_1 - C_6 fluoroalkyl;

R^3 is halogen, -OR^b, C_1 - C_6 alkyl, C_2 - C_6 alkynyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, or C_1 - C_6 heteroalkyl;

wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{3a} ;

each R^{3a} is independently oxo (when feasible) halogen, or -OR^b;

R^4 and R^7 are independently hydrogen, halogen, or -OR^b;

R^5 and R^6 are independently hydrogen, halogen, or C_1 - C_6 alkyl;

R^8 is hydrogen;

R^9 and R^{10} are hydrogen;

R^{11} is halogen, -CN, -OR¹³, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -C(=O)OR¹³, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} ;

R^{12} is hydrogen, halogen, -OR¹³, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkynyl, or C_1 - C_6 heteroalkyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{12a} ;

or R^{11} and R^{12} are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b} ;

each R^{11a} , R^{11b} , and R^{12a} is independently oxo (when feasible), halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} ;

each R^{11c} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

each R^{13} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a} ;

each R^{14} is independently C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{14a} ;

each R^{15} and R^{16} is independently hydrogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{15a} ;

or R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b} ;

each R^{13a} , R^{14a} , R^{15a} , and R^{15b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

R^{21} and R^{22} are independently hydrogen, or C_1 - C_{20} alkyl;


each R^a is independently C_1 - C_6 alkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

each R^b is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; and

each R^c and R^d is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;


or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.

[0089] In some embodiments provided herein is a compound having the structure of Formula (II), or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof:



Formula (II);

wherein:



Ring A is ;

Q^1 is N and Q^2 is CW or Q^1 is N and Q^2 is N;

Q^3 and Q^4 are independently N or CW; provided that at least one of Q^3 or Q^4 is N;

each W is hydrogen;

A is -O-;

X is -O-;

R^1 and R^2 are independently hydrogen, C_1 - C_6 alkyl, cycloalkyl, C_1 - C_6 alkyl(aryl), or C_1 - C_6 alkyl(cycloalkyl);

wherein each alkyl, cycloalkyl, and aryl is independently optionally substituted with one, two, or three

R^{1a} ;

each R^{1a} is independently halogen or C_1 - C_6 alkyl;

R^3 is halogen, -OR^b, C_2 - C_6 alkynyl, or C_1 - C_6 hydroxyalkyl; wherein each alkyl and alkynyl is independently

optionally substituted with one, two, or three R^{3a} ;

each R^{3a} is independently oxo (when feasible) halogen, or -OR^b;

R^4 and R^7 are independently hydrogen, halogen, or -OR^b;

R^5 and R^6 are independently hydrogen, halogen, or C_1 - C_6 alkyl;

R^8 is hydrogen;

R^9 and R^{10} are hydrogen;

R^{11} is -CN, -S(=O)₂R¹⁴, -C(=O)OR¹³, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkynyl, or heteroaryl; wherein each alkyl, alkynyl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} ;

R^{12} is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 hydroxyalkyl, or C_2 - C_6 alkynyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{12a} ;

or R^{11} and R^{12} are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b} ;

each R^{11a} , R^{11b} , and R^{12a} is independently oxo (when feasible), halogen, $-OR^{13}$, $-SR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)OR^{13}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, heterocycloalkyl, aryl, or heteroaryl; wherein each heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} ;

each R^{11c} is independently $-OR^b$, $-C(=O)OR^b$, or C_1 - C_6 hydroxyalkyl;

each R^{13} is independently C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, or cycloalkyl; wherein each alkyl and cycloalkyl is independently optionally substituted with one, two, or three R^{13a} ;

each R^{14} is independently C_1 - C_6 alkyl;

each R^{15} and R^{16} is independently hydrogen or C_1 - C_6 alkyl;

each R^{13a} is independently $-OR^b$, $-C(=O)OR^b$, cycloalkyl, aryl, or heteroaryl;

R^{21} and R^{22} are hydrogen;


each R^a is independently C_1 - C_6 alkyl optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

each R^b is independently hydrogen or C_1 - C_6 alkyl optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; and

each R^c and R^d is independently hydrogen or C_1 - C_6 alkyl optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;


or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.

[0090] In some embodiments provided herein is a compound having the structure of Formula (II), or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof:



Formula (II);

wherein:



Ring A is

Q^1 is N and Q^2 is CW or Q^1 is N and Q^2 is N;

Q^3 and Q^4 are N;

W is hydrogen;

A is $-O-$;

X is $-O-$;

R¹ is cycloalkyl or C₁-C₆ alkyl(cycloalkyl);

R² hydrogen;

R³ is halogen or C₁-C₆ hydroxyalkyl;

R⁴ and R⁷ are independently -OR^b;

R⁵ and R⁶ hydrogen;

R⁸ is hydrogen;

R⁹ and R¹⁰ are hydrogen;

R¹¹ is C₁-C₆ alkyl or C₁-C₆ hydroxyalkyl; wherein each alkyl is independently optionally substituted with one R^{11a};

R¹² is C₁-C₆ alkyl or C₁-C₆ hydroxyalkyl;

each R^{11a} is -OR¹³ or heteroaryl;

R¹³ is C₁-C₆ alkyl;

R²¹ and R²² are hydrogen;

each R^a is independently C₁-C₆ alkyl optionally substituted with one, two, or three halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

each R^b is independently hydrogen or C₁-C₆ alkyl optionally substituted with one, two, or three halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl; and

each R^c and R^d is independently hydrogen or C₁-C₆ alkyl optionally substituted with one, two, or three halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.

[0091] In some embodiments of a compound of Formula (II), Q¹ is N and Q² is CW. In some embodiments of a compound of Formula (II), Q¹ is N and Q² is N.

[0092] In some embodiments of a compound of Formula (II), Q³ is N and Q⁴ is CW. In some embodiments of a compound of Formula (II), Q⁴ is N and Q³ is CW. In some embodiments of a compound of Formula (II), Q³ is N and Q⁴ is N.

[0093] In some embodiments of a compound of Formula (II), Q¹ is N, Q² is CW, Q³ is N, and Q⁴ is CW. In some embodiments of a compound of Formula (II), Q¹ is N, Q² is CW, Q³ is CW, and Q⁴ is N. In some embodiments of a compound of Formula (II), Q¹ is N, Q² is CW, Q³ is N, and Q⁴ is N. In some embodiments of a compound of Formula (II), Q¹ is N, Q² is N, Q³ is N, and Q⁴ is CW. In some embodiments of a compound of Formula (II), Q¹ is N, Q² is N, Q³ is CW, and Q⁴ is N. In some embodiments of a compound of Formula (II), Q¹ is N, Q² is N, Q³ is N, and Q⁴ is N.

[0094] In some embodiments of a compound of Formula (II), each W is independently hydrogen, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl. In some embodiments of a compound of Formula (II), each W is independently hydrogen, halogen, or C₁-C₆ alkyl. In some embodiments of a compound of Formula (II), each W is hydrogen.

[0095] In some embodiments of a compound of Formula (II), R^3 is halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1-C_6 alkyl, C_2-C_6 alkynyl, C_1-C_6 haloalkyl, C_1-C_6 hydroxyalkyl, C_1-C_6 heteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, alkynyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R^{3a} . In some embodiments of a compound of Formula (II), R^3 is halogen, C_1-C_6 alkyl, C_2-C_6 alkynyl, C_1-C_6 hydroxyalkyl, or C_1-C_6 heteroalkyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{3a} . In some embodiments of a compound of Formula (II), R^3 is halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 hydroxyalkyl, C_1-C_6 heteroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), R^3 is halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 hydroxyalkyl, C_1-C_6 heteroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), R^3 is halogen, or C_1-C_6 hydroxyalkyl, C_1-C_6 heteroalkyl. In some embodiments of a compound of Formula (II), R^3 is halogen. In some embodiments of a compound of Formula (II), R^3 is halogen, $-OR^b$, C_1-C_6 alkyl, C_2-C_6 alkynyl, C_1-C_6 haloalkyl, C_1-C_6 hydroxyalkyl, or C_1-C_6 heteroalkyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{3a} . In some embodiments of a compound of Formula (II), R^3 is halogen, $-OR^b$, C_2-C_6 alkynyl, or C_1-C_6 hydroxyalkyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{3a} . In some embodiments of a compound of Formula (II), R^3 is halogen or C_1-C_6 hydroxyalkyl.

[0096] In some embodiments of a compound of Formula (II), each R^{3a} is independently oxo (when feasible) halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), each R^{3a} is independently oxo (when feasible) halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), each R^{3a} is independently oxo (when feasible) halogen, C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), each R^{3a} is independently oxo (when feasible) halogen, C_1-C_6 alkyl, or C_1-C_6 fluoroalkyl. In some embodiments of a compound of Formula (II), each R^{3a} is independently halogen or C_1-C_6 alkyl. In some embodiments of a compound of Formula (II), each R^{3a} is independently halogen, $-OR^b$, C_1-C_6 alkyl, or cycloalkyl. In some embodiments of a compound of Formula (II), each R^{3a} is independently oxo (when feasible) halogen, or $-OR^b$.

[0097] In some embodiments of a compound of Formula (II), R^1 is C_1-C_6 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6 alkyl(aryl), C_1-C_6 alkyl(heteroaryl), C_1-C_6 alkyl(cycloalkyl), or C_1-C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a} . In some embodiments of a compound of Formula (II), R^1 is C_1-C_6 alkyl, cycloalkyl, heterocycloalkyl, C_1-C_6 alkyl(aryl), C_1-C_6 alkyl(heteroaryl), C_1-C_6 alkyl(cycloalkyl), or C_1-C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a} . In some embodiments of a compound of Formula (II), R^1 is cycloalkyl or C_1-C_6 alkyl(cycloalkyl); wherein each alkyl and cycloalkyl is independently optionally substituted with one, two, or three R^{1a} . In some embodiments of a

compound of Formula (II), R^1 is cycloalkyl optionally substituted with one, two, or three R^{1a} . In some embodiments of a compound of Formula (II), R^1 is C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, cycloalkyl, heterocycloalkyl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a} . In some embodiments of a compound of Formula (II), R^1 is C_1 - C_6 alkyl, cycloalkyl, C_1 - C_6 alkyl(aryl), or C_1 - C_6 alkyl(cycloalkyl); wherein each alkyl, cycloalkyl, and aryl is independently optionally substituted with one, two, or three R^{1a} . In some embodiments of a compound of Formula (II), R^1 is cycloalkyl or C_1 - C_6 alkyl(cycloalkyl).

[0098] In some embodiments of a compound of Formula (II), each R^{1a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), each R^{1a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), each R^{1a} is independently oxo (when feasible) halogen, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), each R^{1a} is independently oxo (when feasible) halogen, C_1 - C_6 alkyl, or C_1 - C_6 fluoroalkyl. In some embodiments of a compound of Formula (II), each R^{1a} is independently halogen or C_1 - C_6 alkyl. In some embodiments of a compound of Formula (II), each R^{1a} is independently oxo (when feasible) halogen, -CN, -OR^b, C_1 - C_6 alkyl, or C_1 - C_6 fluoroalkyl. In some embodiments of a compound of Formula (II), each R^{1a} is independently halogen or C_1 - C_6 alkyl.

[0099] In some embodiments of a compound of Formula (II), R^2 is hydrogen or C_1 - C_6 alkyl. In some embodiments of a compound of Formula (II), R^2 is hydrogen. In some embodiments of a compound of Formula (II), R^1 and R^2 are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{1b} .

[00100] In some embodiments of a compound of Formula (II), each R^{1b} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), each R^{1b} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), each R^{1b} is independently oxo (when feasible) halogen, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), each R^{1b} is independently oxo (when feasible) halogen, C_1 - C_6 alkyl, or C_1 - C_6 fluoroalkyl. In some embodiments of a compound of Formula (II), each R^{1b} is independently halogen or C_1 - C_6 alkyl.

[00101] In some embodiments of a compound of Formula (II), R^8 is hydrogen or C_1 - C_6 alkyl. In some embodiments of a compound of Formula (II), R^8 is hydrogen.

[00102] In some embodiments of a compound of Formula (II), R^9 and R^{10} are independently hydrogen or C_1 - C_6 alkyl. In some embodiments of a compound of Formula (II), R^9 and R^{10} are hydrogen.

[00103] In some embodiments of a compound of Formula (II), X is -O-. In some embodiments of a compound of Formula (II), X is -S-.

[00104] In some embodiments of a compound of Formula (II), R⁵ and R⁶ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, or C₁-C₆ haloalkyl. In some embodiments of a compound of Formula (II), R⁵ and R⁶ are independently hydrogen, halogen, -OR^b, or C₁-C₆ alkyl. In some embodiments of a compound of Formula (II), R⁵ and R⁶ are hydrogen.

[00105] In some embodiments of a compound of Formula (II), R⁴ and R⁷ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, or C₁-C₆ haloalkyl. In some embodiments of a compound of Formula (II), R⁴ and R⁷ are independently hydrogen, halogen, -OR^b, or C₁-C₆ alkyl. In some embodiments of a compound of Formula (II), R⁴ and R⁷ are independently hydrogen, halogen, or -OR^b. In some embodiments of a compound of Formula (II), R⁴ and R⁷ are independently hydrogen, halogen, or -OH. In some embodiments of a compound of Formula (II), R⁴ and R⁷ are independently halogen or -OH. In some embodiments of a compound of Formula (II), R⁴ and R⁷ are independently hydrogen or -OH. In some embodiments of a compound of Formula (II), R⁴ and R⁷ are -OH.

[00106] In some embodiments of a compound of Formula (II), R⁵ and R⁶ are hydrogen and R⁴ and R⁷ are -OH. In some embodiments of a compound of Formula (II), R⁵ and R⁶ are hydrogen and R⁴ and R⁷ are independently halogen or -OH. In some embodiments of a compound of Formula (II), R⁵ and R⁶ are hydrogen and R⁴ and R⁷ are independently hydrogen or -OH.

[00107] In some embodiments of a compound of Formula (II), R²¹ and R²² are independently hydrogen, C₁-C₂₀ alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a}. In some embodiments of a compound of Formula (II), R²¹ and R²² are independently hydrogen, C₁-C₂₀ alkyl or aryl; wherein each alkyl and aryl is independently optionally substituted with one, two, or three R^{21a}. In some embodiments of a compound of Formula (II), R²¹ and R²² are independently hydrogen, C₁-C₂₀ alkyl optionally substituted with one, two, or three R^{21a}. In some embodiments of a compound of Formula (II), R²¹ and R²² are hydrogen.

[00108] In some embodiments of a compound of Formula (II), each R^{21a} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, or C₁-C₆ alkyl. In some embodiments of a compound of Formula (II), each R^{21a} is independently -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, or -OC(=O)NR^cR^d. In some embodiments of a compound of Formula (II), each R^{21a} is independently -C(=O)OR^b or -OC(=O)OR^b.

[00109] In some embodiments of a compound of Formula (II), R²¹ and R²² are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b}.

[00110] In some embodiments of a compound of Formula (II), each R^{21b} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -OC(=O)NR^cR^d, -

$\text{NR}^b\text{C}(=\text{O})\text{NR}^c\text{R}^d$, $-\text{NR}^b\text{C}(=\text{O})\text{R}^a$, $-\text{NR}^b\text{C}(=\text{O})\text{OR}^b$, $\text{C}_1\text{-C}_6$ alkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), each R^{21b} is independently halogen, $-\text{CN}$, $-\text{OR}^b$, $-\text{NR}^c\text{R}^d$, $\text{C}_1\text{-C}_6$ alkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), each R^{21b} is independently halogen or $\text{C}_1\text{-C}_6$ alkyl.

[00111] In some embodiments of a compound of Formula (II), R^{12} is hydrogen, halogen, $-\text{CN}$, $-\text{OR}^{13}$, $-\text{NR}^{15}\text{R}^{16}$, $-\text{C}(=\text{O})\text{R}^{14}$, $-\text{C}(=\text{O})\text{OR}^{13}$, $-\text{C}(=\text{O})\text{NR}^{15}\text{R}^{16}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), R^{12} is halogen, $-\text{CN}$, $-\text{OR}^{13}$, $-\text{NR}^{15}\text{R}^{16}$, $-\text{C}(=\text{O})\text{R}^{14}$, $-\text{C}(=\text{O})\text{OR}^{13}$, $-\text{C}(=\text{O})\text{NR}^{15}\text{R}^{16}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), R^{12} is hydrogen, halogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, or $\text{C}_1\text{-C}_6$ hydroxyalkyl. In some embodiments of a compound of Formula (II), R^{12} is $\text{C}_1\text{-C}_6$ alkyl. In some embodiments of a compound of Formula (II), R^{12} is $\text{C}_1\text{-C}_6$ hydroxyalkyl. In some embodiments of a compound of Formula (II), R^{12} is hydrogen. In some embodiments of a compound of Formula (II), R^{12} is not hydrogen. In some embodiments of a compound of Formula (II), R^{12} is hydrogen, halogen, $-\text{OR}^{13}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, $\text{C}_2\text{-C}_6$ alkynyl, or $\text{C}_1\text{-C}_6$ heteroalkyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{12a} . In some embodiments of a compound of Formula (II), R^{12} is hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, or $\text{C}_2\text{-C}_6$ alkynyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{12a} .

[00112] In some embodiments of a compound of Formula (II), each R^{12a} is independently halogen, $-\text{CN}$, $-\text{OR}^{13}$, $-\text{NR}^{15}\text{R}^{16}$, $-\text{S}(=\text{O})_2\text{R}^{14}$, $-\text{NR}^{14}\text{S}(=\text{O})_2\text{R}^{14}$, $-\text{S}(=\text{O})_2\text{NR}^{15}\text{R}^{16}$, $-\text{C}(=\text{O})\text{R}^{14}$, $-\text{OC}(=\text{O})\text{R}^{14}$, $-\text{C}(=\text{O})\text{OR}^{13}$, $-\text{C}(=\text{O})\text{NR}^{15}\text{R}^{16}$, $-\text{NR}^{13}\text{C}(=\text{O})\text{R}^{14}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (II), each R^{12a} is independently halogen, $-\text{CN}$, $-\text{OR}^{13}$, $-\text{NR}^{15}\text{R}^{16}$, $-\text{S}(=\text{O})_2\text{R}^{14}$, $-\text{NR}^{14}\text{S}(=\text{O})_2\text{R}^{14}$, $-\text{S}(=\text{O})_2\text{NR}^{15}\text{R}^{16}$, $-\text{C}(=\text{O})\text{R}^{14}$, $-\text{OC}(=\text{O})\text{R}^{14}$, $-\text{C}(=\text{O})\text{OR}^{13}$, $-\text{C}(=\text{O})\text{NR}^{15}\text{R}^{16}$, $-\text{NR}^{13}\text{C}(=\text{O})\text{R}^{14}$, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (II), each R^{12a} is independently $-\text{OR}^{13}$, $-\text{S}(=\text{O})_2\text{R}^{14}$, $-\text{NR}^{13}\text{C}(=\text{O})\text{R}^{14}$, cycloalkyl, aryl, or heteroaryl; wherein each cycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (II), each R^{12a} is independently oxo (when feasible), halogen, $-\text{CN}$, $-\text{OR}^{13}$, $-\text{SR}^{13}$, $-\text{S}(=\text{O})\text{R}^{14}$, $-\text{NR}^{15}\text{R}^{16}$, $-\text{S}(=\text{O})_2\text{R}^{14}$, $-\text{NR}^{13}\text{S}(=\text{O})_2\text{R}^{14}$, $-\text{S}(=\text{O})_2\text{NR}^{15}\text{R}^{16}$, $-\text{C}(=\text{O})\text{R}^{14}$, $-\text{C}(=\text{O})\text{OR}^{13}$, $-\text{C}(=\text{O})\text{NR}^{15}\text{R}^{16}$, $-\text{OC}(=\text{O})\text{NR}^{15}\text{R}^{16}$, $-\text{NR}^{13}\text{C}(=\text{O})\text{R}^{14}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (II), each R^{12a} is independently oxo (when feasible), halogen, $-\text{OR}^{13}$, $-\text{SR}^{13}$, $-\text{NR}^{15}\text{R}^{16}$, $-\text{S}(=\text{O})_2\text{R}^{14}$, $-\text{NR}^{13}\text{S}(=\text{O})_2\text{R}^{14}$, $-\text{S}(=\text{O})_2\text{NR}^{15}\text{R}^{16}$, $-\text{C}(=\text{O})\text{OR}^{13}$, $-\text{OC}(=\text{O})\text{NR}^{15}\text{R}^{16}$, $-\text{NR}^{13}\text{C}(=\text{O})\text{R}^{14}$, heterocycloalkyl, aryl, or heteroaryl;

wherein each heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} .

[00113] In some embodiments of a compound of Formula (II), R^{11} is halogen, $-CN$, $-OR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-C(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} . In some embodiments of a compound of Formula (II), R^{11} is halogen, $-CN$, $-S(=O)_2R^{14}$, $-C(=O)R^{14}$, $-C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} . In some embodiments of a compound of Formula (II), R^{11} is $-CN$, $-S(=O)_2R^{14}$, $-C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, or heteroaryl; wherein each alkyl and heteroaryl is independently optionally substituted with one, two, or three R^{11a} . In some embodiments of a compound of Formula (II), R^{11} is C_1 - C_6 alkyl optionally substituted with one, two, or three R^{11a} . In some embodiments of a compound of Formula (II), R^{11} is C_1 - C_6 alkyl substituted with one R^{11a} . In some embodiments of a compound of Formula (II), R^{11} is C_1 - C_6 hydroxyalkyl. In some embodiments of a compound of Formula (II), R^{11} is halogen, $-CN$, $-OR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} . In some embodiments of a compound of Formula (II), R^{11} is $-CN$, $-S(=O)_2R^{14}$, $-C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkynyl, or heteroaryl; wherein each alkyl, alkynyl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} . In some embodiments of a compound of Formula (II), R^{11} is C_1 - C_6 alkyl or C_1 - C_6 hydroxyalkyl; wherein each alkyl is independently optionally substituted with one R^{11a} .

[00114] In some embodiments of a compound of Formula (II), each R^{11a} is independently halogen, $-CN$, $-OR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{14}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (II), each R^{11a} is independently halogen, $-CN$, $-OR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{14}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (II), each R^{11a} is independently $-OR^{13}$, $-S(=O)_2R^{14}$, $-NR^{13}C(=O)R^{14}$, cycloalkyl, aryl, or heteroaryl; wherein each cycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (II), each R^{11a} is independently aryl optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (II), each R^{11a} is independently $-OR^{13}$. In some embodiments of a compound of Formula (II), each R^{11a} is

independently $-S(=O)_2R^{14}$. In some embodiments of a compound of Formula (II), each R^{11a} is independently cycloalkyl optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (II), each R^{11a} is independently $-NR^{13}C(=O)R^{14}$. In some embodiments of a compound of Formula (II), each R^{11a} is independently oxo (when feasible), halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (II), each R^{11a} is independently oxo (when feasible), halogen, $-OR^{13}$, $-SR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)OR^{13}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, heterocycloalkyl, aryl, or heteroaryl; wherein each heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (II), each R^{11a} is independently $-OR^{13}$ or heteroaryl.

[00115] In some embodiments of a compound of Formula (II), each R^{11c} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (II), each R^{11c} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, or C_1 - C_6 hydroxyalkyl. In some embodiments of a compound of Formula (II), each R^{11c} is independently halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (II), each R^{11c} is independently halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (II), each R^{11c} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl. In some embodiments of a compound of Formula (II), each R^{11c} is independently $-OR^b$, $-C(=O)OR^b$, or C_1 - C_6 hydroxyalkyl.

[00116] In some embodiments of a compound of Formula (II), R^{11} and R^{12} are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b} . In some embodiments of a compound of Formula (II), R^{11} and R^{12} are taken together to form a cycloalkyl optionally substituted with one, two, or three R^{11b} . In some embodiments of a compound of Formula (II), R^{11} and R^{12} are taken together to form a heterocycloalkyl optionally substituted with one, two, or three R^{11b} .

[00117] In some embodiments of a compound of Formula (II), each R^{11b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (II), each R^{11b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (II), each R^{11b} is independently oxo (when feasible), halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.

[00118] In some embodiments of a compound of Formula (II), each R^{13} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl,

cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R^{13a} . In some embodiments of a compound of Formula (II), each R^{13} is independently hydrogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{13a} . In some embodiments of a compound of Formula (II), each R^{13} is independently hydrogen or C_1 - C_6 alkyl. In some embodiments of a compound of Formula (II), each R^{13} is independently C_1 - C_6 alkyl. In some embodiments of a compound of Formula (II), each R^{13} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a} . In some embodiments of a compound of Formula (II), each R^{13} is independently C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, or cycloalkyl; wherein each alkyl and cycloalkyl is independently optionally substituted with one, two, or three R^{13a} .

[00119] In some embodiments of a compound of Formula (II), each R^{13a} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), each R^{13a} is independently halogen, -CN, -OR^b, -NR^cR^d, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), each R^{13a} is independently halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (II), each R^{13a} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (II), each R^{13a} is independently -OR^b, -C(=O)OR^b, cycloalkyl, aryl, or heteroaryl; wherein each cycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (II), each R^{13a} is independently -OR^b, -C(=O)OR^b, cycloalkyl, aryl, or heteroaryl.

[00120] In some embodiments of a compound of Formula (II), each R^{14} is independently C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R^{14a} . In some embodiments of a compound of Formula (II), each R^{14} is independently C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{14a} . In some embodiments of a compound of Formula (II), each R^{14} is independently C_1 - C_6 alkyl.

[00121] In some embodiments of a compound of Formula (II), each R^{14a} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), each R^{14a} is independently halogen, -CN, -OR^b, -NR^cR^d, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), each R^{14a} is independently halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.


[00122] In some embodiments of a compound of Formula (II), each R^{15} and R^{16} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R^{15a} . In some embodiments of a compound of Formula (II), each R^{15} and R^{16} is independently hydrogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{15a} . In some embodiments of a compound of Formula (II), each R^{15} and R^{16} is independently hydrogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{15a} . In some embodiments of a compound of Formula (II), each R^{15} and R^{16} is independently hydrogen or C_1 - C_6 alkyl.

[00123] In some embodiments of a compound of Formula (II), each R^{15a} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), each R^{15a} is independently halogen, -CN, -OR^b, -NR^cR^d, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), each R^{15a} is independently halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.

In some embodiments of a compound of Formula (II), R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b} . In some embodiments of a compound of Formula (II), R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl.


[00124] In some embodiments of a compound of Formula (II), each R^{15b} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), each R^{15b} is independently halogen, -CN, -OR^b, -NR^cR^d, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (II), each R^{15b} is independently halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.

[00125] In some embodiments provided herein is a compound having the structure of Formula (III), or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof:



Formula (III);

wherein:



Ring A is

Q^1 is CW and Q^2 is N;

Q^3 and Q^4 are independently N or CW; provided that at least one of Q^3 or Q^4 is N;

each W is independently hydrogen, halogen, -CN, -OR^b, NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

A is -O- or -CH₂-;

X is -O-, -S-, or -S(=O)₂-;

R¹ and R² are independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a}, or R¹ and R² are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{1b};

each R^{1a} and R^{1b} is independently oxo (when feasible) halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

R³ is hydrogen, halogen, -CN, -OR^b, -SR^b, -NR^cR^d, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{3a};

each R^{3a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁴ and R⁷ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁵ and R⁶ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁸ is hydrogen, halogen, -OR^b, -NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

R⁹ and R¹⁰ are independently hydrogen, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

R¹¹ is halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -OC(=O)NR¹⁵R¹⁶, -NR¹³C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, -NR¹³C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl,

or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} ,

R^{12} is hydrogen, halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{12a} ,

or R^{11} and R^{12} are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b} ;

each R^{11a} , R^{11b} , and R^{12a} is independently oxo (when feasible), halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} ;

each R^{11c} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

each R^{13} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a} ;

each R^{14} is independently C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{14a} ;

each R^{15} and R^{16} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{15a} ;

or R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b} ;

each R^{13a} , R^{14a} , R^{15a} , and R^{15b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6 alkyl(aryl), C_1-C_6 alkyl(heteroaryl), C_1-C_6 alkyl(cycloalkyl), or C_1-C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-CN$, $-OR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl;

R^{21} and R^{22} are independently hydrogen, C_1-C_{20} alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6 alkyl(aryl), C_1-C_6 alkyl(heteroaryl), C_1-C_6 alkyl(cycloalkyl), C_1-C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a} ,

or R^{21} and R^{22} are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b} ;

each R^{21a} and R^{21b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6 alkyl(aryl), C_1-C_6 alkyl(heteroaryl), C_1-C_6 alkyl(cycloalkyl), or C_1-C_6 alkyl(heterocycloalkyl);


each R^a is independently C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1-C_6 alkyl, or C_1-C_6 haloalkyl;

each R^b is independently hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1-C_6 alkyl, or C_1-C_6 haloalkyl; and

each R^c and R^d is independently hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1-C_6 alkyl, or C_1-C_6 haloalkyl;


or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, C_1-C_6 alkyl, or C_1-C_6 haloalkyl.

[00126] In some embodiments provided herein is a compound having the structure of Formula (III), or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof:



Formula (III);

wherein:



Ring A is

Q^1 is CW and Q^2 is N;

Q^3 and Q^4 are independently N or CW; provided that at least one of Q^3 or Q^4 is N;

each W is independently hydrogen, halogen, -CN, -OR^b, NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

A is -O- or -CH₂-;

X is -O-, -S-, or -S(=O)₂-;

R¹ and R² are independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,

cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl,

heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a},

or R¹ and R² are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{1b};

each R^{1a} and R^{1b} is independently oxo (when feasible) halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

R³ is hydrogen, halogen, -CN, -OR^b, -SR^b, -NR^cR^d, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{3a};

each R^{3a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁴ and R⁷ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^5 and R^6 are independently hydrogen, halogen, $-OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^8 is hydrogen, halogen, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

R^9 and R^{10} are independently hydrogen, halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

R^{11} is halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} ;

R^{12} is hydrogen, halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{12a} ;

or R^{11} and R^{12} are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b} ;

each R^{11a} , R^{11b} , and R^{12a} is independently oxo (when feasible), halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} ;

each R^{11c} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

each R^{13} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a} ;

each R^{14} is independently C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl,

heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{14a} ;

each R^{15} and R^{16} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{15a} ;

or R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b} ;

each R^{13a} , R^{14a} , R^{15a} , and R^{15b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

R^{21} and R^{22} are independently hydrogen, C_1 - C_{20} alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), C_1 - C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a} ;

or R^{21} and R^{22} are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b} ;

each R^{21a} and R^{21b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);


each R^a is independently C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

each R^b is independently hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; and

each R^c and R^d is independently hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;


or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.

[00127] In some embodiments provided herein is a compound having the structure of Formula (III), or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof:



Formula (III);

wherein:



Ring A is ;

Q^1 is CW and Q^2 is N;

Q^3 and Q^4 are independently N or CW; provided that at least one of Q^3 or Q^4 is N;

each W is independently hydrogen, halogen, -CN, -OR^b, NR^cR^d, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

A is -O- or -CH₂-;

X is -O-, -S-, or -S(=O)₂-;

R^1 and R^2 are independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl,

cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6

alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl,

heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a} ;

or R^1 and R^2 are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{1b} ;

each R^{1a} and R^{1b} is independently oxo (when feasible) halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -

S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -

C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C_1 - C_6 alkyl, C_1 - C_6

fluoroalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6

alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

R^3 is hydrogen, halogen, -CN, -OR^b, -SR^b, -NR^cR^d, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6

heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 -

C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

R^4 and R^7 are independently hydrogen, halogen, -OR^b, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6

alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^5 and R^6 are independently hydrogen, halogen, $-OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^8 is hydrogen, halogen, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

R^9 and R^{10} are independently hydrogen, halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

R^{11} is halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} ;

R^{12} is hydrogen, halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{12a} ;

or R^{11} and R^{12} are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b} ;

each R^{11a} , R^{11b} , and R^{12a} is independently oxo (when feasible), halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} ;

each R^{11c} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

each R^{13} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a} ;

each R^{14} is independently C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl,

heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{14a} ;

each R^{15} and R^{16} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{15a} ;

or R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b} ;

each R^{13a} , R^{14a} , R^{15a} , and R^{15b} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

R^{21} and R^{22} are independently hydrogen, C_1 - C_{20} alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), C_1 - C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a} ;

or R^{21} and R^{22} are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b} ;


each R^{21a} and R^{21b} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

each R^a is independently C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

each R^b is independently hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; and


each R^c and R^d is independently hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.



Formula (III);

wherein:



Ring A is

Q^1 is CW and Q^2 is N;

Q^3 and Q^4 are independently N or CW; provided that at least one of Q^3 or Q^4 is N;

each W is independently hydrogen, halogen, -CN, -OR^b, NR^cR^d, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

A is -O- or -CH₂-;

X is -O-, -S-, or -S(=O)₂-;

R^1 and R^2 are independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a} , provided that one of R^1 or R^2 is not hydrogen;

or R^1 and R^2 are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{1b} ;

each R^{1a} and R^{1b} is independently oxo (when feasible) halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

R^3 is halogen, -CN, -OR^b, -SR^b, -NR^cR^d, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{3a} ;

each R^{3a} is independently oxo (when feasible) halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^4 and R^7 are independently hydrogen, halogen, $-OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^5 and R^6 are independently hydrogen, halogen, $-OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^8 is hydrogen, halogen, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

R^9 and R^{10} are independently hydrogen, halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

R^{11} is halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-OC(=O)OR^{13}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} ; provided that R^{11} is not CF_3 ;

R^{12} is hydrogen, halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{12a} ;

or R^{11} and R^{12} are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b} ;

each R^{11a} , R^{11b} , and R^{12a} is independently oxo (when feasible), halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} ;

each R^{11c} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

each R^{13} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl,

cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a};

each R¹⁴ is independently C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{14a};

each R¹⁵ and R¹⁶ is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{15a};

or R¹⁵ and R¹⁶ are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b};

each R^{13a}, R^{14a}, R^{15a}, and R^{15b} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -CN, -OR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl;

R²¹ and R²² are independently hydrogen, C₁-C₂₀ alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a};

or R²¹ and R²² are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b};

each R^{21a} and R^{21b} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

each R^a is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

each R^b is independently hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; and

each R^c and R^d is independently hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.

[00128] In some embodiments of a compound of Formula (III), Q^3 is N and Q^4 is CW. In some embodiments of a compound of Formula (III), Q^4 is N and Q^3 is CW. In some embodiments of a compound of Formula (III), Q^3 is N and Q^4 is N.

[00129] In some embodiments of a compound of Formula (III), each W is independently hydrogen, halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (III), each W is independently hydrogen, halogen, or C_1 - C_6 alkyl. In some embodiments of a compound of Formula (III), each W is hydrogen.

[00130] In some embodiments of a compound of Formula (III), R^3 is halogen, -CN, -OR^b, -NR^cR^d, C_1 - C_6 alkyl, C_2 - C_6 alkynyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, alkynyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R^{3a} . In some embodiments of a compound of Formula (III), R^3 is halogen, C_1 - C_6 alkyl, C_2 - C_6 alkynyl, C_1 - C_6 hydroxyalkyl, or C_1 - C_6 heteroalkyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{3a} .

[00131] In some embodiments of a compound of Formula (III), R^3 is halogen, -CN, -OR^b, -NR^cR^d, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), R^3 is halogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), R^3 is halogen, or C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl. In some embodiments of a compound of Formula (III), R^3 is halogen. In some embodiments of a compound of Formula (III), R^3 is not hydrogen.

[00132] In some embodiments of a compound of Formula (III), each R^{3a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), each R^{3a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), each R^{3a} is independently oxo (when feasible) halogen, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), each R^{3a} is independently oxo (when feasible) halogen, C_1 - C_6

alkyl, or C₁-C₆ fluoroalkyl. In some embodiments of a compound of Formula (III), each R^{3a} is independently halogen or C₁-C₆ alkyl. In some embodiments of a compound of Formula (III), each R^{3a} is independently halogen, -OR^b, C₁-C₆ alkyl, or cycloalkyl.

[00133] In some embodiments of a compound of Formula (III), R¹ is C₁-C₆ alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a}. In some embodiments of a compound of Formula (III), R¹ is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a}. In some embodiments of a compound of Formula (III), R¹ is C₁-C₆ alkyl, cycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), or C₁-C₆ alkyl(cycloalkyl); wherein each alkyl, cycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a}. In some embodiments of a compound of Formula (III), R¹ is C₁-C₆ alkyl, cycloalkyl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), or C₁-C₆ alkyl(cycloalkyl); wherein each alkyl, cycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a}. In some embodiments of a compound of Formula (III), R¹ is C₁-C₆ alkyl, cycloalkyl, heterocycloalkyl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a}. In some embodiments of a compound of Formula (III), R¹ is cycloalkyl or C₁-C₆ alkyl(cycloalkyl); wherein each alkyl and cycloalkyl is independently optionally substituted with one, two, or three R^{1a}. In some embodiments of a compound of Formula (III), R¹ is cycloalkyl optionally substituted with one, two, or three R^{1a}.

[00134] In some embodiments of a compound of Formula (III), each R^{1a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), each R^{1a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), each R^{1a} is independently oxo (when feasible) halogen, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), each R^{1a} is independently oxo (when feasible) halogen, C₁-C₆ alkyl, or C₁-C₆ fluoroalkyl. In some embodiments of a compound of Formula (III), each R^{1a} is independently halogen or C₁-C₆ alkyl.

[00135] In some embodiments of a compound of Formula (III), R² is hydrogen or C₁-C₆ alkyl. In some embodiments of a compound of Formula (III), R² is hydrogen. In some embodiments of a compound of Formula (III), R¹ and R² are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{1b}.

[00136] In some embodiments of a compound of Formula (III), each R^{1b} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl,

cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), each R^{1b} is independently oxo (when feasible) halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), each R^{1b} is independently oxo (when feasible) halogen, C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), each R^{1b} is independently oxo (when feasible) halogen, C_1-C_6 alkyl, or C_1-C_6 fluoroalkyl. In some embodiments of a compound of Formula (III), each R^{1b} is independently halogen or C_1-C_6 alkyl.

[00137] In some embodiments of a compound of Formula (III), R^8 is hydrogen or C_1-C_6 alkyl. In some embodiments of a compound of Formula (III), R^8 is hydrogen.

[00138] In some embodiments of a compound of Formula (III), R^9 and R^{10} are independently hydrogen or C_1-C_6 alkyl. In some embodiments of a compound of Formula (III), R^9 and R^{10} are hydrogen.

[00139] In some embodiments of a compound of Formula (III), X is $-O-$ or $-S-$. In some embodiments of a compound of Formula (III), X is $-O-$. In some embodiments of a compound of Formula (III), X is $-S-$.

[00140] In some embodiments of a compound of Formula (III), A is $-O-$. In some embodiments of a compound of Formula (III), A is $-CH_2-$.

[00141] In some embodiments of a compound of Formula (III), R^5 and R^6 are independently hydrogen, halogen, $-OR^b$, C_1-C_6 alkyl, or C_1-C_6 haloalkyl. In some embodiments of a compound of Formula (III), R^5 and R^6 are independently hydrogen, halogen, $-OR^b$, or C_1-C_6 alkyl. In some embodiments of a compound of Formula (III), R^5 and R^6 are hydrogen.

[00142] In some embodiments of a compound of Formula (III), R^4 and R^7 are independently hydrogen, halogen, $-OR^b$, C_1-C_6 alkyl, or C_1-C_6 haloalkyl. In some embodiments of a compound of Formula (III), R^4 and R^7 are independently hydrogen, halogen, $-OR^b$, or C_1-C_6 alkyl. In some embodiments of a compound of Formula (III), R^4 and R^7 are independently hydrogen, halogen, or $-OR^b$. In some embodiments of a compound of Formula (III), R^4 and R^7 are independently hydrogen, halogen, or $-OH$. In some embodiments of a compound of Formula (III), R^4 and R^7 are independently halogen or $-OH$. In some embodiments of a compound of Formula (III), R^4 and R^7 are independently hydrogen or $-OH$. In some embodiments of a compound of Formula (III), R^4 and R^7 are $-OH$.

[00143] In some embodiments of a compound of Formula (III), R^5 and R^6 are hydrogen and R^4 and R^7 are $-OH$. In some embodiments of a compound of Formula (III), R^5 and R^6 are hydrogen and R^4 and R^7 are independently halogen or $-OH$. In some embodiments of a compound of Formula (III), R^5 and R^6 are hydrogen and R^4 and R^7 are independently hydrogen or $-OH$.

[00144] In some embodiments of a compound of Formula (III), R^{21} and R^{22} are independently hydrogen, C_1-C_{20} alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a} . In some embodiments of a compound of Formula (III), R^{21} and R^{22} are independently hydrogen, C_1-C_{20} alkyl or aryl; wherein each alkyl and aryl is independently optionally substituted with one, two, or three R^{21a} . In

some embodiments of a compound of Formula (III), R^{21} and R^{22} are independently hydrogen, C_1 - C_{20} alkyl optionally substituted with one, two, or three R^{21a} . In some embodiments of a compound of Formula (III), R^{21} and R^{22} are hydrogen.

[00145] In some embodiments of a compound of Formula (III), each R^{21a} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, or C_1 - C_6 alkyl. In some embodiments of a compound of Formula (III), each R^{21a} is independently -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, or -OC(=O)NR^cR^d. In some embodiments of a compound of Formula (III), each R^{21a} is independently -C(=O)OR^b or -OC(=O)OR^b.

[00146] In some embodiments of a compound of Formula (III), R^{21} and R^{22} are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b} .

[00147] In some embodiments of a compound of Formula (III), each R^{21b} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C_1 - C_6 alkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), each R^{21b} is independently halogen, -CN, -OR^b, -NR^cR^d, C_1 - C_6 alkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), each R^{21b} is independently halogen or C_1 - C_6 alkyl.

[00148] In some embodiments of a compound of Formula (III), R^{12} is hydrogen, halogen, -CN, -OR¹³, -NR¹⁵R¹⁶, -C(=O)R¹⁴, -C(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), R^{12} is halogen, -CN, -OR¹³, -NR¹⁵R¹⁶, -C(=O)R¹⁴, -C(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), R^{12} is hydrogen, halogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, or C_1 - C_6 hydroxyalkyl. In some embodiments of a compound of Formula (III), R^{12} is halogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, or C_1 - C_6 hydroxyalkyl. In some embodiments of a compound of Formula (III), R^{12} is C_1 - C_6 alkyl. In some embodiments of a compound of Formula (III), R^{12} is C_1 - C_6 hydroxyalkyl. In some embodiments of a compound of Formula (III), R^{12} is hydrogen. In some embodiments of a compound of Formula (III), R^{12} is not hydrogen.

[00149] In some embodiments of a compound of Formula (III), each R^{12a} is independently halogen, -CN, -OR¹³, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹⁴S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (III), each R^{12a} is independently halogen, -CN, -OR¹³, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹⁴S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each cycloalkyl, heterocycloalkyl, aryl, and

heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (III), each R^{12a} is independently $-OR^{13}$, $-S(=O)_2R^{14}$, $-NR^{13}C(=O)R^{14}$, cycloalkyl, aryl, or heteroaryl; wherein each cycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} .

[00150] In some embodiments of a compound of Formula (III), R^{11} is halogen, $-CN$, $-OR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-C(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} .

[00151] In some embodiments of a compound of Formula (III), R^{11} is halogen, $-CN$, $-OR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-C(=O)R^{14}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} ; provided that R^{11} is not CF_3 .

[00152] In some embodiments of a compound of Formula (III), R^{11} is halogen, $-CN$, $-OR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-C(=O)R^{14}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, or aryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, and aryl is independently optionally substituted with one, two, or three R^{11a} .

[00153] In some embodiments of a compound of Formula (III), R^{11} is halogen, $-CN$, $-OR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-C(=O)R^{14}$, $-C(=O)NR^{15}R^{16}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} .

[00154] In some embodiments of a compound of Formula (III), R^{11} is halogen, $-CN$, $-OR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-C(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, or aryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, and aryl is independently optionally substituted with one, two, or three R^{11a} .

[00155] In some embodiments of a compound of Formula (III), R^{11} is halogen, $-CN$, $-OR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-C(=O)R^{14}$, $-C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} .

[00156] In some embodiments of a compound of Formula (III), R^{11} is halogen, $-CN$, $-S(=O)_2R^{14}$, $-C(=O)R^{14}$, $-C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} .

[00157] In some embodiments of a compound of Formula (III), R^{11} is halogen, $-CN$, $-S(=O)_2R^{14}$, $-C(=O)R^{14}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} , provided that R^{11} is not CF_3 .

[00158] In some embodiments of a compound of Formula (III), R^{11} is halogen, $-\text{CN}$, $-\text{S}(=\text{O})_2R^{14}$, $-\text{C}(=\text{O})R^{14}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, cycloalkyl, heterocycloalkyl, or aryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, and aryl is independently optionally substituted with one, two, or three R^{11a} .

[00159] In some embodiments of a compound of Formula (III), R^{11} is halogen, $-\text{CN}$, $-\text{S}(=\text{O})_2R^{14}$, $-\text{C}(=\text{O})R^{14}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} .

[00160] In some embodiments of a compound of Formula (III), R^{11} is halogen, $-\text{CN}$, $-\text{S}(=\text{O})_2R^{14}$, $-\text{C}(=\text{O})R^{14}$, $-\text{C}(=\text{O})\text{OR}^{13}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, cycloalkyl, heterocycloalkyl, or aryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, and aryl is independently optionally substituted with one, two, or three R^{11a} .

[00161] In some embodiments of a compound of Formula (III), R^{11} is $-\text{CN}$, $-\text{S}(=\text{O})_2R^{14}$, $-\text{C}(=\text{O})\text{OR}^{13}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, or heteroaryl; wherein each alkyl and heteroaryl is independently optionally substituted with one, two, or three R^{11a} .

[00162] In some embodiments of a compound of Formula (III), R^{11} is $-\text{CN}$, $-\text{S}(=\text{O})_2R^{14}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, or heteroaryl; wherein each alkyl and heteroaryl is independently optionally substituted with one, two, or three R^{11a} ; provided that R^{11} is not CF_3 .

[00163] In some embodiments of a compound of Formula (III), R^{11} is $-\text{CN}$, $-\text{S}(=\text{O})_2R^{14}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, or $\text{C}_1\text{-C}_6$ hydroxyalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{11a} .

[00164] In some embodiments of a compound of Formula (III), R^{11} is $-\text{CN}$, $-\text{S}(=\text{O})_2R^{14}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, or heteroaryl; wherein each alkyl and heteroaryl is independently optionally substituted with one, two, or three R^{11a} .

[00165] In some embodiments of a compound of Formula (III), R^{11} is $-\text{CN}$, $-\text{S}(=\text{O})_2R^{14}$, $-\text{C}(=\text{O})\text{OR}^{13}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, or $\text{C}_1\text{-C}_6$ hydroxyalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{11a} .

[00166] In some embodiments of a compound of Formula (III), R^{11} is $\text{C}_1\text{-C}_6$ alkyl optionally substituted with one, two, or three R^{11a} . In some embodiments of a compound of Formula (III), R^{11} is $\text{C}_1\text{-C}_6$ alkyl optionally substituted with one, two, or three R^{11a} ; provided that R^{11} is not CF_3 . In some embodiments of a compound of Formula (III), R^{11} is $\text{C}_1\text{-C}_6$ alkyl substituted with one R^{11a} . In some embodiments of a compound of Formula (III), R^{11} is $\text{C}_1\text{-C}_6$ hydroxyalkyl.

[00167] In some embodiments of a compound of Formula (III), R^{11} is not CF_3 .

[00168] In some embodiments of a compound of Formula (III), each R^{11a} is independently halogen, $-\text{CN}$, $-\text{OR}^{13}$, $-\text{NR}^{15}\text{R}^{16}$, $-\text{S}(=\text{O})_2R^{14}$, $-\text{NR}^{14}\text{S}(=\text{O})_2R^{14}$, $-\text{S}(=\text{O})_2\text{NR}^{15}\text{R}^{16}$, $-\text{C}(=\text{O})R^{14}$, $-\text{OC}(=\text{O})R^{14}$, $-\text{C}(=\text{O})\text{OR}^{13}$, $-\text{C}(=\text{O})\text{NR}^{15}\text{R}^{16}$, $-\text{NR}^{13}\text{C}(=\text{O})R^{14}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_1\text{-C}_6$ hydroxyalkyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and

heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (III), each R^{11a} is independently halogen, $-CN$, $-OR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{14}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (III), each R^{11a} is independently $-OR^{13}$, $-S(=O)_2R^{14}$, $-NR^{13}C(=O)R^{14}$, cycloalkyl, aryl, or heteroaryl; wherein each cycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (III), each R^{11a} is independently aryl optionally substituted with one, two, or three R^{11c} .

[00169] In some embodiments of a compound of Formula (III), each R^{11a} is independently $-OR^{13}$. In some embodiments of a compound of Formula (III), each R^{11a} is independently $-S(=O)_2R^{14}$. In some embodiments of a compound of Formula (III), each R^{11a} is independently cycloalkyl optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (III), each R^{11a} is independently $-NR^{13}C(=O)R^{14}$.

[00170] In some embodiments of a compound of Formula (III), each R^{11c} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (III), each R^{11c} is independently halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (III), each R^{11c} is independently halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.

[00171] In some embodiments of a compound of Formula (III), R^{11} and R^{12} are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b} . In some embodiments of a compound of Formula (III), R^{11} and R^{12} are taken together to form a cycloalkyl optionally substituted with one, two, or three R^{11b} . In some embodiments of a compound of Formula (III), R^{11} and R^{12} are taken together to form a heterocycloalkyl optionally substituted with one, two, or three R^{11b} .

[00172] In some embodiments of a compound of Formula (III), each R^{11b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (III), each R^{11b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (III), each R^{11b} is independently oxo (when feasible), halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.

[00173] In some embodiments of a compound of Formula (III), each R^{13} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R^{13a} . In some embodiments of a compound of Formula (III), each R^{13} is independently hydrogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{13a} . In some embodiments of a compound of Formula (III), each R^{13} is independently hydrogen or C_1 - C_6 alkyl.

[00174] In some embodiments of a compound of Formula (III), each R^{13a} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), each R^{13a} is independently halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), each R^{13a} is independently halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.

[00175] In some embodiments of a compound of Formula (III), each R^{14} is independently C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ heteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R^{14a} . In some embodiments of a compound of Formula (III), each R^{14} is independently C₁-C₆ alkyl, or C₁-C₆ haloalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{14a} . In some embodiments of a compound of Formula (III), each R^{14} is independently C₁-C₆ alkyl.

[00176] In some embodiments of a compound of Formula (III), each R^{14a} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), each R^{14a} is independently halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), each R^{14a} is independently halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.


[00177] In some embodiments of a compound of Formula (III), each R^{15} and R^{16} is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ heteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R^{15a} . In some embodiments of a compound of Formula (III), each R^{15} and R^{16} is independently hydrogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{15a} . In some embodiments of a compound of Formula (III), each R^{15} and R^{16} is independently hydrogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{15a} . In some embodiments of a compound of Formula (III), each R^{15} and R^{16} is independently hydrogen or C₁-C₆ alkyl.

[00178] In some embodiments of a compound of Formula (III), each R^{15a} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), each R^{15a} is independently halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), each R^{15a} is independently halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.

In some embodiments of a compound of Formula (III), R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b} . In some embodiments of a compound of Formula (III), R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl.


[00179] In some embodiments of a compound of Formula (III), each R^{15b} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), each R^{15b} is independently halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (III), each R^{15b} is independently halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.

[00180] In some embodiments provided herein is a compound having the structure of Formula (IV), or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof:



Formula (IV);

wherein:



Ring A is

Q^2 is N or CW;

Q^3 is N and Q^4 is CW;

or Q^3 is CW and Q^4 is N;

each W is independently hydrogen, halogen, -CN, -OR^b, NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

A is -O- or -CH₂-;

X is -O-, -S-, -S(=O)₂-, -NR¹⁷-, or -C(R¹⁸)₂-;

R^1 and R^2 are independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,

cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆

alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl,

heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a} ;

or R^1 and R^2 are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{1b} ;

each R^{1a} and R^{1b} is independently oxo (when feasible) halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

R^3 is hydrogen, halogen, -CN, -OR^b, -SR^b, -NR^cR^d, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{3a};

each R^{3a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^4 and R^7 are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^5 and R^6 are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^8 is hydrogen, halogen, -OR^b, -NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

R^9 and R^{10} are independently hydrogen, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

R^{11} is hydrogen, halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -OC(=O)NR¹⁵R¹⁶, -NR¹³C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, -NR¹³C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a};

R^{12} is hydrogen, halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -OC(=O)NR¹⁵R¹⁶, -NR¹³C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, -NR¹³C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{12a};

or R^{11} and R^{12} are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b};

each R^{11a}, R^{11b}, and R^{12a} is independently oxo (when feasible), halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -OC(=O)NR¹⁵R¹⁶, -NR¹³C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, -NR¹³C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c};

each R^{11c} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -

$C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

each R^{13} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a} ;

each R^{14} is independently C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{14a} ;

each R^{15} and R^{16} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{15a} ;

or R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b} ;

each R^{13a} , R^{14a} , R^{15a} , and R^{15b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NHS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-CN$, $-OR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, or C_2 - C_6 alkynyl;

R^{17} is hydrogen, $-CN$, $-OR^b$, $-S(=O)_2R^a$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

each R^{18} is independently hydrogen, halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NHS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

R^{21} and R^{22} are independently hydrogen, C_1 - C_{20} alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), C_1 - C_6 alkyl(heterocycloalkyl); wherein

each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a} ;

or R^{21} and R^{22} are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b} ;

each R^{21a} and R^{21b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NHS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);


each R^a is independently C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

each R^b is independently hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; and

each R^c and R^d is independently hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;


or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.

[00181] In some embodiments provided herein is a compound having the structure of Formula (IV), or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof:



Formula (IV);

wherein:



Q^2 is N or CW;

Q^3 is N and Q^4 is CW;

or Q^3 is CW and Q^4 is N;

each W is independently hydrogen, halogen, -CN, -OR^b, NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

A is -O- or -CH₂-;

X is -O-, -S-, -S(=O)₂-, -NR¹⁷-, or -C(R¹⁸)₂-;

R¹ and R² are independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a}, or R¹ and R² are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{1b};

each R^{1a} and R^{1b} is independently oxo (when feasible) halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

R³ is hydrogen, halogen, -CN, -OR^b, -SR^b, -NR^cR^d, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{3a};

each R^{3a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁴ and R⁷ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁵ and R⁶ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁸ is hydrogen, halogen, -OR^b, -NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

R⁹ and R¹⁰ are independently hydrogen, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

R¹¹ is hydrogen, halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -OC(=O)NR¹⁵R¹⁶, -NR¹³C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, -NR¹³C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a};

R^{12} is hydrogen, halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{12a} ;

or R^{11} and R^{12} are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b} ;

each R^{11a} , R^{11b} , and R^{12a} is independently oxo (when feasible), halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} ;

each R^{11c} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

each R^{13} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a} ;

each R^{14} is independently C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{14a} ;

each R^{15} and R^{16} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{15a} ;

or R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b} ;

each R^{13a} , R^{14a} , R^{15a} , and R^{15b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NHS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6

alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

R¹⁷ is hydrogen, -CN, -OR^b, -S(=O)₂R^a, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

each R¹⁸ is independently hydrogen, halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NHS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

R²¹ and R²² are independently hydrogen, C₁-C₂₀ alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a};

or R²¹ and R²² are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b};

each R^{21a} and R^{21b} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NHS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

each R^a is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

each R^b is independently hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl; and

each R^c and R^d is independently hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.

[00182] In some embodiments of a compound of Formula (IV), Q² is CW. In some embodiments of a compound of Formula (IV), Q² is N.

[00183] In some embodiments of a compound of Formula (IV), Q^3 is N and Q^4 is CW. In some embodiments of a compound of Formula (IV), Q^4 is N and Q^3 is CW.

[00184] In some embodiments of a compound of Formula (IV), Q^2 is CW, Q^3 is N, and Q^4 is CW. In some embodiments of a compound of Formula (IV), Q^2 is CW, Q^3 is CW, and Q^4 is N. In some embodiments of a compound of Formula (IV), Q^2 is N, Q^3 is N, and Q^4 is CW. In some embodiments of a compound of Formula (IV), Q^2 is N, Q^3 is CW, and Q^4 is N.

[00185] In some embodiments of a compound of Formula (IV), each W is independently hydrogen, halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (IV), each W is independently hydrogen, halogen, or C_1 - C_6 alkyl. In some embodiments of a compound of Formula (IV), each W is hydrogen.

[00186] In some embodiments of a compound of Formula (IV), R^3 is halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, C_2 - C_6 alkynyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, alkynyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R^{3a} . In some embodiments of a compound of Formula (IV), R^3 is halogen, C_1 - C_6 alkyl, C_2 - C_6 alkynyl, C_1 - C_6 hydroxyalkyl, or C_1 - C_6 heteroalkyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{3a} . In some embodiments of a compound of Formula (IV), R^3 is halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), R^3 is halogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), R^3 is halogen, or C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl. In some embodiments of a compound of Formula (IV), R^3 is halogen. In some embodiments of a compound of Formula (IV), R^3 is halogen, $-OR^b$, C_1 - C_6 alkyl, C_2 - C_6 alkynyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, or C_1 - C_6 heteroalkyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{3a} . In some embodiments of a compound of Formula (IV), R^3 is halogen, $-OR^b$, C_2 - C_6 alkynyl, or C_1 - C_6 hydroxyalkyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{3a} . In some embodiments of a compound of Formula (IV), R^3 is halogen or C_1 - C_6 hydroxyalkyl.

[00187] In some embodiments of a compound of Formula (IV), each R^{3a} is independently oxo (when feasible) halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), each R^{3a} is independently oxo (when feasible) halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), each R^{3a} is independently oxo (when feasible) halogen, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), each R^{3a} is independently oxo (when feasible) halogen, C_1 - C_6 alkyl, or C_1 - C_6 fluoroalkyl. In some embodiments of a compound of Formula (IV), each R^{3a} is independently halogen or C_1 - C_6 alkyl. In some embodiments of a compound of Formula (IV), each R^{3a} is independently

halogen, $-OR^b$, C_1-C_6 alkyl, or cycloalkyl. In some embodiments of a compound of Formula (IV), each R^{3a} is independently oxo (when feasible) halogen, or $-OR^b$.

[00188] In some embodiments of a compound of Formula (IV), R^1 is C_1-C_6 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6 alkyl(aryl), C_1-C_6 alkyl(heteroaryl), C_1-C_6 alkyl(cycloalkyl), or C_1-C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a} . In some embodiments of a compound of Formula (IV), R^1 is C_1-C_6 alkyl, cycloalkyl, heterocycloalkyl, C_1-C_6 alkyl(aryl), C_1-C_6 alkyl(heteroaryl), C_1-C_6 alkyl(cycloalkyl), or C_1-C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a} . In some embodiments of a compound of Formula (IV), R^1 is cycloalkyl or C_1-C_6 alkyl(cycloalkyl); wherein each alkyl and cycloalkyl is independently optionally substituted with one, two, or three R^{1a} . In some embodiments of a compound of Formula (IV), R^1 is cycloalkyl optionally substituted with one, two, or three R^{1a} . In some embodiments of a compound of Formula (IV), R^1 is C_1-C_6 alkyl, C_1-C_6 haloalkyl, cycloalkyl, heterocycloalkyl, C_1-C_6 alkyl(aryl), C_1-C_6 alkyl(heteroaryl), C_1-C_6 alkyl(cycloalkyl), or C_1-C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a} . In some embodiments of a compound of Formula (IV), R^1 is C_1-C_6 alkyl, cycloalkyl, C_1-C_6 alkyl(aryl), or C_1-C_6 alkyl(cycloalkyl); wherein each alkyl, cycloalkyl, and aryl is independently optionally substituted with one, two, or three R^{1a} . In some embodiments of a compound of Formula (IV), R^1 is cycloalkyl or C_1-C_6 alkyl(cycloalkyl).

[00189] In some embodiments of a compound of Formula (IV), each R^{1a} is independently oxo (when feasible) halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), each R^{1a} is independently oxo (when feasible) halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), each R^{1a} is independently oxo (when feasible) halogen, C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), each R^{1a} is independently oxo (when feasible) halogen, C_1-C_6 alkyl, or C_1-C_6 fluoroalkyl. In some embodiments of a compound of Formula (IV), each R^{1a} is independently halogen or C_1-C_6 alkyl. In some embodiments of a compound of Formula (IV), each R^{1a} is independently oxo (when feasible) halogen, $-CN$, $-OR^b$, C_1-C_6 alkyl, or C_1-C_6 fluoroalkyl. In some embodiments of a compound of Formula (IV), each R^{1a} is independently halogen or C_1-C_6 alkyl.

[00190] In some embodiments of a compound of Formula (IV), R^2 is hydrogen or C_1-C_6 alkyl. In some embodiments of a compound of Formula (IV), R^2 is hydrogen. In some embodiments of a compound of Formula (IV), R^1 and R^2 are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{1b} .

[00191] In some embodiments of a compound of Formula (IV), each R^{1b} is independently oxo (when feasible) halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), each R^{1b} is

independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), each R^{1b} is independently oxo (when feasible) halogen, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), each R^{1b} is independently oxo (when feasible) halogen, C₁-C₆ alkyl, or C₁-C₆ fluoroalkyl. In some embodiments of a compound of Formula (IV), each R^{1b} is independently halogen or C₁-C₆ alkyl.

[00192] In some embodiments of a compound of Formula (IV), R⁸ is hydrogen or C₁-C₆ alkyl. In some embodiments of a compound of Formula (IV), R⁸ is hydrogen.

[00193] In some embodiments of a compound of Formula (IV), R⁹ and R¹⁰ are independently hydrogen or C₁-C₆ alkyl. In some embodiments of a compound of Formula (IV), R⁹ and R¹⁰ are hydrogen.

[00194] In some embodiments of a compound of Formula (IV), A is -O-. In some embodiments of a compound of Formula (IV), A is -CH₂-.

[00195] In some embodiments of a compound of Formula (IV), R⁵ and R⁶ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, or C₁-C₆ haloalkyl. In some embodiments of a compound of Formula (IV), R⁵ and R⁶ are independently hydrogen, halogen, -OR^b, or C₁-C₆ alkyl. In some embodiments of a compound of Formula (IV), R⁵ and R⁶ are hydrogen.

[00196] In some embodiments of a compound of Formula (IV), R⁴ and R⁷ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, or C₁-C₆ haloalkyl. In some embodiments of a compound of Formula (IV), R⁴ and R⁷ are independently hydrogen, halogen, -OR^b, or C₁-C₆ alkyl. In some embodiments of a compound of Formula (IV), R⁴ and R⁷ are independently hydrogen, halogen, or -OR^b. In some embodiments of a compound of Formula (IV), R⁴ and R⁷ are independently hydrogen, halogen, or -OH. In some embodiments of a compound of Formula (IV), R⁴ and R⁷ are independently halogen or -OH. In some embodiments of a compound of Formula (IV), R⁴ and R⁷ are independently hydrogen or -OH. In some embodiments of a compound of Formula (IV), R⁴ and R⁷ are -OH.

[00197] In some embodiments of a compound of Formula (IV), R⁵ and R⁶ are hydrogen and R⁴ and R⁷ are -OH. In some embodiments of a compound of Formula (IV), R⁵ and R⁶ are hydrogen and R⁴ and R⁷ are independently halogen or -OH. In some embodiments of a compound of Formula (IV), R⁵ and R⁶ are hydrogen and R⁴ and R⁷ are independently hydrogen or -OH.

[00198] In some embodiments of a compound of Formula (IV), X is -O- or -S(=O)₂-. In some embodiments of a compound of Formula (IV), X is -O-. In some embodiments of a compound of Formula (IV), X is -S(=O)₂-. In some embodiments of a compound of Formula (IV), X is -NR¹⁷-. In some embodiments of a compound of Formula (IV), X is -C(R¹⁸)₂-.

[00199] In some embodiments of a compound of Formula (IV), R¹⁷ is hydrogen, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), R¹⁷ is hydrogen, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), R¹⁷ is hydrogen or C₁-C₆ alkyl. In some embodiments of a compound of Formula (IV), R¹⁷ is hydrogen.

[00200] In some embodiments of a compound of Formula (IV), each R^{18} is independently hydrogen, halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), each R^{18} is independently hydrogen, halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), each R^{18} is independently hydrogen, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl. In some embodiments of a compound of Formula (IV), each R^{18} is independently hydrogen or halogen. In some embodiments of a compound of Formula (IV), each R^{18} is hydrogen.

[00201] In some embodiments of a compound of Formula (IV), R^{21} and R^{22} are independently hydrogen, C₁-C₂₀ alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a} . In some embodiments of a compound of Formula (IV), R^{21} and R^{22} are independently hydrogen, C₁-C₂₀ alkyl or aryl; wherein each alkyl and aryl is independently optionally substituted with one, two, or three R^{21a} . In some embodiments of a compound of Formula (IV), R^{21} and R^{22} are independently hydrogen, C₁-C₂₀ alkyl optionally substituted with one, two, or three R^{21a} . In some embodiments of a compound of Formula (IV), R^{21} and R^{22} are hydrogen.

[00202] In some embodiments of a compound of Formula (IV), each R^{21a} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, or C₁-C₆ alkyl. In some embodiments of a compound of Formula (IV), each R^{21a} is independently -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, or -OC(=O)NR^cR^d. In some embodiments of a compound of Formula (IV), each R^{21a} is independently -C(=O)OR^b or -OC(=O)OR^b.

[00203] In some embodiments of a compound of Formula (IV), R^{21} and R^{22} are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b} .

[00204] In some embodiments of a compound of Formula (IV), each R^{21b} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), each R^{21b} is independently halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), each R^{21b} is independently halogen or C₁-C₆ alkyl.

[00205] In some embodiments of a compound of Formula (IV), R^{12} is hydrogen, halogen, -CN, -OR¹³, -NR¹⁵R¹⁶, -C(=O)R¹⁴, -C(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), R^{12} is halogen, -CN, -OR¹³, -NR¹⁵R¹⁶, -C(=O)R¹⁴, -C(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), R^{12} is hydrogen, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ hydroxyalkyl. In some embodiments of a compound of Formula (IV), R^{12} is C₁-C₆ alkyl. In some embodiments of a

compound of Formula (IV), R^{12} is C_1 - C_6 hydroxyalkyl. In some embodiments of a compound of Formula (IV), R^{12} is hydrogen. In some embodiments of a compound of Formula (IV), R^{12} is not hydrogen. In some embodiments of a compound of Formula (IV), R^{12} is hydrogen, halogen, $-OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkynyl, or C_1 - C_6 heteroalkyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{12a} . In some embodiments of a compound of Formula (IV), R^{12} is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 hydroxyalkyl, or C_2 - C_6 alkynyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{12a} . In some embodiments of a compound of Formula (IV), R^{12} is hydrogen, halogen, $-CN$, $-OR^{13}$, $-NR^{15}R^{16}$, $-C(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), R^{12} is hydrogen, halogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, or C_1 - C_6 hydroxyalkyl.

[00206] In some embodiments of a compound of Formula (IV), each R^{12a} is independently halogen, $-CN$, $-OR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{14}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} .

[00207] In some embodiments of a compound of Formula (IV), each R^{12a} is independently halogen, $-CN$, $-OR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{14}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} .

[00208] In some embodiments of a compound of Formula (IV), each R^{12a} is independently $-OR^{13}$, $-S(=O)_2R^{14}$, $-NR^{13}C(=O)R^{14}$, cycloalkyl, aryl, or heteroaryl; wherein each cycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (IV), each R^{12a} is independently oxo (when feasible), halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (IV), each R^{12a} is independently oxo (when feasible), halogen, $-OR^{13}$, $-SR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)OR^{13}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, heterocycloalkyl, aryl, or heteroaryl; wherein each heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} .

[00209] In some embodiments of a compound of Formula (IV), R^{11} is hydrogen, halogen, $-CN$, $-OR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-C(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} . In some embodiments of a compound of Formula (IV), R^{11} is hydrogen, halogen, $-CN$, $-$

$S(=O)_2R^{14}$, $-C(=O)R^{14}$, $-C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} . In some embodiments of a compound of Formula (IV), R^{11} is hydrogen, $-CN$, $-S(=O)_2R^{14}$, $-C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, or heteroaryl; wherein each alkyl and heteroaryl is independently optionally substituted with one, two, or three R^{11a} . In some embodiments of a compound of Formula (IV), R^{11} is hydrogen or C_1 - C_6 alkyl optionally substituted with one, two, or three R^{11a} . In some embodiments of a compound of Formula (IV), R^{11} is hydrogen or C_1 - C_6 alkyl substituted with one R^{11a} . In some embodiments of a compound of Formula (IV), R^{11} is C_1 - C_6 hydroxyalkyl.

[00210] In some embodiments of a compound of Formula (IV), R^{11} is hydrogen, halogen, $-CN$, $-OR^{13}$, $-NR^{15}R^{16}$, $-C(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), R^{11} is hydrogen, halogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, or C_1 - C_6 hydroxyalkyl. In some embodiments of a compound of Formula (IV), R^{11} is hydrogen. In some embodiments of a compound of Formula (IV), R^{11} is not hydrogen.

In some embodiments of a compound of Formula (IV), R^{11} is halogen, $-CN$, $-OR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} . In some embodiments of a compound of Formula (IV), R^{11} is $-CN$, $-S(=O)_2R^{14}$, $-C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkynyl, or heteroaryl; wherein each alkyl, alkynyl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} . In some embodiments of a compound of Formula (IV), R^{11} is C_1 - C_6 alkyl or C_1 - C_6 hydroxyalkyl; wherein each alkyl is independently optionally substituted with one R^{11a} .

[00211] In some embodiments of a compound of Formula (IV), each R^{11a} is independently halogen, $-CN$, $-OR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{14}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (IV), each R^{11a} is independently halogen, $-CN$, $-OR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{14}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (IV), each R^{11a} is independently $-OR^{13}$, $-S(=O)_2R^{14}$, $-NR^{13}C(=O)R^{14}$, cycloalkyl, aryl, or heteroaryl; wherein each cycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (IV), each R^{11a} is independently aryl optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (IV),

each R^{11a} is independently $-OR^{13}$. In some embodiments of a compound of Formula (IV), each R^{11a} is independently $-S(=O)_2R^{14}$. In some embodiments of a compound of Formula (IV), each R^{11a} is independently cycloalkyl optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (IV), each R^{11a} is independently $-NR^{13}C(=O)R^{14}$. In some embodiments of a compound of Formula (IV), each R^{11a} is independently oxo (when feasible), halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (IV), each R^{11a} is independently oxo (when feasible), halogen, $-OR^{13}$, $-SR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)OR^{13}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, heterocycloalkyl, aryl, or heteroaryl; wherein each heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (II), each R^{11a} is independently $-OR^{13}$ or heteroaryl.

[00212] In some embodiments of a compound of Formula (IV), each R^{11c} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (IV), each R^{11c} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, or C_1 - C_6 hydroxyalkyl. In some embodiments of a compound of Formula (IV), each R^{11c} is independently halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (IV), each R^{11c} is independently halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (IV), each R^{11c} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl. In some embodiments of a compound of Formula (IV), each R^{11c} is independently $-OR^b$, $-C(=O)OR^b$, or C_1 - C_6 hydroxyalkyl.

[00213] In some embodiments of a compound of Formula (IV), R^{11} and R^{12} are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b} . In some embodiments of a compound of Formula (IV), R^{11} and R^{12} are taken together to form a cycloalkyl optionally substituted with one, two, or three R^{11b} . In some embodiments of a compound of Formula (IV), R^{11} and R^{12} are taken together to form a heterocycloalkyl optionally substituted with one, two, or three R^{11b} .

[00214] In some embodiments of a compound of Formula (IV), each R^{11b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (IV), each R^{11b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (IV), each R^{11b} is independently oxo (when feasible), halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.

[00215] In some embodiments of a compound of Formula (IV), each R^{13} is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ heteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R^{13a} . In some embodiments of a compound of Formula (IV), each R^{13} is independently hydrogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{13a} . In some embodiments of a compound of Formula (IV), each R^{13} is independently hydrogen or C₁-C₆ alkyl. In some embodiments of a compound of Formula (IV), each R^{13} is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a} . In some embodiments of a compound of Formula (IV), each R^{13} is independently C₁-C₆ alkyl, C₁-C₆ haloalkyl, or cycloalkyl; wherein each alkyl and cycloalkyl is independently optionally substituted with one, two, or three R^{13a} .

[00216] In some embodiments of a compound of Formula (IV), each R^{13a} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), each R^{13a} is independently halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), each R^{13a} is independently halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.

[00217] In some embodiments of a compound of Formula (IV), each R^{13a} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl. In some embodiments of a compound of Formula (IV), each R^{13a} is independently -OR^b, -C(=O)OR^b, cycloalkyl, aryl, or heteroaryl; wherein each cycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl. In some embodiments of a compound of Formula (IV), each R^{13a} is independently -OR^b, -C(=O)OR^b, cycloalkyl, aryl, or heteroaryl.

[00218] In some embodiments of a compound of Formula (IV), each R^{14} is independently C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ heteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R^{14a} . In some embodiments of a compound of Formula (IV), each R^{14} is independently C₁-C₆ alkyl, or C₁-C₆ haloalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{14a} . In some embodiments of a compound of Formula (IV), each R^{14} is independently C₁-C₆ alkyl.

[00219] In some embodiments of a compound of Formula (IV), each R^{14a} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), each R^{14a} is independently halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl.

In some embodiments of a compound of Formula (IV), each R^{14a} is independently halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.


[00220] In some embodiments of a compound of Formula (IV), each R^{15} and R^{16} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R^{15a} . In some embodiments of a compound of Formula (IV), each R^{15} and R^{16} is independently hydrogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{15a} . In some embodiments of a compound of Formula (IV), each R^{15} and R^{16} is independently hydrogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{15a} . In some embodiments of a compound of Formula (IV), each R^{15} and R^{16} is independently hydrogen or C_1 - C_6 alkyl.

[00221] In some embodiments of a compound of Formula (IV), each R^{15a} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), each R^{15a} is independently halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), each R^{15a} is independently halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.

[00222] In some embodiments of a compound of Formula (IV), R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b} . In some embodiments of a compound of Formula (IV), R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl.


[00223] In some embodiments of a compound of Formula (IV), each R^{15b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), each R^{15b} is independently halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (IV), each R^{15b} is independently halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.

[00224] In some embodiments provided herein is a compound having the structure of Formula (V), or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof:



Formula (V);

wherein:



Ring A is

Q^3 and Q^4 are independently N or CW; provided that at least one of Q^3 or Q^4 is N;

each W is independently hydrogen, halogen, -CN, -OR^b, NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

A is -O-;

X is -O-, -S-, -S(=O)₂-, -NR¹⁷-, or -C(R¹⁸)₂-;

R¹ and R² are independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,

cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆

alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl,

heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a};

or R¹ and R² are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{1b};

each R^{1a} and R^{1b} is independently oxo (when feasible) halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

R³ is hydrogen, halogen, -CN, -OR^b, -SR^b, -NR^cR^d, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{3a};

each R^{3a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁴ and R⁷ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁵ and R⁶ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁸ is hydrogen, halogen, -OR^b, -NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

R⁹ and R¹⁰ are independently hydrogen, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

R¹¹ is halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -

S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -

OC(=O)NR¹⁵R¹⁶, -NR¹³C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, -NR¹³C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl,

or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} ;

R^{12} is hydrogen, halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{12a} ;

or R^{11} and R^{12} are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b} ;

each R^{11a} , R^{11b} , and R^{12a} is independently oxo (when feasible), halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} ;

each R^{11c} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

each R^{13} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a} ;

each R^{14} is independently C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{14a} ;

each R^{15} and R^{16} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{15a} ;

or R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b} ;

each R^{13a} , R^{14a} , R^{15a} , and R^{15b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6 alkyl(aryl), C_1-C_6 alkyl(heteroaryl), C_1-C_6 alkyl(cycloalkyl), or C_1-C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-CN$, $-OR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl;

R^{17} is hydrogen, $-CN$, $-OR^b$, $-S(=O)_2R^a$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6 alkyl(aryl), C_1-C_6 alkyl(heteroaryl), C_1-C_6 alkyl(cycloalkyl), or C_1-C_6 alkyl(heterocycloalkyl);

each R^{18} is independently hydrogen, halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NHS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6 alkyl(aryl), C_1-C_6 alkyl(heteroaryl), C_1-C_6 alkyl(cycloalkyl), or C_1-C_6 alkyl(heterocycloalkyl);

R^{21} and R^{22} are independently hydrogen, C_1-C_{20} alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6 alkyl(aryl), C_1-C_6 alkyl(heteroaryl), C_1-C_6 alkyl(cycloalkyl), C_1-C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a} ;


or R^{21} and R^{22} are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b} ;

each R^{21a} and R^{21b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6 alkyl(aryl), C_1-C_6 alkyl(heteroaryl), C_1-C_6 alkyl(cycloalkyl), or C_1-C_6 alkyl(heterocycloalkyl);

each R^a is independently C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1-C_6 alkyl, or C_1-C_6 haloalkyl;

each R^b is independently hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-OH$, C_1-C_6 alkyl, or C_1-C_6 haloalkyl; and

[00225] In some embodiments provided herein is a compound having the structure of Formula (V), or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof:



wherein:



R³ is hydrogen, halogen, -CN, -OR^b, -SR^b, -NR^eR^d, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein

each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{3a} ,

each R^{3a} is independently oxo (when feasible) halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^4 and R^7 are independently hydrogen, halogen, $-OR^b$, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^5 and R^6 are independently hydrogen, halogen, $-OR^b$, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^8 is hydrogen, halogen, $-OR^b$, $-NR^cR^d$, C_1-C_6 alkyl, or C_1-C_6 haloalkyl;

R^9 and R^{10} are independently hydrogen, halogen, C_1-C_6 alkyl, or C_1-C_6 haloalkyl;

R^{11} is halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 hydroxyalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} ,

R^{12} is hydrogen, halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 hydroxyalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{12a} ,

or R^{11} and R^{12} are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b} ,

each R^{11a} , R^{11b} , and R^{12a} is independently oxo (when feasible), halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 hydroxyalkyl, C_1-C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} ,

each R^{11c} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1-C_6 alkyl(aryl), C_1-C_6 alkyl(heteroaryl), C_1-C_6 alkyl(cycloalkyl), or C_1-C_6 alkyl(heterocycloalkyl);

each R^{13} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a} ;

each R^{14} is independently C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{14a} ;

each R^{15} and R^{16} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{15a} ;

or R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b} ;

each R^{13a} , R^{14a} , R^{15a} , and R^{15b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

R^{17} is hydrogen, $-CN$, $-OR^b$, $-S(=O)_2R^a$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 fluoroalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

each R^{18} is independently hydrogen, halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NHS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl);

R^{21} and R^{22} are independently hydrogen, C_1 - C_{20} alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), C_1 - C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a} ;

or R^{21} and R^{22} are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b} ;

each R^{21a} and R^{21b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_2 - C_6

alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

each R^a is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

each R^b is independently hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl; and

each R^c and R^d is independently hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.

[00226] In some embodiments of a compound of Formula (V), Q³ is N and Q⁴ is CW. In some embodiments of a compound of Formula (V), Q⁴ is N and Q³ is CW. In some embodiments of a compound of Formula (V), Q³ is N and Q⁴ is N.

[00227] In some embodiments of a compound of Formula (V), each W is independently hydrogen, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl. In some embodiments of a compound of Formula (V), each W is independently hydrogen, halogen, or C₁-C₆ alkyl. In some embodiments of a compound of Formula (V), each W is hydrogen.

[00228] In some embodiments of a compound of Formula (V), R³ is halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, alkynyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R^{3a}. In some embodiments of a compound of Formula (V), R³ is halogen, C₁-C₆ alkyl, C₂-C₆ alkynyl, C₁-C₆ hydroxyalkyl, or C₁-C₆ heteroalkyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{3a}.

[00229] In some embodiments of a compound of Formula (V), R³ is halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), R³ is halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), R³ is halogen, or C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl. In some embodiments of a compound of Formula (V), R³ is halogen.

[00230] In some embodiments of a compound of Formula (V), each R^{3a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl,

cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), each R^{3a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), each R^{3a} is independently oxo (when feasible) halogen, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), each R^{3a} is independently oxo (when feasible) halogen, C₁-C₆ alkyl, or C₁-C₆ fluoroalkyl. In some embodiments of a compound of Formula (V), each R^{3a} is independently halogen or C₁-C₆ alkyl. In some embodiments of a compound of Formula (V), each R^{3a} is independently halogen, -OR^b, C₁-C₆ alkyl, or cycloalkyl.

[00231] In some embodiments of a compound of Formula (V), R¹ is C₁-C₆ alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a}. In some embodiments of a compound of Formula (V), R¹ is C₁-C₆ alkyl, cycloalkyl, heterocycloalkyl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a}. In some embodiments of a compound of Formula (V), R¹ is cycloalkyl or C₁-C₆ alkyl(cycloalkyl); wherein each alkyl and cycloalkyl is independently optionally substituted with one, two, or three R^{1a}. In some embodiments of a compound of Formula (V), R¹ is cycloalkyl optionally substituted with one, two, or three R^{1a}.

[00232] In some embodiments of a compound of Formula (V), each R^{1a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), each R^{1a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), each R^{1a} is independently oxo (when feasible) halogen, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), each R^{1a} is independently oxo (when feasible) halogen, C₁-C₆ alkyl, or C₁-C₆ fluoroalkyl. In some embodiments of a compound of Formula (V), each R^{1a} is independently halogen or C₁-C₆ alkyl.

[00233] In some embodiments of a compound of Formula (V), R² is hydrogen or C₁-C₆ alkyl. In some embodiments of a compound of Formula (V), R² is hydrogen. In some embodiments of a compound of Formula (V), R¹ and R² are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{1b}.

[00234] In some embodiments of a compound of Formula (V), each R^{1b} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), each R^{1b} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), each R^{1b} is independently oxo (when feasible) halogen, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some

embodiments of a compound of Formula (V), each R^{1b} is independently oxo (when feasible) halogen, C_1 - C_6 alkyl, or C_1 - C_6 fluoroalkyl. In some embodiments of a compound of Formula (V), each R^{1b} is independently halogen or C_1 - C_6 alkyl.

[00235] In some embodiments of a compound of Formula (V), R^8 is hydrogen or C_1 - C_6 alkyl. In some embodiments of a compound of Formula (V), R^8 is hydrogen.

[00236] In some embodiments of a compound of Formula (V), R^9 and R^{10} are independently hydrogen or C_1 - C_6 alkyl. In some embodiments of a compound of Formula (V), R^9 and R^{10} are hydrogen.

[00237] In some embodiments of a compound of Formula (V), R^5 and R^6 are independently hydrogen, halogen, $-OR^b$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (V), R^5 and R^6 are independently hydrogen, halogen, $-OR^b$, or C_1 - C_6 alkyl. In some embodiments of a compound of Formula (V), R^5 and R^6 are hydrogen.

[00238] In some embodiments of a compound of Formula (V), R^4 and R^7 are independently hydrogen, halogen, $-OR^b$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (V), R^4 and R^7 are independently hydrogen, halogen, $-OR^b$, or C_1 - C_6 alkyl. In some embodiments of a compound of Formula (V), R^4 and R^7 are independently hydrogen, halogen, or $-OR^b$. In some embodiments of a compound of Formula (V), R^4 and R^7 are independently hydrogen, halogen, or $-OH$. In some embodiments of a compound of Formula (V), R^4 and R^7 are independently halogen or $-OH$. In some embodiments of a compound of Formula (V), R^4 and R^7 are independently hydrogen or $-OH$. In some embodiments of a compound of Formula (V), R^4 and R^7 are $-OH$.

[00239] In some embodiments of a compound of Formula (V), R^5 and R^6 are hydrogen and R^4 and R^7 are $-OH$. In some embodiments of a compound of Formula (V), R^5 and R^6 are hydrogen and R^4 and R^7 are independently halogen or $-OH$. In some embodiments of a compound of Formula (V), R^5 and R^6 are hydrogen and R^4 and R^7 are independently hydrogen or $-OH$.

[00240] In some embodiments of a compound of Formula (V), X is $-O-$ or $-S(=O)_2-$. In some embodiments of a compound of Formula (V), X is $-O-$. In some embodiments of a compound of Formula (V), X is $-S(=O)_2-$. In some embodiments of a compound of Formula (V), X is $-NR^{17}-$. In some embodiments of a compound of Formula (V), X is $-C(R^{18})_2-$.

[00241] In some embodiments of a compound of Formula (V), R^{17} is hydrogen, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), R^{17} is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), R^{17} is hydrogen or C_1 - C_6 alkyl. In some embodiments of a compound of Formula (V), R^{17} is hydrogen.

[00242] In some embodiments of a compound of Formula (V), each R^{18} is independently hydrogen, halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), each R^{18} is independently hydrogen, halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), each R^{18} is independently hydrogen, halogen, C_1 - C_6

alkyl, or C₁-C₆ haloalkyl. In some embodiments of a compound of Formula (V), each R¹⁸ is independently hydrogen or halogen. In some embodiments of a compound of Formula (V), each R¹⁸ is hydrogen.

[00243] In some embodiments of a compound of Formula (V), R²¹ and R²² are independently hydrogen, C₁-C₂₀ alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a}. In some embodiments of a compound of Formula (V), R²¹ and R²² are independently hydrogen, C₁-C₂₀ alkyl or aryl; wherein each alkyl and aryl is independently optionally substituted with one, two, or three R^{21a}. In some embodiments of a compound of Formula (V), R²¹ and R²² are independently hydrogen, C₁-C₂₀ alkyl optionally substituted with one, two, or three R^{21a}. In some embodiments of a compound of Formula (V), R²¹ and R²² are hydrogen.

[00244] In some embodiments of a compound of Formula (V), each R^{21a} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, or C₁-C₆ alkyl. In some embodiments of a compound of Formula (V), each R^{21a} is independently -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, or -OC(=O)NR^cR^d. In some embodiments of a compound of Formula (V), each R^{21a} is independently -C(=O)OR^b or -OC(=O)OR^b.

[00245] In some embodiments of a compound of Formula (V), R²¹ and R²² are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b}.

[00246] In some embodiments of a compound of Formula (V), each R^{21b} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), each R^{21b} is independently halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), each R^{21b} is independently halogen or C₁-C₆ alkyl.

[00247] In some embodiments of a compound of Formula (V), R¹² is hydrogen, halogen, -CN, -OR¹³, -NR¹⁵R¹⁶, -C(=O)R¹⁴, -C(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), R¹² is halogen, -CN, -OR¹³, -NR¹⁵R¹⁶, -C(=O)R¹⁴, -C(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), R¹² is hydrogen, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ hydroxyalkyl. In some embodiments of a compound of Formula (V), R¹² is C₁-C₆ alkyl. In some embodiments of a compound of Formula (V), R¹² is C₁-C₆ hydroxyalkyl. In some embodiments of a compound of Formula (V), R¹² is hydrogen. In some embodiments of a compound of Formula (V), R¹² is not hydrogen.

[00248] In some embodiments of a compound of Formula (V), each R^{12a} is independently halogen, -CN, -OR¹³, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹⁴S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl,

cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} .

[00249] In some embodiments of a compound of Formula (V), each R^{12a} is independently halogen, -CN, $-OR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{14}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} .

[00250] In some embodiments of a compound of Formula (V), each R^{12a} is independently $-OR^{13}$, $-S(=O)_2R^{14}$, $-NR^{13}C(=O)R^{14}$, cycloalkyl, aryl, or heteroaryl; wherein each cycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} .

[00251] In some embodiments of a compound of Formula (V), R^{11} is halogen, -CN, $-OR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-C(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} . In some embodiments of a compound of Formula (V), R^{11} is halogen, -CN, $-S(=O)_2R^{14}$, $-C(=O)R^{14}$, $-C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} . In some embodiments of a compound of Formula (V), R^{11} is -CN, $-S(=O)_2R^{14}$, $-C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, or heteroaryl; wherein each alkyl and heteroaryl is independently optionally substituted with one, two, or three R^{11a} . In some embodiments of a compound of Formula (V), R^{11} is C_1 - C_6 alkyl optionally substituted with one, two, or three R^{11a} . In some embodiments of a compound of Formula (V), R^{11} is C_1 - C_6 alkyl substituted with one R^{11a} . In some embodiments of a compound of Formula (V), R^{11} is C_1 - C_6 hydroxyalkyl.

[00252] In some embodiments of a compound of Formula (V), each R^{11a} is independently halogen, -CN, $-OR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{14}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (V), each R^{11a} is independently halogen, -CN, $-OR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{14}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (V), each R^{11a} is independently $-OR^{13}$, $-S(=O)_2R^{14}$, $-NR^{13}C(=O)R^{14}$, cycloalkyl, aryl, or heteroaryl; wherein each cycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (V), each R^{11a} is independently aryl optionally substituted with one, two, or three R^{11c} .

[00253] In some embodiments of a compound of Formula (V), each R^{11a} is independently $-OR^{13}$. In some embodiments of a compound of Formula (V), each R^{11a} is independently $-S(=O)_2R^{14}$. In some

embodiments of a compound of Formula (V), each R^{11a} is independently cycloalkyl optionally substituted with one, two, or three R^{11c} . In some embodiments of a compound of Formula (V), each R^{11a} is independently $-NR^{13}C(=O)R^{14}$.

[00254] In some embodiments of a compound of Formula (V), each R^{11c} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (V), each R^{11c} is independently halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (V), each R^{11c} is independently halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.

[00255] In some embodiments of a compound of Formula (V), R^{11} and R^{12} are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b} . In some embodiments of a compound of Formula (V), R^{11} and R^{12} are taken together to form a cycloalkyl optionally substituted with one, two, or three R^{11b} . In some embodiments of a compound of Formula (V), R^{11} and R^{12} are taken together to form a heterocycloalkyl optionally substituted with one, two, or three R^{11b} .

[00256] In some embodiments of a compound of Formula (V), each R^{11b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (V), each R^{11b} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl. In some embodiments of a compound of Formula (V), each R^{11b} is independently oxo (when feasible), halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.

[00257] In some embodiments of a compound of Formula (V), each R^{13} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R^{13a} . In some embodiments of a compound of Formula (V), each R^{13} is independently hydrogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{13a} . In some embodiments of a compound of Formula (V), each R^{13} is independently hydrogen or C_1 - C_6 alkyl.

[00258] In some embodiments of a compound of Formula (V), each R^{13a} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), each R^{13a} is independently halogen, $-CN$, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), each R^{13a} is independently halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl.

[00259] In some embodiments of a compound of Formula (V), each R^{14} is independently C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R^{14a} . In some embodiments of a compound of Formula (V), each R^{14} is independently C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{14a} . In some embodiments of a compound of Formula (V), each R^{14} is independently C_1 - C_6 alkyl.

[00260] In some embodiments of a compound of Formula (V), each R^{14a} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), each R^{14a} is independently halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), each R^{14a} is independently halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.

[00261] In some embodiments of a compound of Formula (V), each R^{15} and R^{16} is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ heteroalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R^{15a} . In some embodiments of a compound of Formula (V), each R^{15} and R^{16} is independently hydrogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{15a} . In some embodiments of a compound of Formula (V), each R^{15} and R^{16} is independently hydrogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl; wherein each alkyl is independently optionally substituted with one, two, or three R^{15a} . In some embodiments of a compound of Formula (V), each R^{15} and R^{16} is independently hydrogen or C₁-C₆ alkyl.

[00262] In some embodiments of a compound of Formula (V), each R^{15a} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), each R^{15a} is independently halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), each R^{15a} is independently halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.

[00263] In some embodiments of a compound of Formula (V), R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b} . In some embodiments of a compound of Formula (V), R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl.

[00264] In some embodiments of a compound of Formula (V), each R^{15b} is independently oxo (when feasible), halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), each R^{15b} is independently halogen, -CN, -OR^b, -NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound of Formula (V), each R^{15b} is independently halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.

[00265] In some embodiments of a compound of Formula (I), (II), (III), (IV), or (V), each R^a is independently C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl. In some embodiments of a compound of Formula (I), (II), (III), (IV), or (V), each R^a is independently C₁-C₆ alkyl, C₁-C₆ haloalkyl, or cycloalkyl. In some embodiments of a compound of Formula (I), (II), (III), (IV), or (V), each R^a is independently C₁-C₆ alkyl or C₁-C₆ haloalkyl. In

some embodiments of a compound of Formula (I), (II), (III), (IV), or (V), each R^a is independently C₁-C₆ alkyl.

[00266] In some embodiments of a compound of Formula (I), (II), (III), (IV), or (V), each R^b is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl. In some embodiments of a compound of Formula (I), (II), (III), (IV), or (V), each R^b is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or cycloalkyl. In some embodiments of a compound of Formula (I), (II), (III), (IV), or (V), each R^b is independently hydrogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl. In some embodiments of a compound of Formula (I), (II), (III), (IV), or (V), each R^b is independently hydrogen or C₁-C₆ alkyl. In some embodiments of a compound of Formula (I), (II), (III), (IV), or (V), each R^b is hydrogen. In some embodiments of a compound of Formula (I), (II), (III), (IV), or (V), each R^b is independently C₁-C₆ alkyl.

[00267] In some embodiments of a compound of Formula (I), (II), (III), (IV), or (V), R^c and R^d are each independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl. In some embodiments of a compound of Formula (I), (II), (III), (IV), or (V), R^c and R^d are each independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or cycloalkyl. In some embodiments of a compound of Formula (I), (II), (III), (IV), or (V), R^c and R^d are each independently hydrogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl. In some embodiments of a compound of Formula (I), (II), (III), (IV), or (V), R^c and R^d are each independently hydrogen or C₁-C₆ alkyl. In some embodiments of a compound of Formula (I), (II), (III), (IV), or (V), R^c and R^d are each hydrogen. In some embodiments of a compound of Formula (I), (II), (III), (IV), or (V), R^c and R^d are each independently C₁-C₆ alkyl.

[00268] In some embodiments of a compound of Formula (I), (II), (III), (IV), or (V), R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl. In some embodiments of a compound of Formula (I), (II), (III), (IV), or (V), R^c and R^d are taken together with the nitrogen atom to which they are attached to form a pyrrolidine optionally substituted with one, two, or three halogen or C₁-C₆ alkyl. In some embodiments of a compound of Formula (I), (II), (III), (IV), or (V), R^c and R^d are taken together with the nitrogen atom to which they are attached to form a piperidine optionally substituted with one, two, or three halogen or C₁-C₆ alkyl. In some embodiments of a compound of Formula (I), (II), (III), (IV), or (V), R^c and R^d are taken together with the nitrogen atom to which they are attached to form a piperazine optionally substituted with one, two, or three halogen or C₁-C₆ alkyl.

[00269] Any combination of the groups described above for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.

[00270] In some embodiments is a compound, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, having a structure selected from Table 1.

TABLE 1

Ex	Structure	Name
1		(1-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-ethoxy-2-oxoethyl)phosphonic acid
2		((((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(cyano)methyl)phosphonic acid
3		((S)-1-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid
4		((R)-1-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid
5		(1-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)ethyl)phosphonic acid
6		((S)-1-(((2S,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)sulfonyl)ethyl)phosphonic acid
7		((R)-1-(((2S,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)sulfonyl)ethyl)phosphonic acid
8		(2-(((2S,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)sulfonyl)-1-hydroxypropan-2-yl)phosphonic acid

Ex	Structure	Name
9		((S)-1-((((2S,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)sulfonyl)-2-phenylethyl)phosphonic acid
10		((R)-1-((((2S,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)sulfonyl)-2-phenylethyl)phosphonic acid
11		((1S,2S)-1-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxypropyl)phosphonic acid
12		((1R,2S)-1-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxypropyl)phosphonic acid
13		(1-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid
14		(1-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)propyl)phosphonic acid
15		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
16		(((2S,3S,4R,5R)-5-(5-chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)sulfonyl)methyl)phosphonic acid

Ex	Structure	Name
17		(((2R,3S,4R,5R)-5-(5-chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonic acid
18		((S)-1-(((2R,3S,4R,5R)-5-(6-chloro-4-((cyclopropylmethylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-phenylethyl)phosphonic acid
19		((R)-1-(((2R,3S,4R,5R)-5-(6-chloro-4-((cyclopropylmethylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-phenylethyl)phosphonic acid
20		(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-[1,2,3]triazolo[4,5-c]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonic acid
21		(((2R,3S,4R,5R)-5-(5-chloro-7-((cyclopropylmethylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonic acid
22		(((2R,3S,4R,5R)-5-(5-chloro-7-((3-chlorobenzylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonic acid
23		(((2R,3S,4R,5R)-5-(5-chloro-7-(cyclobutylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonic acid
24		(((2R,3S,4R,5R)-5-(5-chloro-7-((cyclobutylmethylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonic acid
25		(((2S,3S,4R,5R)-5-(5-chloro-7-((cyclopropylmethylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)sulfonyl)methyl)phosphonic acid

Ex	Structure	Name
26		(((2R,3S,4R,5R)-5-(5-chloro-7-((2-chlorobenzyl)amino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonic acid
27		(((2S,3S,4R,5R)-5-(5-chloro-7-((2-chlorobenzyl)amino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)sulfonyl)methyl)phosphonic acid
28		2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-phosphonoacetic acid
29		(1-(((2R,3S,4R,5R)-5-(6-chloro-4-(methylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid
30		(1-(((2R,3S,4R,5R)-5-(6-chloro-4-((cyclopropylmethyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid
31		(1-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-methoxyethyl)phosphonic acid
32		((S)-1-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)ethyl)phosphonic acid
33		((R)-1-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)ethyl)phosphonic acid
34		(1-(((2S,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)sulfonyl)-3-hydroxypropyl)phosphonic acid

Ex	Structure	Name
35		((((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(1H-tetrazol-5-yl)methyl)phosphonic acid
36		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,4-dihydroxybutan-2-yl)phosphonic acid
37		(2-(((2R,3S,4R,5R)-5-(6-bromo-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,4-dihydroxybutan-2-yl)phosphonic acid
38		((((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(methylsulfonyl)methyl)phosphonic acid
39		(1-(((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid
40		(1-(((2S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-4-hydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid
41		(1-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-oxo-2-phenylethyl)phosphonic acid
42		(1-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxypropyl)phosphonic acid









Ex	Structure	Name
43		(1-(((2R,3R,4S,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid
44		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxypropan-2-yl)phosphonic acid
45		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxybutan-2-yl)phosphonic acid
46		((R)-1-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-methoxyethyl)phosphonic acid
47		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-(N-methylacetamido)propan-2-yl)phosphonic acid
48		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-(N-methylmethylsulfonamido)propan-2-yl)phosphonic acid
49		((R)-1-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-sulfamoyl)ethyl)phosphonic acid
50		((S)-1-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-sulfamoyl)ethyl)phosphonic acid

Ex	Structure	Name
51		(3-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)tetrahydrofuran-3-yl)phosphonic acid
52		(2-(carbamoyloxy)-1-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)ethyl)phosphonic acid
53		(((2R,3S,4R,5R)-5-(5-chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid
54		(((2R,3S,4R,5R)-5-(5-chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(methoxy)phosphoryl)methyl)phosphonic acid
55		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-(methylthio)propan-2-yl)phosphonic acid
56		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-4-hydroxybutan-2-yl)phosphonic acid
57		(1-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid
58		(1-(((2R,3S,4R,5R)-5-(5-chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid

Ex	Structure	Name
59		(1-(((2R,3S,4R,5R)-5-(4-amino-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid
60		(1-(((2R,3S,4R,5R)-5-(5-chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid
61		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(((R)-2,3-dihydro-1H-inden-1-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
62		((S)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
63		((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
64		((S)-1-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-methoxyethyl)phosphonic acid
65		((S)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxypropan-2-yl)phosphonic acid
66		(2-(((2R,3S,4R,5R)-5-(5-chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid

Ex	Structure	Name
67		(2-(((2R,3S,4R,5R)-5-(5-chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
68		(2-(((2R,3S,4R,5R)-5-(4-(cyclopentylamino)-6-(2-hydroxyethoxy)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
69		((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxypropan-2-yl)phosphonic acid
70		(2-(((2S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-4-hydroxytetrahydrofuran-2-yl)methoxy)-1-methoxypropan-2-yl)phosphonic acid
71		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-morpholinopropan-2-yl)phosphonic acid
72		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-methoxypropan-2-yl)phosphonic acid
73		((S)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-(methylsulfonyl)propan-2-yl)phosphonic acid
74		((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-(methylsulfonyl)propan-2-yl)phosphonic acid

Ex	Structure	Name
75		(1-(((2R,3S,4R,5R)-5-(2-chloro-6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid
76		(2-(((2R,3S,4R,5R)-5-(2-chloro-6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
77		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(((R)-2,3-dihydro-1H-inden-1-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxypropan-2-yl)phosphonic acid
78		(2-(((2R,3S,4R,5R)-5-(5-chloro-7-(((R)-2,3-dihydro-1H-inden-1-yl)amino)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
79		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-((cyclopropylmethyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxypropan-2-yl)phosphonic acid
80		(1-(((2R,3S,4R,5R)-5-(6-chloro-4-((cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2,2,2-trifluoroethyl)phosphonic acid
81		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-((cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-(dimethylamino)propan-2-yl)phosphonic acid
82		(2-(((2R,3S,4R,5R)-5-(5-chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxypropan-2-yl)phosphonic acid

Ex	Structure	Name
83		(((((2S,3S,4R,5R)-5-(5-chloro-7-((R)-2,3-dihydro-1H-inden-1-yl)amino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)sulfonyl)methyl)phosphonic acid
84		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(2H-tetrazol-5-yl)propan-2-yl)phosphonic acid
85		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-(2-hydroxyethoxy)propan-2-yl)phosphonic acid
86		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dihydroxypropan-2-yl)phosphonic acid
87		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dimethoxypropan-2-yl)phosphonic acid
88		(2-(((2R,3S,4R,5R)-5-(4-(cyclopentylamino)-6-(3-hydroxypropyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
89		(2-(((2R,3S,4R,5R)-5-(4-(cyclopentylamino)-6-(3-hydroxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
90		(2-(((2R,3S,4R,5R)-5-(4-(cyclopentylamino)-6-(hydroxymethyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxypropan-2-yl)phosphonic acid

Ex	Structure	Name
91		(2-(((2R,3S,4R,5R)-5-(2-chloro-4-(cyclopentylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
92		((S)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(oxazol-2-yl)propan-2-yl)phosphonic acid
93		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(pyridin-2-yl)propan-2-yl)phosphonic acid
94		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(1-methyl-1H-imidazol-4-yl)propan-2-yl)phosphonic acid
95		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(2,2,2-trifluoroethoxy)propan-2-yl)phosphonic acid
96		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(2-methyl-2H-tetrazol-5-yl)propan-2-yl)phosphonic acid
97		((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxyhex-4-yn-2-yl)phosphonic acid
98		((S)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxyhex-4-yn-2-yl)phosphonic acid

Ex	Structure	Name
99		((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-((R)-6-fluoro-2,3-dihydro-1H-inden-1-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
100		(2-(((2R,3S,4R,5R)-5-(4-(((R)-2,3-dihydro-1H-inden-1-yl)amino)-6-(2-hydroxyethoxy)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dihydroxypropan-2-yl)phosphonic acid
101		((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclobutylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
102		((S)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclobutylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
103		((S)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(2H-tetrazol-5-yl)propan-2-yl)phosphonic acid
104		((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(2H-tetrazol-5-yl)propan-2-yl)phosphonic acid
105		((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-((1-methylcyclopentyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
106		((S)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-((1-methylcyclopentyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid

Ex	Structure	Name
107		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(methylsulfonyl)propan-2-yl)phosphonic acid
108		((S)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(((R)-6-fluoro-2,3-dihydro-1H-inden-1-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
109		((S)-2-(((2R,3S,4R,5R)-5-(5-chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxypropan-2-yl)phosphonic acid
110		((R)-2-(((2R,3S,4R,5R)-5-(5-chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxypropan-2-yl)phosphonic acid
111		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxypropan-2-yl)phosphonic acid
112		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dihydroxypropan-2-yl)ethyl)phosphinic acid
113		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(((R)-2,3-dihydro-1H-inden-1-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dihydroxypropan-2-yl)phosphonic acid
114		((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-isopropoxypropan-2-yl)phosphonic acid

Ex	Structure	Name
115		((S)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-isopropoxypropan-2-yl)phosphonic acid
116		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclobutylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dihydroxypropan-2-yl)phosphonic acid
117		(1-(((2R,3S,4R,5R)-5-(2-chloro-4-(cyclopentylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid
118		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-isopropoxypropan-2-yl)phosphonic acid
119		((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-(2H-tetrazol-5-yl)propan-2-yl)phosphonic acid
120		((S)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-(2H-tetrazol-5-yl)propan-2-yl)phosphonic acid
121		((S)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-((R)-5-fluoro-2,3-dihydro-1H-inden-1-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
122		((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-((R)-5-fluoro-2,3-dihydro-1H-inden-1-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid

Ex	Structure	Name
123		((S)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(spiro[3.3]heptan-2-ylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
124		((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-(2-hydroxyethoxy)propan-2-yl)phosphonic acid
125		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-((cyclopropylmethyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dimethoxypropan-2-yl)phosphonic acid
126		((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(spiro[3.3]heptan-2-ylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
127		((S)-2-(((2R,3S,4R,5R)-5-(4-(cyclopentylamino)-6-(hydroxymethyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
128		((R)-2-(((2R,3S,4R,5R)-5-(4-(cyclopentylamino)-6-(hydroxymethyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
129		((S)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-((cyclopropylmethyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxypropan-2-yl)phosphonic acid
130		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclobutylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid

Ex	Structure	Name
131		((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-((cyclopropylmethyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxypropan-2-yl)phosphonic acid
132		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-((cyclopropylmethyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dihydroxypropan-2-yl)phosphonic acid
133		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(((1R,3aR,6aR)-octahydropentalen-1-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
134		((R)-2-(((2R,3S,4R,5R)-5-(4-(cyclopentylamino)-6-(2-hydroxyethoxy)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
135		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(((R)-spiro[3.3]heptan-1-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
136		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-spiro[3.3]heptan-1-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
137		((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-(ethylsulfonyl)propan-2-yl)phosphonic acid
138		((S)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-(ethylsulfonyl)propan-2-yl)phosphonic acid

Ex	Structure	Name
139		((R)-2-(((2R,3S,4R,5R)-5-(5-chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
140		((S)-2-(((2R,3S,4R,5R)-5-(5-chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
141		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(((1S,3aS,6aS)-octahydropentalen-1-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
142		(1-(((2R,3S,4R,5R)-5-(5-chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-methoxyethyl)phosphonic acid
143		((S)-2-(((2R,3S,4R,5R)-5-(5-chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxypropan-2-yl)phosphonic acid
144		((R)-1-(((2R,3S,4R,5R)-5-(5-chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid
145		(2-(((2R,3S,4R,5R)-5-(4-(cyclopentylamino)-6-(2-methoxyethoxy)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
146		(2-(((2R,3S,4R,5R)-5-(4-(cyclopentylamino)-6-(2-hydroxy-2-methylpropoxy)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid

Ex	Structure	Name
147		((S)-2-(((2R,3S,4R,5R)-5-(4-(cyclopentylamino)-6-(2-hydroxyethoxy)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
148		((R)-2-(((2R,3S,4R,5R)-5-(5-chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxypropan-2-yl)phosphonic acid
149		((S)-1-(((2R,3S,4R,5R)-5-(5-chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid
150		((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-methoxypropan-2-yl)phosphonic acid
151		((S)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-methoxypropan-2-yl)phosphonic acid
152		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
153		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-(cyclopropylmethoxy)propan-2-yl)phosphonic acid
154		(2-(((2R,3S,4R,5S)-5-(5-chloro-7-(((R)-2,3-dihydro-1H-inden-1-yl)amino)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxypropan-2-yl)phosphonic acid

Ex	Structure	Name
155		(2-(((2R,3S,4R,5R)-5-(5-chloro-7-(((R)-2,3-dihydro-1H-inden-1-yl)amino)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxypropan-2-yl)phosphonic acid
156		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-ethoxypropan-2-yl)phosphonic acid
157		((R)-1-(((2R,3S,4R,5R)-5-(5-chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-methoxyethyl)phosphonic acid
158		(2-(((2R,3S,4R,5R)-5-(2-chloro-6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxypropan-2-yl)phosphonic acid
159		(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclobutylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxypropan-2-yl)phosphonic acid
160		(1-(((2R,3S,4R,5R)-5-(2-chloro-6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-methoxyethyl)phosphonic acid
161		((S)-1-(((2R,3S,4R,5R)-5-(5-chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-methoxyethyl)phosphonic acid
162		(((2S,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)sulfonyl)methyl)phosphonic acid

Ex	Structure	Name
163		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-cyclobutoxy-3-hydroxypropan-2-yl)phosphonic acid
164		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(((1R,3aR,6aR)-octahydropentalen-1-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dihydroxypropan-2-yl)phosphonic acid
165		rac-((R)-2-(((2R,3S,4R,5R)-5-(4-(cyclopentylamino)-6-((R)-2-hydroxypropoxy)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
166		rac-(1-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-(2-hydroxyethoxy)ethyl)phosphonic acid
167		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(oxetan-3-yl)propan-2-yl)phosphonic acid
168		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(pyrimidin-2-yl)propan-2-yl)phosphonic acid
169		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-ethoxy-3-hydroxypropan-2-yl)phosphonic acid
170		rac-((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-(cyclopropylmethoxy)-3-hydroxypropan-2-yl)phosphonic acid

Ex	Structure	Name
171		rac-((R)-2-(((2S,3R,4S,5S)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-(cyclopropylmethoxy)-3-hydroxypropan-2-yl)phosphonic acid
172		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(2-hydroxyethoxy)propan-2-yl)phosphonic acid
173		rac-((R)-2-(((2S,3R,4S,5S)-5-(6-chloro-4-(((1S,3aS,6aS)-octahydropentalen-1-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
174		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclobutylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dimethoxypropan-2-yl)phosphonic acid
175		rac-(2-(((2R,3S,4R,5R)-5-(4-(cyclopentylamino)-6-(2-hydroxy-2-methylpropoxy)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dihydroxypropan-2-yl)phosphonic acid
176		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(((R)-5-fluoro-2,3-dihydro-1H-inden-1-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dihydroxypropan-2-yl)phosphonic acid
177		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-(2-hydroxyethoxy)-3-(2-methoxyethoxy)propan-2-yl)phosphonic acid
178		rac-(1-(carbamoyloxy)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-3-hydroxypropan-2-yl)phosphonic acid

Ex	Structure	Name
179		rac-((R)-1-(benzyloxy)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-3-hydroxypropan-2-yl)phosphonic acid
180		rac-((R)-1-(benzyloxy)-2-(((2S,3R,4S,5S)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-3-hydroxypropan-2-yl)phosphonic acid
181		rac-(2-(((2R,3S,4R,5R)-5-(4-(cyclopentylamino)-6-((S)-2-hydroxypropoxy)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dihydroxypropan-2-yl)phosphonic acid
182		rac-((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(((1R,3aR,6aR)-octahydropentalen-1-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
183		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(4-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
184		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(((cyclopropylmethyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(2H-tetrazol-5-yl)propan-2-yl)phosphonic acid
185		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-diethoxypropan-2-yl)phosphonic acid
186		rac-(3-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-5-oxotetrahydrofuran-3-yl)phosphonic acid

Ex	Structure	Name
187		rac-4-((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-3-hydroxy-2-phosphonopropyl)benzoic acid
188		rac-4-((R)-2-(((2S,3R,4S,5S)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-3-hydroxy-2-phosphonopropyl)benzoic acid
189		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dihydroxypropan-2-yl)phosphonic acid
190		rac-3-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-3-hydroxy-2-phosphonopropyl)benzoic acid
191		rac-(2-(((2R,3S,4R,5R)-5-(4-(cyclopentylamino)-6-((R)-2-hydroxypropoxy)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dihydroxypropan-2-yl)phosphonic acid
192		rac-(2-(((2R,3S,4R,5R)-5-(4-(cyclopentylamino)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
193		rac-((R)-2-(((2S,3R,4S,5S)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
194		rac-((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid

Ex	Structure	Name
195		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(3-hydroxyisoxazol-5-yl)propan-2-yl)phosphonic acid
196		rac-((R)-2-(((2S,3R,4S,5S)-5-(6-chloro-4-((cyclopropylmethyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(2H-tetrazol-5-yl)propan-2-yl)phosphonic acid
197		rac-((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-((cyclopropylmethyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(2H-tetrazol-5-yl)propan-2-yl)phosphonic acid
198		rac-2-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-3-hydroxy-2-phosphonopropoxy)acetic acid
199		rac-((R)-2-(((2S,3R,4S,5S)-5-(4-(cyclopentylamino)-6-(3-hydroxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
200		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dihydroxypropan-2-yl)phosphonic acid
201		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-((4-chlorobenzyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dihydroxypropan-2-yl)phosphonic acid
202		rac-(2-(((2R,3S,4R,5R)-5-(4-((cyclopropylmethyl)amino)-6-(hydroxymethyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dihydroxypropan-2-yl)phosphonic acid
203		rac-(2-(((2R,3S,4R,5S)-5-(6-chloro-4-((4-chlorobenzyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dihydroxypropan-2-yl)phosphonic acid

Ex	Structure	Name
204		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(spiro[3.3]heptan-1-ylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dihydroxypropan-2-yl)phosphonic acid
205		rac-((R)-2-(((2R,3S,4R,5R)-5-(4-(cyclopentylamino)-6-(3-hydroxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid
206		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)propan-2-yl)phosphonic acid
207		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(2,2,2-trifluoroethoxy)propan-2-yl)phosphonic acid
208		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(2,2,2-trifluoroethoxy)propan-2-yl)phosphonic acid
209		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(((1S,2R)-2-methylcyclopentyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(2H-tetrazol-5-yl)propan-2-yl)phosphonic acid
210		rac-3-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-4-methoxy-3-phosphonobutanoic acid

Ex	Structure	Name
211		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentyl(methyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dihydroxypropan-2-yl)phosphonic acid
212		rac-((R)-2-(((2S,3R,4S,5S)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxy-3-(2H-tetrazol-5-yl)propan-2-yl)phosphonic acid
213		rac-((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclobutylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(2H-tetrazol-5-yl)propan-2-yl)phosphonic acid
214		rac-((R)-2-(((2S,3R,4S,5S)-5-(6-chloro-4-(cyclobutylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(2H-tetrazol-5-yl)propan-2-yl)phosphonic acid
215		rac-((R)-1-(carbamoyloxy)-2-(((2S,3R,4S,5S)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-3-hydroxypropan-2-yl)phosphonic acid
216		rac-((R)-1-(carbamoyloxy)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-3-hydroxypropan-2-yl)phosphonic acid
217		rac-((R)-2-(((2S,3R,4S,5S)-5-(4-(cyclopentylamino)-6-(hydroxymethyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(2H-tetrazol-5-yl)propan-2-yl)phosphonic acid
218		rac-((R)-2-(((2R,3S,4R,5R)-5-(4-(cyclopentylamino)-6-(hydroxymethyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(2H-tetrazol-5-yl)propan-2-yl)phosphonic acid

Ex	Structure	Name
219		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(1H-1,2,4-triazol-3-yl)propan-2-yl)phosphonic acid
220		rac-(R)-2-(((2S,3R,4S,5S)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-3-methoxy-2-phosphonopropanoic acid
221		rac-(R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-3-methoxy-2-phosphonopropanoic acid
222		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(((R)-1-(4-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dihydroxypropan-2-yl)phosphonic acid
223		rac-((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclobutylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxy-3-(2H-tetrazol-5-yl)propan-2-yl)phosphonic acid
224		rac-(2-(((2R,3S,4R,5R)-5-(4-(cyclopentylamino)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dihydroxypropan-2-yl)phosphonic acid
225		rac-((R)-2-(((2S,3R,4S,5S)-5-(6-chloro-4-((cyclopropylmethyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxy-3-(2H-tetrazol-5-yl)propan-2-yl)phosphonic acid
226		rac-(1-((2H-tetrazol-5-yl)methoxy)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-3-hydroxypropan-2-yl)phosphonic acid


Ex	Structure	Name
227		rac-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-3-hydroxy-2-phosphonopropoxy)methyl)benzoic acid
228		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(((1S,2R)-2-methylcyclopentyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dihydroxypropan-2-yl)phosphonic acid
229		rac-6-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-3-hydroxy-2-phosphonopropyl)picolinic acid
230		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(6-(hydroxymethyl)pyridin-2-yl)propan-2-yl)phosphonic acid
231		rac-6-(2-carboxy-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-phosphonoethyl)picolinic acid
232		rac-(R)-3-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-4-methoxy-3-phosphonobutanoic acid
233		rac-(R)-3-(((2S,3R,4S,5S)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-4-methoxy-3-phosphonobutanoic acid
234		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(((1R,2S)-2-methylcyclopentyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(2H-tetrazol-5-yl)propan-2-yl)phosphonic acid


Ex	Structure	Name
235		rac-((R)-2-(((2S,3R,4S,5S)-5-(4-(cyclopentylamino)-6-(hydroxymethyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxy-3-(1H-tetrazol-5-yl)propan-2-yl)phosphonic acid
236		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-ethoxy-3-methoxy-1-oxopropan-2-yl)phosphonic acid
237		rac-((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-((cyclopropylmethyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-methoxypropan-2-yl)phosphonic acid
238		rac-((R)-2-(((2S,3R,4S,5S)-5-(6-chloro-4-((cyclopropylmethyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-methoxypropan-2-yl)phosphonic acid
239		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(isopropylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(2H-tetrazol-5-yl)propan-2-yl)phosphonic acid
240		rac-((R)-1-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxy-1-(2H-tetrazol-5-yl)ethyl)phosphonic acid
241		rac-((R)-1-(((2S,3R,4S,5S)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxy-1-(2H-tetrazol-5-yl)ethyl)phosphonic acid
242		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(((1R,2R)-2-methylcyclopentyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1,3-dihydroxypropan-2-yl)phosphonic acid


Ex	Structure	Name
243		rac-((R)-2-(((2S,3R,4S,5S)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-(2-ethoxy-2-oxoethoxy)-3-hydroxypropan-2-yl)phosphonic acid
244		rac-((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-(2-ethoxy-2-oxoethoxy)-3-hydroxypropan-2-yl)phosphonic acid
245		rac-2-((R)-2-(((2S,3R,4S,5S)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-3-hydroxy-2-phosphonopropoxy)acetic acid
246		rac-2-((R)-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-3-hydroxy-2-phosphonopropoxy)acetic acid
247		rac-2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-3-hydroxy-2-phosphonopropanoic acid
248		rac-(2-(((2R,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-ethoxy-3-hydroxy-1-oxopropan-2-yl)phosphonic acid

[00271] In some embodiments is a compound, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, having a structure selected from:













[00272] In some embodiments is a compound, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, having a structure selected from:













[00273] In some embodiments is a compound, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, having a structure selected from:





[00275] In some embodiments is a compound, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, having a structure selected from:










The figure displays six chemical structures of nucleoside analogs, labeled 1 through 6, arranged in a 3x2 grid. Each structure consists of a ribose sugar moiety linked to a phosphate group (HO-P(=O)(OH)-CH₂-SO₂-) and a nucleobase. The ribose sugar has hydroxyl groups at the 2' and 3' positions, with the 3' OH group being dashed and the 2' OH group being wedged. The phosphate group is attached to the 5' carbon of the ribose. The nucleobase is attached to the 1' carbon of the ribose. The structures are as follows:


- 1**: Guanine base with a 4-chloro substituent and a 2-(cyclopentylamino) substituent.
- 2**: Guanine base with a 4-chloro substituent and a 2-(cyclopentylamino) substituent.
- 3**: Guanine base with a 4-chloro substituent and a 2-(cyclopentylamino) substituent.
- 4**: Guanine base with a 4-chloro substituent and a 2-(cyclopentylamino) substituent.
- 5**: Guanine base with a 4-chloro substituent and a 2-(cyclopentylamino) substituent.
- 6**: Guanine base with a 4-chloro substituent and a 2-(cyclopentylamino) substituent.




[00278] In some embodiments is a compound, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, having a structure selected from:







[00279] In some embodiments is a compound, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, having a structure selected from:



Further Forms of Compounds Disclosed Herein

Isomers/Stereoisomers

[00280] In some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein possess one or more double bonds. The compounds presented herein include all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as the corresponding mixtures thereof. In some situations, the compounds described herein possess one or more chiral centers and each center exists in the R configuration, or S configuration. The compounds described

herein include all diastereomeric, enantiomeric, and epimeric forms as well as the corresponding mixtures thereof. In additional embodiments of the compounds and methods provided herein, mixtures of enantiomers and/or diastereoisomers, resulting from a single preparative step, combination, or interconversion are useful for the applications described herein. In some embodiments, the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers. In some embodiments, dissociable complexes are preferred. In some embodiments, the diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and are separated by taking advantage of these dissimilarities. In some embodiments, the diastereomers are separated by chiral chromatography, or preferably, by separation/resolution techniques based upon differences in solubility. In some embodiments, the optically pure enantiomer is then recovered, along with the resolving agent.

Labeled compounds

[00281] In some embodiments, the compounds described herein exist in their isotopically-labeled forms. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such isotopically-labeled compounds. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such isotopically-labeled compounds as pharmaceutical compositions. Thus, in some embodiments, the compounds disclosed herein include isotopically-labeled compounds, which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds disclosed herein, or a solvate, or stereoisomer thereof, include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, and chloride, such as ^2H , ^3H , ^{13}C , ^{14}C , ^{15}N , ^{18}O , ^{17}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F , and ^{36}Cl , respectively. Compounds described herein, and the metabolites, pharmaceutically acceptable salts, esters, prodrugs, solvate, hydrates or derivatives thereof which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically-labeled compounds, for example those into which radioactive isotopes such as ^3H and ^{14}C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., ^3H and carbon-14, i.e., ^{14}C , isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavy isotopes such as deuterium, i.e., ^2H , produces certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements. In some embodiments, the isotopically labeled compound or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof is prepared by any suitable method.

[00282] In some embodiments, the compounds described herein are labeled by other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.

Pharmaceutically acceptable salts

[00283] In some embodiments, the compounds described herein exist as their pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions.

[00284] In some embodiments, the compounds described herein possess acidic or basic groups and therefor react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. In some embodiments, these salts are prepared *in situ* during the final isolation and purification of the compounds disclosed herein, or by separately reacting a purified compound in its free form with a suitable acid or base, and isolating the salt thus formed.

[00285] Examples of pharmaceutically acceptable salts include those salts prepared by reaction of the compounds described herein with a mineral, organic acid, or inorganic base, such salts including acetate, acrylate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, bisulfite, bromide, butyrate, butyn-1,4-dioate, camphorate, camphorsulfonate, caproate, caprylate, chlorobenzoate, chloride, citrate, cyclopentanepropionate, decanoate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hexyne-1,6-dioate, hydroxybenzoate, γ -hydroxybutyrate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isobutyrate, lactate, maleate, malonate, methanesulfonate, mandelate metaphosphate, methanesulfonate, methoxybenzoate, methylbenzoate, monohydrogenphosphate, 1-naphthalenesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, pyrosulfate, pyrophosphate, propiolate, phthalate, phenylacetate, phenylbutyrate, propanesulfonate, salicylate, succinate, sulfate, sulfite, succinate, suberate, sebacate, sulfonate, tartrate, thiocyanate, tosylate, undecanoate, and xylenesulfonate.

[00286] Further, the compounds described herein can be prepared as pharmaceutically acceptable salts formed by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, including, but not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, metaphosphoric acid, and the like; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and muconic acid.

[00287] In some embodiments, those compounds described herein which comprise a free acid group react with a suitable base, such as the hydroxide, carbonate, bicarbonate, sulfate, of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine. Representative salts include the alkali or alkaline earth salts, like lithium, sodium, potassium, calcium, and magnesium, and aluminum salts and the like. Illustrative examples of bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, $N^+(C_{1-4} \text{ alkyl})_4$, and the like.

[00288] Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like. It should be understood that the compounds described herein also include the quaternization of any basic nitrogen-containing groups they contain. In some embodiments, water or oil-soluble or dispersible products are obtained by such quaternization.

Solvates

[00289] In some embodiments, the compounds described herein exist as solvates. The invention provides for methods of treating diseases by administering such solvates. The invention further provides for methods of treating diseases by administering such solvates as pharmaceutical compositions.

[00290] Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and, in some embodiments, are formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein can be conveniently prepared or formed during the processes described herein. By way of example only, hydrates of the compounds described herein can be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents including, but not limited to, dioxane, tetrahydrofuran, or methanol. In addition, the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.

Tautomers

[00291] In some situations, compounds exist as tautomers. The compounds described herein include all possible tautomers within the formulas described herein. Tautomers are compounds that are interconvertible by migration of a hydrogen atom, accompanied by a switch of a single bond and adjacent double bond. In bonding arrangements where tautomerization is possible, a chemical equilibrium of the tautomers will exist. All tautomeric forms of the compounds disclosed herein are contemplated. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH.

Preparation of the Compounds


[00292] The compounds used in the reactions described herein are made according to organic synthesis techniques known to those skilled in this art, starting from commercially available chemicals and/or from compounds described in the chemical literature. "Commercially available chemicals" are obtained from


standard commercial sources including Acros Organics (Pittsburgh, PA), Aldrich Chemical (Milwaukee, WI, including Sigma Chemical and Fluka), Apin Chemicals Ltd. (Milton Park, UK), Avocado Research (Lancashire, U.K.), BDH Inc. (Toronto, Canada), Bionet (Cornwall, U.K.), Chemservice Inc. (West Chester, PA), Crescent Chemical Co. (Hauppauge, NY), Eastman Organic Chemicals, Eastman Kodak Company (Rochester, NY), Fisher Scientific Co. (Pittsburgh, PA), Fisons Chemicals (Leicestershire, UK), Frontier Scientific (Logan, UT), ICN Biomedicals, Inc. (Costa Mesa, CA), Key Organics (Cornwall, U.K.), Lancaster Synthesis (Windham, NH), Maybridge Chemical Co. Ltd. (Cornwall, U.K.), Parish Chemical Co. (Orem, UT), Pfaltz & Bauer, Inc. (Waterbury, CN), Polyorganix (Houston, TX), Pierce Chemical Co. (Rockford, IL), Riedel de Haen AG (Hanover, Germany), Spectrum Quality Product, Inc. (New Brunswick, NJ), TCI America (Portland, OR), Trans World Chemicals, Inc. (Rockville, MD), and Wako Chemicals USA, Inc. (Richmond, VA).

[00293] Suitable reference books and treatise that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation, include for example, "Synthetic Organic Chemistry", John Wiley & Sons, Inc., New York; S. R. Sandler et al., "Organic Functional Group Preparations," 2nd Ed., Academic Press, New York, 1983; H. O. House, "Modern Synthetic Reactions", 2nd Ed., W. A. Benjamin, Inc. Menlo Park, Calif. 1972; T. L. Gilchrist, "Heterocyclic Chemistry", 2nd Ed., John Wiley & Sons, New York, 1992; J. March, "Advanced Organic Chemistry: Reactions, Mechanisms and Structure", 4th Ed., Wiley-Interscience, New York, 1992. Additional suitable reference books and treatise that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation, include for example, Fuhrhop, J. and Penzlin G. "Organic Synthesis: Concepts, Methods, Starting Materials", Second, Revised and Enlarged Edition (1994) John Wiley & Sons ISBN: 3-527-29074-5; Hoffman, R.V. "Organic Chemistry, An Intermediate Text" (1996) Oxford University Press, ISBN 0-19-509618-5; Larock, R. C. "Comprehensive Organic Transformations: A Guide to Functional Group Preparations" 2nd Edition (1999) Wiley-VCH, ISBN: 0-471-19031-4; March, J. "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure" 4th Edition (1992) John Wiley & Sons, ISBN: 0-471-60180-2; Otera, J. (editor) "Modern Carbonyl Chemistry" (2000) Wiley-VCH, ISBN: 3-527-29871-1; Patai, S. "Patai's 1992 Guide to the Chemistry of Functional Groups" (1992) Interscience ISBN: 0-471-93022-9; Solomons, T. W. G. "Organic Chemistry" 7th Edition (2000) John Wiley & Sons, ISBN: 0-471-19095-0; Stowell, J.C., "Intermediate Organic Chemistry" 2nd Edition (1993) Wiley-Interscience, ISBN: 0-471-57456-2; "Industrial Organic Chemicals: Starting Materials and Intermediates: An Ullmann's Encyclopedia" (1999) John Wiley & Sons, ISBN: 3-527-29645-X, in 8 volumes; "Organic Reactions" (1942-2000) John Wiley & Sons, in over 55 volumes; and "Chemistry of Functional Groups" John Wiley & Sons, in 73 volumes.


[00294] Specific and analogous reactants are optionally identified through the indices of known chemicals prepared by the Chemical Abstract Service of the American Chemical Society, which are available in most public and university libraries, as well as through on-line databases (contact the American Chemical Society, Washington, D.C for more details). Chemicals that are known but not commercially available in catalogs are

[00295] In some embodiments, the compounds described herein are prepared as outlined in Schemes 1-7.







Scheme 3




Scheme 4




Scheme 5



Scheme 6



Scheme 7



Pharmaceutical Compositions

[00296] In certain embodiments, the compound disclosed herein is administered as a pure chemical. In some embodiments, the compound disclosed herein is combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) selected on the basis of a chosen route of administration and standard pharmaceutical practice as described, for example, in *Remington: The Science and Practice of Pharmacy* (Gennaro, 21st Ed. Mack Pub. Co., Easton, PA (2005)).

[00297] Accordingly, provided herein is a pharmaceutical composition comprising at least one compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, together with one or more pharmaceutically acceptable carriers. The carrier(s) (or excipient(s)) is acceptable or suitable if the carrier is compatible with the other ingredients of the composition and not deleterious to the recipient (*i.e.*, the subject) of the composition.

[00298] One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof.

[00299] In certain embodiments, the compound disclosed herein is substantially pure, in that it contains less than about 5%, or less than about 1%, or less than about 0.1%, of other organic small molecules, such as unreacted intermediates or synthesis by-products that are created, for example, in one or more of the steps of a synthesis method.

[00300] Pharmaceutical compositions are administered in a manner appropriate to the disease to be treated (or prevented). An appropriate dose and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient's disease, the particular form of the active ingredient, and the method of administration. In general, an appropriate dose and treatment regimen provides the composition(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit (e.g., an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity). Optimal doses are generally determined using experimental models and/or clinical trials. The optimal dose depends upon the body mass, weight, or blood volume of the patient.

[00301] Oral doses typically range from about 1.0 mg to about 1000 mg, one to four times, or more, per day.

Methods of Treatment

[00302] The compounds disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, are useful as inhibitors of CD73 and, therefore, useful in the treatment of diseases or disorders in which it is believed CD73 activity plays a role. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is an infection. In some embodiments, the disease or

disorder is a neurodegenerative disease. In some embodiments, the disease or disorder is a psychiatric disorder.

[00303] Disclosed herein are methods of treating a subject with a disorder mediated by CD73 comprising the step of administering to the subject an effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof.

Cancer

[00304] CD73 has been found to be overexpressed in many cancer cell lines and tumor types including breast cancer, colorectal cancer, ovarian cancer, gastric cancer, and gallbladder cancer and associated with poor prognosis. Increasing evidence suggests that CD73 is a key protein molecule in cancer development.

[00305] Higher expression levels of CD73 are associated with tumor neovascularization, invasiveness, resistance to chemotherapy and metastasis, and with shorter patient survival time in cancer. In some embodiments, the compounds disclosed herein are useful in reducing tumor neovascularization, invasiveness, resistance to chemotherapy and metastasis, as well as to lengthen patient survival time in cancer patients. In some embodiments, the CD73 inhibitors disclosed herein are used to control tumor neovascularization, progression, resistance to chemotherapy, and metastasis.

[00306] One embodiment provides a method of treating cancer in a subject in need thereof, comprising administering to the subject a compound of disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof.

[00307] In some embodiments, the cancer is chemoresistant cancer, radio resistant cancer, anti-hormonal therapy resistant cancer, or treatment refractory cancer. In some embodiments, the cancer is relapsed cancer, persistent cancer, or recurrent cancer. Another embodiment provided herein describes a method of reducing incidences of cancer recurrence. Also provided here in some embodiments, is a method for treating a therapy-resistant cancer. In some embodiments, the cancer is metastatic cancer.

[00308] In certain embodiments, the cancer treatable with the methods provided herein includes, but is not limited to, (1) leukemias, including, but not limited to, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemias such as myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia leukemias and myelodysplastic syndrome or a symptom thereof (such as anemia, thrombocytopenia, neutropenia, bicytopenia, or pancytopenia), refractory anemia (RA), RA with ringed sideroblasts (RARS), RA with excess blasts (RAEB), RAEB in transformation (RAEB-T), preleukemia, and chronic myelomonocytic leukemia (CMML); (2) chronic leukemias, including, but not limited to, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, and hairy cell leukemia; (3) polycythemia vera; (4) lymphomas, including, but not limited to, Hodgkin's disease and non-Hodgkin's disease; (5) multiple myelomas, including, but not limited to, smoldering multiple myeloma, non-secretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma, and extramedullary plasmacytoma; (6) Waldenstrom's macroglobulinemia; (7) monoclonal gammopathy of undetermined significance; (8) benign monoclonal gammopathy; (9) heavy chain disease; (10) bone and connective tissue

sarcomas, including, but not limited to, bone sarcoma, osteosarcoma, chondrosarcoma, Ewing's sarcoma, malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal sarcoma, soft-tissue sarcomas, angiosarcoma (hemangiosarcoma), fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, metastatic cancers, neurilemmoma, rhabdomyosarcoma, and synovial sarcoma; (11) brain tumors, including, but not limited to, glioma, astrocytoma, brain stem glioma, ependymoma, oligodendroglioma, nonglial tumor, acoustic neurinoma, craniopharyngioma, medulloblastoma, meningioma, pineocytoma, pineoblastoma, and primary brain lymphoma; (12) breast cancer, including, but not limited to, adenocarcinoma, lobular (small cell) carcinoma, intraductal carcinoma, medullary breast cancer, mucinous breast cancer, tubular breast cancer, papillary breast cancer, primary cancers, Paget's disease, and inflammatory breast cancer; (13) adrenal cancer, including, but not limited to, pheochromocytoma and adrenocortical carcinoma; (14) thyroid cancer, including, but not limited to, papillary or follicular thyroid cancer, medullary thyroid cancer, and anaplastic thyroid cancer; (15) pancreatic cancer, including, but not limited to, insulinoma, gastrinoma, glucagonoma, vipoma, somatostatin-secreting tumor, and carcinoid or islet cell tumor; (16) pituitary cancer, including, but limited to, Cushing's disease, prolactin-secreting tumor, acromegaly, and diabetes insipidus; (17) eye cancer, including, but not limited to, ocular melanoma such as iris melanoma, choroidal melanoma, and ciliary body melanoma, and retinoblastoma; (18) vaginal cancer, including, but not limited to, squamous cell carcinoma, adenocarcinoma, and melanoma; (19) vulvar cancer, including, but not limited to, squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget's disease; (20) cervical cancers, including, but not limited to, squamous cell carcinoma, and adenocarcinoma; (21) uterine cancer, including, but not limited to, endometrial carcinoma and uterine sarcoma; (22) ovarian cancer, including, but not limited to, ovarian epithelial carcinoma, borderline tumor, germ cell tumor, and stromal tumor; (23) esophageal cancer, including, but not limited to, squamous cancer, adenocarcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma, and oat cell (small cell) carcinoma; (24) stomach cancer, including, but not limited to, adenocarcinoma, fungating (polypoid), ulcerating, superficial spreading, diffusely spreading, malignant lymphoma, liposarcoma, fibrosarcoma, and carcinosarcoma; (25) colon cancer; (26) rectal cancer; (27) liver cancer, including, but not limited to, hepatocellular carcinoma and hepatoblastoma; (28) gallbladder cancer, including, but not limited to, adenocarcinoma; (29) cholangiocarcinomas, including, but not limited to, papillary, nodular, and diffuse; (30) lung cancer, including, but not limited to, non-small cell lung cancer, squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma, large-cell carcinoma, and small-cell lung cancer; (31) testicular cancer, including, but not limited to, germinal tumor, seminoma, anaplastic, classic (typical), spermatocytic, nonseminoma, embryonal carcinoma, teratoma carcinoma, and choriocarcinoma (yolk-sac tumor); (32) prostate cancer, including, but not limited to, adenocarcinoma, leiomyosarcoma, and rhabdomyosarcoma; (33) penile cancer; (34) oral cancer, including, but not limited to, squamous cell carcinoma; (35) basal cancer; (36) salivary gland cancer, including, but not limited to, adenocarcinoma, mucoepidermoid carcinoma, and adenoidcystic carcinoma; (37) pharynx cancer, including,

but not limited to, squamous cell cancer and verrucous; (38) skin cancer, including, but not limited to, basal cell carcinoma, squamous cell carcinoma and melanoma, superficial spreading melanoma, nodular melanoma, lentigo malignant melanoma, and acral lentiginous melanoma; (39) kidney cancer, including, but not limited to, renal cell cancer, adenocarcinoma, hypernephroma, fibrosarcoma, and transitional cell cancer (renal pelvis and/or uterine); (40) Wilms' tumor; (41) bladder cancer, including, but not limited to, transitional cell carcinoma, squamous cell cancer, adenocarcinoma, and carcinosarcoma; (42) reproductive cancers, such as cervical cancer, uterus cancer, ovarian cancer, or testicular cancer; (43) esophagus cancer; (44) laryngeal cancer; (45) head and neck cancers (including mouth, nose, throat, larynx, sinuses, or salivary glands cancers); and other cancer, including, not limited to, myxosarcoma, osteogenic sarcoma, endotheliosarcoma, lymphangio-endotheliosarcoma, mesothelioma, synovium, hemangioblastoma, epithelial carcinoma, cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, and papillary adenocarcinomas (See Fishman et al., 1985, *Medicine*, 2d Ed., J.B. Lippincott Co., Philadelphia and Murphy et al., 1997, *Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery*, Viking Penguin, Penguin Books U.S.A., Inc., United States of America).

[00309] In certain embodiments, the cancer treatable with the methods provided herein is a hematological malignancy. In certain embodiments, the hematological malignancy is a T-cell malignancy. In certain embodiments, T-cell malignancies include peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), anaplastic large cell lymphoma, angioimmunoblastic lymphoma, cutaneous T-cell lymphoma, adult T-cell leukemia/lymphoma (ATLL), blastic NK-cell lymphoma, enteropathy-type T-cell lymphoma, hematosplenic gamma-delta T-cell lymphoma, lymphoblastic lymphoma, nasal NK/T-cell lymphomas, or treatment-related T-cell lymphomas.

[00310] In certain embodiments, the hematological malignancy is a B-cell malignancy. In certain embodiments, B-cell malignancies include acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), acute monocytic leukemia (AMoL), chronic lymphocytic leukemia (CLL), high-risk chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), high-risk small lymphocytic lymphoma (SLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Waldenström's macroglobulinemia, multiple myeloma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, Burkitt's lymphoma, non-Burkitt high grade B cell lymphoma, primary mediastinal B-cell lymphoma (PMBL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, B cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, or lymphomatoid granulomatosis. In certain embodiments, the B-cell malignancy is diffuse large B-cell lymphoma (DLBCL). In certain embodiments, the DLBCL is an activated B-cell DLBCL (ABC-DLBCL), a germinal center B-cell like DLBCL (GBC-DLBCL), a double hit DLBCL (DH-DLBCL), or a triple hit DLBCL (TH-DLBCL).

[00311] In certain embodiments, the cancer treatable with the methods provided herein is lung cancer, melanoma, breast cancer, ovarian cancer, colorectal cancer, gastric cancer, gallbladder cancer, or prostate cancer.

Infections

[00312] A number of studies have shown changes in the activity of the CD39/CD73 axis during infections induced by a variety of microorganisms. One embodiment provides a method of treating an infection in a subject in need thereof, comprising administering to the subject a compound of disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof.

[00313] In some embodiments, the infection is a viral infection, a bacterial infection, or a parasitic infection.

Parasitic infections

[00314] In some embodiments, the infection is a parasitic infection. In some embodiments, the parasitic infection is caused by infection of the subject with a protozoan organism. In some embodiments, the protozoan organism selected from the group consisting of the genera Acanthamoeba, Babesia, Balantidium, Cryptosporidium, Dientamoeba, Eimeria, Entamoeba, Giardia, Isospora, Leishmania, Naegleria, Neospora, Plasmodium, Sarcocystis, Theileria, Toxoplasma, Trichomonas, Trypanosoma, or any combinations thereof. In some embodiments, the parasitic infection is caused by an infection with *Toxoplasma gondii* (*T. gondii*). In some embodiments, the parasitic infection is toxoplasmosis. In some embodiments, the toxoplasmosis is acute toxoplasmosis, latent toxoplasmosis, or cutaneous toxoplasmosis.

[00315] Acute toxoplasmosis: acute toxoplasmosis is often asymptomatic in healthy adults. However, symptoms may manifest and are often influenza-like: swollen lymph nodes, headaches, fever, fatigue, or muscle aches and pains that last for a month or more. Rarely will a human with a fully functioning immune system develop severe symptoms following infection. People with weakened immune systems are likely to experience headache, confusion, poor coordination, seizures, lung problems that may resemble tuberculosis or Pneumocystis jirovecii pneumonia (a common opportunistic infection that occurs in people with AIDS), or blurred vision caused by severe inflammation of the retina (ocular toxoplasmosis). Young children and immunocompromised people, such as those with HIV/AIDS, those taking certain types of chemotherapy, or those who have recently received an organ transplant, may develop severe toxoplasmosis. In some instances, toxoplasmosis causes damage to the brain (encephalitis) or the eyes (necrotizing retinochoroiditis). Infants infected via placental transmission may be born with either of these problems, or with nasal malformations, although these complications are rare in newborns. The toxoplasmic trophozoites causing acute toxoplasmosis are referred to as tachyzoites, and are typically found in bodily fluids.

[00316] Latent toxoplasmosis: due to its asymptomatic nature, it is easy for a host to become infected with *Toxoplasma gondii* and develop toxoplasmosis without knowing it. Although mild, flu-like symptoms occasionally occur during the first few weeks following exposure, infection with *T. gondii* produces no readily observable symptoms in healthy human adults. In most immunocompetent people, the infection enters a latent phase, during which only bradyzoites (tissue cysts) are present; these tissue cysts and even

lesions can occur in the retinas, alveolar lining of the lungs (where an acute infection may mimic a *Pneumocystis jirovecii* infection), heart, skeletal muscle, and the central nervous system (CNS), including the brain. Cysts form in the CNS (brain tissue) upon infection with *T. gondii* and persist for the lifetime of the host. Most infants who are infected while in the womb have no symptoms at birth, but may develop symptoms later in life.

[00317] Cutaneous toxoplasmosis: in some embodiments, skin lesions occur in the acquired form of the disease, including roseola and erythema multiforme-like eruptions, prurigo-like nodules, urticaria, and maculopapular lesions. Newborns may have punctate macules or ecchymoses. Diagnosis of cutaneous toxoplasmosis is based on the tachyzoite form of *T. gondii* being found in the epidermis.

Viral Infections

[00318] In some embodiments, the infection is a viral infection. In certain embodiments, the viral infection treatable with the methods provided herein includes, but is not limited to, chickenpox, the flu (influenza), herpes, human immunodeficiency virus (HIV/AIDS), human papillomavirus (HPV), Infectious mononucleosis, mumps, measles, rubella, shingles, viral gastroenteritis (stomach flu), viral hepatitis, viral meningitis, and viral pneumonia.

Neurodegenerative diseases

[00319] In the central nervous system, adenosine plays a critical role in controlling a multitude of neural functions. Through the activation of P1 receptors, adenosine is involved in diverse physiological and pathological processes such as regulation of sleep, general arousal state and activity, local neuronal excitability, and coupling of the cerebral blood flow to the energy demand. In some embodiments, the manipulation of adenosine production via CD73 inhibitors has therapeutic potential in neurodegenerative diseases. One embodiment provides a method of treating a neurodegenerative disease in a subject in need thereof, comprising administering to the subject a compound of disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof. In certain embodiments, the neurodegenerative disease treatable with the methods provided herein includes, but is not limited to, Alzheimer's disease, Parkinson's disease, and Huntington's disease. One embodiment provides a method of treating a psychiatric disorder in a subject in need thereof, comprising administering to the subject a compound of disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof. In some embodiments, the psychiatric disorder is schizophrenia or autism.

Combination Therapy

[00320] In certain instances, the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, is administered in combination with a second therapeutic agent.

[00321] In some embodiments, the benefit experienced by a patient is increased by administering one of the compounds described herein with a second therapeutic agent (which also includes a therapeutic regimen) that also has therapeutic benefit.

[00322] In one specific embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, is co-administered with a second therapeutic agent, wherein the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, and the second therapeutic agent modulate different aspects of the disease, disorder or condition being treated, thereby providing a greater overall benefit than administration of either therapeutic agent alone.

[00323] In any case, regardless of the disease, disorder or condition being treated, the overall benefit experienced by the patient is simply additive of the two therapeutic agents or the patient experiences a synergistic benefit.

[00324] In certain embodiments, different therapeutically-effective dosages of the compounds disclosed herein will be utilized in formulating a pharmaceutical composition and/or in treatment regimens when the compounds disclosed herein are administered in combination with a second therapeutic agent. Therapeutically-effective dosages of drugs and other agents for use in combination treatment regimens are optionally determined by means similar to those set forth hereinabove for the actives themselves. Furthermore, the methods of prevention/treatment described herein encompasses the use of metronomic dosing, i.e., providing more frequent, lower doses in order to minimize toxic side effects. In some embodiments, a combination treatment regimen encompasses treatment regimens in which administration of a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, is initiated prior to, during, or after treatment with a second agent described herein, and continues until any time during treatment with the second agent or after termination of treatment with the second agent. It also includes treatments in which a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, and the second agent being used in combination are administered simultaneously or at different times and/or at decreasing or increasing intervals during the treatment period. Combination treatment further includes periodic treatments that start and stop at various times to assist with the clinical management of the patient.

[00325] It is understood that the dosage regimen to treat, prevent, or ameliorate the condition(s) for which relief is sought, is modified in accordance with a variety of factors (e.g., the disease, disorder or condition from which the subject suffers; the age, weight, sex, diet, and medical condition of the subject). Thus, in some instances, the dosage regimen actually employed varies and, in some embodiments, deviates from the dosage regimens set forth herein.

[00326] For combination therapies described herein, dosages of the co-administered compounds vary depending on the type of co-drug employed, on the specific drug employed, on the disease or condition being treated, and so forth. In additional embodiments, when co-administered with a second therapeutic agent, the compound provided herein is administered either simultaneously with the second therapeutic agent, or sequentially.

[00327] In combination therapies, the multiple therapeutic agents (one of which is one of the compounds described herein) are administered in any order or even simultaneously. If administration is

simultaneous, the multiple therapeutic agents are, by way of example only, provided in a single, unified form, or in multiple forms (e.g., as a single pill or as two separate pills).

[00328] The compounds disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, as well as combination therapies, are administered before, during or after the occurrence of a disease or condition, and the timing of administering the composition containing a compound varies. Thus, in one embodiment, the compounds described herein are used as a prophylactic and are administered continuously to subjects with a propensity to develop conditions or diseases in order to prevent the occurrence of the disease or condition. In another embodiment, the compounds and compositions are administered to a subject during or as soon as possible after the onset of the symptoms. In specific embodiments, a compound described herein is administered as soon as is practicable after the onset of a disease or condition is detected or suspected, and for a length of time necessary for the treatment of the disease. In some embodiments, the length required for treatment varies, and the treatment length is adjusted to suit the specific needs of each subject. For example, in specific embodiments, a compound described herein or a formulation containing the compound is administered for at least 2 weeks, about 1 month to about 5 years.

[00329] In certain embodiments, the second therapeutic agent is an adjuvant. In certain embodiments, the second therapeutic agent is an anti-cancer agent. In certain embodiments, the second therapeutic agent is an antiemetic. In certain embodiments, the second therapeutic agent is an anti-infective agent. In certain embodiments, the second therapeutic agent is an antiviral agent. In certain embodiments, the second therapeutic agent is an antibacterial agent.

[00330] In some embodiments, the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, is administered in combination with an adjuvant. In one embodiment, the therapeutic effectiveness of one of the compounds described herein is enhanced by administration of an adjuvant (i.e., by itself the adjuvant has minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced).

In some embodiments, the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, is administered in combination with an anti-cancer agent.

[00331] In some embodiments, the anti-cancer agent is a hormone blocking therapy. Hormone blocking therapy includes the use of agents that block the production of estrogens or block the estrogen receptors. In some embodiments, hormone blocking therapy includes the use of estrogen receptor modulators and/aromatase inhibitors. Estrogen receptor modulators include triphenylethylene derivatives (e.g., tamoxifen, toremifene, droloxifene, 3-hydroxytamoxifen, idoxifene, TAT-59 (a phosphorylated derivative of 4-hydroxytamoxifen) and GW5638 (a carboxylic acid derivative of tamoxifen)); non-steroidal estrogen receptor modulators (e.g., raloxifene, LY353381 (SERM3) and LY357489); steroidal estrogen receptor modulators (e.g., ICI-182,780). Aromatase inhibitors include steroidal aromatase inhibitors and non-steroidal aromatase inhibitors. Steroidal aromatase inhibitors include, but are not limited to, exemestane. Non-steroidal aromatase inhibitors include, but are not limited to, anastrozole and letrozole.

[00332] In certain embodiments, compounds disclosed herein are used in combination with one or more passive immunotherapies, including but not limited to, naked monoclonal antibody drugs and conjugated monoclonal antibody drugs. Examples of naked monoclonal antibody drugs that can be used include, but are not limited to, rituximab, an antibody against the CD20 antigen; trastuzumab, an antibody against the HER2 protein; alemtuzumab, an antibody against the CD52 antigen; cetuximab, an antibody against the EGFR protein; and bevacizumab which is an anti-angiogenesis inhibitor of VEGF protein.

[00333] Examples of conjugated monoclonal antibodies include, but are not limited to, radiolabeled antibody ibritumomab tiuxetan; radiolabeled antibody tositumomab; and immunotoxin gemtuzumab ozogamicin which contains calicheamicin; BL22, an anti-CD22 monoclonal antibody-immunotoxin conjugate; radiolabeled antibodies such as OncoScint (Registered trademark) and ProstaScint (Registered trademark) ; brentuximab vedotin; and ado-trastuzumab emtansine.

[00334] Further examples of therapeutic antibodies that can be used include, but are not limited to, abciximab, an antibody against the glycoprotein IIb/IIIa receptor on platelets; daclizumab, an immunosuppressive, humanized anti-CD25 monoclonal antibody; edrecolomab, a murine anti-17-1A cell surface antigen IgG2a antibody; BEC2, a murine anti-idiotypic (GD3 epitope) IgG antibody; IMC-C225, a chimeric anti-EGFR IgG antibody; VITAXIN (Registered Trademark) a humanized anti- α v β 3 integrin antibody; Campath 1H/LDP-03, a humanized anti CD52 IgG1 antibody; Smart M195, a humanized anti-CD33 IgG antibody; epratuzumab, a humanized anti-CD22 IgG antibody; Lymphoscan; visilizumab; CM3, a humanized anti-ICAM3 antibody; IDEC-114 a primatized anti-CD80 antibody; IDEC-131 a humanized anti-CD40L antibody; IDEC-151 a primatized anti-CD4 antibody; IDEC-152 a primatized anti-CD23 antibody; SMART anti-CD3, a humanized anti-CD3 IgG; 5G1.1, a humanized anti-complement factor 5 (C5) antibody; D2E7, a humanized anti-TNF- α antibody; CDP870, a humanized anti-TNF- α Fab fragment; IDEC-151, a primatized anti-CD4 IgG1 antibody; MDX-CD4, a human anti-CD4 IgG antibody; CD20-streptavidin (+biotin- ^{90} Yttrium); CDP571, a humanized anti-TNF- α IgG4 antibody; LDP-02, a humanized anti- α 4 β 7 antibody; OrthoClone OKT4A, a humanized anti-CD4 IgG antibody; ANTOVA (Registered Trademark), a humanized anti-CD40L IgG antibody; ANTEGREN (Registered Trademark), a humanized anti-VLA-4 IgG antibody; and CAT-152, a human anti-TGF- β 2 antibody.

[00335] In some embodiments, the second therapeutic agent for use in combination with a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, include one or more of the following: abiraterone; abarelix; adriamycin; actinomycin; acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; alemtuzumab; allopurinol; alitretinoin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; aminolevulinic acid; amifostine; amsacrine; anastrozole; anthramycin; aprepitant; arsenic trioxide; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; bendamustine hydrochloride; benzodepa; bevacizumab; bexarotene; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin; bleomycin sulfate; bortezomib; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; capecitabine; cedefingol;

cetuximab; chlorambucil; cirolemycin; cisplatin; cladribine; clofarabine; crisnatol mesylate;
 cyclophosphamide; cytarabine; dacarbazine; dasatinib; daunorubicin hydrochloride; dactinomycin;
 darbepoetin alfa; decitabine; degarelix; denileukin diftitox; dexormaplatin; dexrazoxane hydrochloride;
 dezaguanine; dezaguanine mesylate; diaziquone; docetaxel; doxorubicin; doxorubicin hydrochloride;
 droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflornithine
 hydrochloride; elsamitrucin; eltrombopag olamine; enloplatin; enpromate; epipropidine; epirubicin
 hydrochloride; epoetin alfa; erbulozole; erlotinib hydrochloride; esorubicin hydrochloride; estramustine;
 estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; everolimus;
 exemestane; fadrozole hydrochloride; fazarabine; fenretinide; filgrastim; floxuridine; fludarabine phosphate;
 fluorouracil; fluorocitabine; fosquidone; fostriecin sodium; fulvestrant; gefitinib; gemcitabine; gemcitabine
 hydrochloride; gemcitabine cisplatin; gemtuzumab ozogamicin; goserelin acetate; histrelin acetate;
 hydroxyurea; idarubicin hydrochloride; ifosfamide; iimofosine; ibritumomab tiuxetan; idarubicin;
 ifosfamide; imatinib mesylate; imiquimod; interleukin II (including recombinant interleukin II, or rIL2),
 interferon alfa-2a; interferon alfa-2b; interferon alfa-n1; interferon alfa-n3; interferon beta-1a; interferon
 gamma-1b; iproplatin; irinotecan hydrochloride; ixabepilone; lanreotide acetate; lapatinib; lenalidomide;
 letrozole; leuprolide acetate; leucovorin calcium; leuprolide acetate; levamisole; liposomal cytarabine;
 liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol;
 maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril;
 mercaptopurine; methotrexate; methotrexate sodium; methoxsalen; metoprine; meturedapa; mitindomide;
 mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin C; mitosper; mitotane; mitoxantrone
 hydrochloride; mycophenolic acid; nandrolone phenpropionate; nelarabine; nilotinib; nocodazole;
 nofetumomab; nogalamycin; ofatumumab; oprelvekin; ormaplatin; oxaliplatin; oxisuran; paclitaxel;
 palifermin; palonosetron hydrochloride; pamidronate; pegfilgrastim; pemetrexed disodium; pentostatin;
 panitumumab; pazopanib hydrochloride; pemetrexed disodium; plerixafor; pralatrexate; pegaspargase;
 peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone
 hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine
 hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; quinacrine; raloxifene hydrochloride;
 rasburicase; recombinant HPV bivalent vaccine; recombinant HPV quadrivalent vaccine; riboprine;
 rogletimide; rituximab; romidepsin; romiplostim; safingol; safingol hydrochloride; sargramostim; semustine;
 simtrazene; sipuleucel-T; sorafenib; sparfosate sodium; sparsomycin; spirogermanium hydrochloride;
 spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; sunitinib malate; talisomycin; tamoxifen
 citrate; tecogalan sodium; tegafur; teloxantrone hydrochloride; temozolomide; temoporfin; temsirolimus;
 teniposide; teroxirone; testolactone; thalidomide; thiamiprine; thioguanine; thiotepa; tiazofurin;
 tirapazamine; topotecan hydrochloride; toremifene; tositumomab and I 131 Iodine tositumomab;
 trastuzumab; trestolone acetate; tretinoin; tricitabine phosphate; trimetrexate; trimetrexate glucuronate;
 triptorelin; tubulozole hydrochloride; uracil mustard; uredapa; valrubicin; vapreotide; verteporfin;
 vinblastine; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate;

vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorinostat; vorozole; zeniplatin; zinostatin; zoledronic acid; and zorubicin hydrochloride.

[00336] In some embodiments, the second therapeutic agent is an alkylating agent. Examples of alkylating agents for use in combination with a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, include, but are not limited to, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, meiphalan, etc.), ethylenimine and methylmelamines (e.g., hexamethylmelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, semustine, streptozocin, etc.), or triazenes (decarbazine, etc.).

[00337] Other agents that are optionally used in the methods and compositions described herein for the treatment or prevention of cancer include platinum coordination complexes (e.g., cisplatin, carboblatin), anthracenedione (e.g., mitoxantrone), substituted urea (e.g., hydroxyurea), methyl hydrazine derivative (e.g., procarbazine), adrenocortical suppressant (e.g., mitotane, aminoglutethimide).

[00338] In some embodiments, the second therapeutic agent is an immunotherapy agent. Examples of immunotherapy agents for use in combination with a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, include, but are not limited to, checkpoint inhibitors (e.g., anti-PD1 and anti-PD-L1 inhibitors), cancer vaccines (e.g., sipuleucel-T), oncolytic viruses (e.g., talimogene laherparepvec), cytokines (e.g., IL-2 and INF-alpha), CAR-T cells.

[00339] In some embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, is used in combination with anti-emetic agents to treat nausea or emesis, which results from the use of a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, anti-cancer agent(s) and/or radiation therapy. Anti-emetic agents include, but are not limited to: neurokinin-1 receptor antagonists, 5HT3 receptor antagonists (such as ondansetron, granisetron, tropisetron, palonosetron, and zatisetron), GABAB receptor agonists (such as baclofen), corticosteroids (such as dexamethasone, prednisone, prednisolone, or others), dopamine antagonists (such as, but not limited to, domperidone, droperidol, haloperidol, chlorpromazine, promethazine, prochlorperazine, metoclopramide), antihistamines (H1 histamine receptor antagonists, such as but not limited to, cyclizine, diphenhydramine, dimenhydrinate, meclizine, promethazine, hydroxyzine), cannabinoids (such as but not limited to, cannabis, marinol, dronabinol), and others (such as, but not limited to, trimethobenzamide; ginger, emetrol, propofol).

[00340] In some embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, is used in combination with an agent useful in the treatment of anemia. Such an anemia treatment agent is, for example, a continuous erythropoiesis receptor activator (such as epoetin- α).

[00341] In some embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, is used in combination with an agent useful in the treatment of neutropenia. Examples of agents useful in the treatment of neutropenia include, but are not

limited to, a hematopoietic growth factor which regulates the production and function of neutrophils such as a human granulocyte colony stimulating factor, (G-CSF). Examples of a G-CSF include filgrastim.

[00342] In one embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, is administered to a mammal in combination with a non-steroidal anti-inflammatory drug (NSAID). NSAIDs include, but are not limited to: aspirin, salicylic acid, gentisic acid, choline magnesium salicylate, choline salicylate, choline magnesium salicylate, choline salicylate, magnesium salicylate, sodium salicylate, diflunisal, carprofen, fenoprofen, fenoprofen calcium, fluorobiprofen, ibuprofen, ketoprofen, nabutone, ketolorac, ketorolac tromethamine, naproxen, oxaprozin, diclofenac, etodolac, indomethacin, sulindac, tolmetin, meclofenamate, meclofenamate sodium, mefenamic acid, piroxicam, meloxicam, COX-2 specific inhibitors (such as, but not limited to, celecoxib, rofecoxib, valdecoxib, parecoxib, etoricoxib, lumiracoxib, CS-502, JTE-522, L-745 337, and NS398).


[00343] In some embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, is used in combination with radiation therapy (or radiotherapy). Radiation therapy is the treatment of cancer and other diseases with ionizing radiation. Radiation therapy is optionally used to treat localized solid tumors, such as cancers of the skin, tongue, larynx, brain, breast, prostate, colon, uterus, and/or cervix. It is also optionally used to treat leukemia and lymphoma (cancers of the blood-forming cells and lymphatic system, respectively).

EXAMPLES


I. Chemical Synthesis

[00344] Unless otherwise noted, reagents and solvents were used as received from commercial suppliers. Anhydrous solvents and oven-dried glassware were used for synthetic transformations sensitive to moisture and/or oxygen. Yields were not optimized. Reaction times are approximate and were not optimized. Column chromatography and thin layer chromatography (TLC) were performed on silica gel unless otherwise noted.

Example 1. (1-(((2R,3S,4R,5R)-5-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-ethoxy-2-oxoethyl)phosphonic acid (1)




Step A: (2R,3R,4R,5R)-2-(Acetoxymethyl)-5-(4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)tetrahydrofuran-3,4-diyl diacetate (1a)




[00345] β -D-Ribofuranose 1,2,3,5-tetraacetate (5.73 g, 17.99 mmol) was heated at 90°C for 10 min, 4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (1.5g, 17.99 mmol) and SnCl_4 (60 mg) was added successively. After the mixture was heated at 130°C under reduced pressure for 15 min, it was cooled to rt, diluted with water, and extracted with DCM. The combined organics were washed with water, brine, dried and concentrated. The residue was purified by column chromatography (petroleum ether/ethyl acetate from 10:1 to 5:1) to give the title compound (**1a**) (2.4 g, 68%) as a yellow solid.

Step B: (2R,3R,4R,5R)-2-(Acetoxymethyl)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)tetrahydrofuran-3,4-diyl diacetate (1b**)**




[00346] To an oven dried flask was added **1a** (5.2g, 11.63 mmol) followed by ethanol (53.24 mL). To this solution was added triethylamine (2.43 mL, 17.44 mmol) followed by cyclopentylamine (1.38 mL, 13.95 mmol). After the mixture was stirred and heated at 50°C for 15 min, it was cooled to rt, concentrated, and purified by column chromatography (20 to 45% EtOAc in hexanes, a gradient elution) to provide the title compound (**1b**) (5.02g, 87%) as a white solid. m/z (ESI, +ve ion) = 496.1 $[\text{M}+\text{H}]^+$.

Step C: (2R,3R,4R,5R)-2-(Acetoxymethyl)-5-(4-((tert-butoxycarbonyl)(cyclopentyl)amino)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)tetrahydrofuran-3,4-diyl diacetate (1c**)**



[00347] To a solution of **1b** (12.6 g, 25.4 mmol) in MeCN (120 mL) was added triethylamine (5.14g, 50.9 mmol) followed by di-tert-butyl dicarbonate (44.35g, 203.6 mmol) and 4-dimethylaminopyridine (0.31g, 2.54 mmol). After the mixture was allowed to stir overnight, it was concentrated and partitioned between EtOAc (50 mL) and sat. NaHCO_3 . Organic layer was washed with brine, dried with Na_2SO_4 , filtered, concentrated. The residue was purified by column chromatography (petroleum ether/ethyl acetate: 8:1) to provide the title compound (**1c**) (10.56 g, 70% yield) as a yellow solid. m/z (ESI, +ve ion) = 596.72 $[\text{M}+\text{H}]^+$.

Step D: tert-Butyl (6-chloro-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)(cyclopentyl)carbamate (1d**)**




[00348] To an oven dried flask was added **1c** (10.56 g, 17.78 mmol), followed by ammonia (5.0 M in MeOH, 140 mL) in methanol. The mixture was stirred overnight and then concentrated. The crude oil was purified by column chromatography to afford the title compound (**1d**) (7.39g, 89% yield) as a yellow solid. m/z (ESI, +ve ion) = 470.3 $[M+H]^+$.

Step E. tert-Butyl (6-chloro-1-((3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)(cyclopentyl)carbamate (1e**)**




[00349] To a solution of **1d** (7.39 g, 15.75 mmol) and 2,2-dimethoxypropane (4.92 g, 47.27 mmol) in DMF (75 mL) was added $\text{TsOH} \cdot \text{H}_2\text{O}$ (0.6g, 3.15 mmol). After the mixture was stirred at 70°C for 1 h, it was cooled down and quenched with sat. NaHCO_3 (100 mL). The mixture was extracted with EtOAc (50 mL) and the combined organic layers were washed with brine, dried with Na_2SO_4 , filtered, concentrated. The crude oil was purified by column chromatography (petroleum ether/ethyl acetate: 8:1) to afford the title compound (**1e**) (5.5g, 68% yield) as a yellow solid. m/z (ESI, +ve ion) = 510.4 $[M+H]^+$.

Step F. Ethyl 2-(((3aR,4R,6R,6aR)-6-(4-((tert-butoxycarbonyl)(cyclopentyl)amino)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)-2-(diethoxyphosphoryl)acetate (1f**)**




[00350] To a solution of ethyl 2-diazo-2-(diethoxyphosphoryl)acetate (13.5 g, 54.13 mmol) and **1e** (5.5 g, 10.83 mmol) in toluene (80 mL) was added $\text{Rh}_2(\text{OAc})_4$ (0.96g, 2.17 mmol) under N_2 . After the mixture was stirred at 95°C overnight, it was concentrated and purified by column chromatography (petroleum ether/ethyl acetate: 5:1) to afford the title compound (**1f**) (6g, 76% yield) as a yellow oil. m/z (ESI, +ve ion) = 732.2 $[M+H]^+$.

Step G. (1-(((2R,3S,4R,5R)-5-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-ethoxy-2-oxoethyl)phosphonic acid (1)




[00351] The title compound was prepared from **1f** by procedure similar to that described in Example 3, Step C. m/z (ESI, +ve ion) = 536.54 $[M+H]^+$.

Example 2. (((2R,3S,4R,5R)-5-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(cyano)methyl)phosphonic acid (2)




[00352] The title compound was prepared from **1e** by procedures similar to these described in Example 1, Steps F and G, substituting diethyl (cyano(diazo)methyl)phosphonate for ethyl 2-diazo-2-(diethoxyphosphoryl)acetate in Step F. m/z (ESI, +ve ion) = 489.15 $[M+H]^+$.

Examples 3. ((S)-1-(((2R,3S,4R,5R)-5-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid (3)




Step A. tert-Butyl (6-chloro-1-((3aR,4R,6R,6aR)-6-((1-(diethoxyphosphoryl)-2-hydroxyethoxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)(cyclopentyl)carbamate (3a)



[00353] To a solution of **1f** (3.0 g, 4.11 mmol) in THF (40 mL) was added LiBH_4 (0.36 g, 16.44 mmol) at 0°C . The mixture was stirred at rt for 30 min and then quenched with sat. NH_4Cl (10 mL). The solution was extracted with EtOAc and the combined organic layer was washed with brine, dried with


Na₂SO₄, filtered, concentrated. The crude oil was purified by column chromatography (petroleum ether/ethyl acetate: 2:1) to afford the title compound (**3a**) (1.75g, 62% yield) as a yellow oil. *m/z* (ESI, +ve ion) = 690.4 [M+H]⁺.

Step B. *tert*-Butyl (6-chloro-1-((3*aR*,4*R*,6*R*,6*aR*)-6-(((*S*)-1-(diethoxyphosphoryl)-2-hydroxyethoxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl)(cyclopentyl)carbamate (**3b-1**) and *tert*-butyl (6-chloro-1-((3*aR*,4*R*,6*R*,6*aR*)-6-(((*R*)-1-(diethoxyphosphoryl)-2-hydroxyethoxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl)(cyclopentyl)carbamate (**3b-2**)



[00354] **3a** (1.3g, 1.89 mmol) was separated by chiral preparative HPLC (Chiralpak AD, 15% EtOH in hexanes with 0.1% DEA) to provide the title compound (**3b-1**) (390 mg, faster eluting isomer) and (**3b-2**) (525 mg, slower eluting isomer). The stereochemistry of the carbon alpha to the phosphorus center is assigned arbitrarily.


Step C. ((*S*)-1-(((2*R*,3*S*,4*R*,5*R*)-5-(6-Chloro-4-(cyclopentylamino)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid (**3**)



To a solution of **3b-1** (390 mg, 0.57 mmol) and TEA (2.29g, 22.67 mmol) in MeCN (10 mL) was added TMSBr (2.6g, 17.1 mmol). The mixture was stirred at rt for 2 h and then was concentrated under reduced pressure to afford a crude product, which was used directly without further purification.


[00355] To a solution of the crude product was added 50% TFA (15 mL). After the mixture was stirred at rt for 1 h, it was diluted with water (6 mL) and MeCN (5 mL). The solution was purified by reverse preparative HPLC to give the title compound (**3**) (115 mg, 41% yield). *m/z* (ESI, +ve ion)= 494.3 [M+H]⁺.

Example 4. ((*R*)-1-(((2*R*,3*S*,4*R*,5*R*)-5-(6-chloro-4-(cyclopentylamino)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid (**4**)




[00356] The title compound was prepared from **3b-2** by procedure similar to that described in Example 3, Step C. m/z (ESI, +ve ion) = 693.9 $[M+H]^+$.

Example 5. (1-(((2R,3S,4R,5R)-5-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)ethyl)phosphonic acid (5)




Step A. O-(2-(((3aR,4R,6R,6aR)-6-(4-((tert-Butoxycarbonyl)(cyclopentyl)amino)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)-2-(diethoxyphosphoryl)ethyl) 1H-imidazole-1-carbothioate (5a)




[00357] To a solution of **3a** (450 mg, 0.65 mmol) and TEA (66 mg, 0.65 mmol) in DCM (10 mL) was added $(Im)_2CS$ (1.17 g, 6.5 mmol). The mixture was stirred at rt overnight, and then quenched with sat. NH_4Cl (10 mL). The mixture was extracted with DCM and combined organic layer was washed with brine, dried with Na_2SO_4 , filtered, concentrated. The crude oil was purified by column chromatography to afford the title compound (**5a**) (260 mg, 56% yield) as a yellow oil. m/z (ESI, +ve ion) = 800.7 $[M+H]^+$.

Step B. tert-Butyl (6-chloro-1-((3aR,4R,6R,6aR)-6-((1-(diethoxyphosphoryl)ethoxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)(cyclopentyl)carbamate (5b)




[00358] To a solution of Bu_3SnH (110 mg, 0.39 mmol) in toluene (8 mL) was added a solution of **5a** (260 mg, 0.33) in toluene (2 mL). The reaction mixture was heated to reflux. After the mixture was stirred at reflux for 2 h, it was concentrated and purified by column chromatography to afford the title compound (**5b**) (68 mg, 31% yield) as a yellow oil. m/z (ESI, +ve ion) = 674.6 $[\text{M}+\text{H}]^+$.

Step C. (1-(((2R,3S,4R,5R)-5-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)ethyl)phosphonic acid (5**)**




[00359] The title compound was prepared from **5b** by procedure similar to that described in Example 3, Step C. m/z (ESI, +ve ion) = 478.0 $[\text{M}+\text{H}]^+$.

Example 6. ((S)-1-(((2S,3S,4R,5R)-5-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)sulfonyl)ethyl)phosphonic acid (6**)**




Step A. S-(((3aS,4S,6R,6aR)-6-(6-Chloro-4-(cyclopentyl(methyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl) ethanethioate (6a**)**



[00360] To an oven dried flask was added diisopropyl azodicarboxylate (1.96 mL, 9.93 mmol) and THF (50 mL) followed by triphenylphosphine (2600 mg, 9.93 mmol) at 0°C . The mixture was stirred for 5 min and a white precipitate formed. To the mixture was added ((3aR,4R,6R,6aR)-6-(6-chloro-4-


(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol (N-Boc-deprotected analog of **1e**) (1.85g, 4.51 mmol) and thioacetic acid (0.71 mL, 9.9 mmol). The mixture was then stirred overnight and slowly allowed to warm to rt. The clear mixture was quenched with triethylamine (0.3 mL) and concentrated. The residue was purified by flash chromatography (10-50% EtOAc/hexanes, a gradient elution) to give the crude product (**6a**) (2.9g, 99% yield), which was used for the next step without further purification. m/z (ESI, +ve ion)= 468.1 $[M+H]^+$.

Step B. ((3aS,4S,6R,6aR)-6-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanethiol (6b**)**




[00361] To an oven dried flask was added **6a** (5.58 g, 11.9 mmol) and methanol (132 mL) followed by triethylamine (23.6 mL, 169 mmol) and dithiothreitol (2300 mg, 14.9 mmol). The mixture was allowed to stir at rt. After 3 h, the reaction was concentrated and purified by flash chromatography (10-50% EtOAc/hexanes, a gradient elution) to afford the title compound (**6b**) (3.78g, 74% yield). m/z (ESI, +ve ion)= 426.1 $[M+H]^+$.

Step C. di-tert-Butyl (((((3aS,4S,6R,6aR)-6-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)thio)methyl)phosphonate (6c**)**




[00362] To an oven dried flask was added sodium hydride (380 mg, 9.5 mmol) and DMF (50 mL) and the flask was cooled to 0°C. To this flask was added **6b** (3.68 mg, 8.63 mmol) dissolved in DMF (15 mL). After 30 min, di-tert-butoxyphosphorylmethyl trifluoromethanesulfonate (4.65g, 11.2 mmol) dissolved in DMF (4 mL) was added and the mixture was allowed to warm to rt and stirred for 1 h. The reaction mixture was quenched (sat. NH_4Cl) and extracted (EtOAc). The combined organic layers were dried with MgSO_4 , filtered, and concentrated. The resulting residue was purified by flash chromatography (50-100% EtOAc/hexanes, a gradient elution) to provide the title compound (**6c**) (5.4g, 99% yield). m/z (ESI, +ve ion)= 630.2 $[M+H]^+$.

Step D. tert-butyl (6-Chloro-1-((3aR,4R,6S,6aS)-6-(((di-tert-butoxyphosphoryl)methyl)thio)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)(cyclopentyl)carbamate (6d)




[00363] To an oven dried flask with **6c** (5.4g, 8.54 mmol) was added MeCN (77 mL). To this solution was added triethylamine (3.57 mL, 25.6 mmol) followed by di-tert-butyl dicarbonate (5.89 mL, 25.63 mmol) and 4-dimethylaminopyridine (104 mg, 0.850 mmol). The mixture was allowed to stir overnight and then concentrated. The resulting residue was purified by flash chromatography (0-80% EtOAc/hexanes, a gradient elution) to give the title compound (**6d**) (5.6 g, 90% yield). m/z (ESI, +ve ion) = 520.2 $[M+H]^+$.

Step E. tert-Butyl (6-Chloro-1-((3aR,4R,6S,6aS)-6-(((di-tert-butoxyphosphoryl)methyl)sulfonyl)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)(cyclopentyl)carbamate (6e)




[00364] To an oven dried flask was added **6d** (5.6 g, 7.7 mmol) followed by DCM (100 mL). To this mixture was added *m*CPBA (3.52g, 15.3 mmol). After the mixture was stirred at rt for 3 h, it was quenched with sat. NaHCO_3 and extracted with DCM. The combined organic layers were dried with MgSO_4 , filtered, and concentrated. The resulting residue was purified by flash chromatography (0-80% EtOAc/hexanes, a gradient elution) to give the title (**6e**) (4.8 g, 6.3 mmol, 82% yield). m/z (ESI, +ve ion) = 552.1 $[M+H]^+$.

Step F. tert-Butyl (6-chloro-1-((3aR,4R,6S,6aS)-6-(((R)-1-(di-tert-butoxyphosphoryl)ethyl)sulfonyl)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)(cyclopentyl)carbamate (6f-1) and tert-butyl (6-chloro-1-((3aR,4R,6S,6aS)-6-(((S)-1-(di-tert-butoxyphosphoryl)ethyl)sulfonyl)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)(cyclopentyl)carbamate (6f-2)




[00365] To an oven dried flask was added **6e** (187 mg, 0.24 mmol) followed by DMF (7.5 mL). To this solution was added cesium carbonate (168 mg, 0.52 mmol) and the solution was stirred for 20 min. Then methyl iodide (0.03 mL, 0.52 mmol) was added and the mixture was allowed to stir at 45°C for 4 h. The reaction mixture was cooled to rt and partitioned between water and EtOAc. The aqueous layer was extracted an additional time with EtOAc. The combined organic layers were dried with MgSO₄, filtered, and concentrated. The resulting residue was purified by flash column chromatography (0-50% EtOAc/hexanes, a gradient elution) to afford the title compound (**6f-2**) (56.7 mg, faster eluting isomer) and (**6f-1**) (58 mg, slower eluting compound). *m/z* (ESI, +ve ion) = 566.0 [M-2tBu-Boc+4H]⁺. The stereochemistry of the carbon alpha to the phosphorus center is assigned arbitrarily.

Step G. ((S)-1-(((2S,3S,4R,5R)-5-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)sulfonyl)ethyl)phosphonic acid (6)




[00366] To the vial containing **6f-2** was added hexafluoro-2-propanol (HFIPA) (2 mL, 19 mmol) followed by water (0.15 mL, 8.2 mmol) and hydrochloric acid (4 M in dioxane, 0.15 mL, 0.59 mmol). After the mixture was allowed to stir for 30 min, it was quenched with sat. NH₄OH (0.2 mL). The reaction mixture was concentrated and purified by reverse preparative HPLC (0-65% ACN/H₂O with 0.1% TFA) to afford the TFA salt of the title compound (**6**) (29 mg, 63% yield). *m/z* (ESI, +ve ion) = 526.1 [M+H]⁺.

Example 7. ((R)-1-(((2S,3S,4R,5R)-5-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)sulfonyl)ethyl)phosphonic acid (7)




[00367] The title compound was prepared from **6f-1** by procedure similar to that described in Example 6, Step G. m/z (ESI, +ve ion) = 526.1 $[M+H]^+$.

Example 8. (2-(((2S,3S,4R,5R)-5-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)sulfonyl)-1-hydroxypropan-2-yl)phosphonic acid (8)




Step A. S-(((3aS,4S,6R,6aR)-6-(4-((tert-Butoxycarbonyl)(cyclopentyl)amino)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)ethanethioate (8a)




[00368] To an oven dried flask was added (*E*)-diisopropyl azodicarboxylate (1.75 mL, 8.89 mmol) and THF (45 mL) followed by triphenylphosphine (2.33g, 8.89 mmol) at 0°C. The mixture was stirred for 5 min and a white precipitate formed. To the mixture was added tert-butyl (6-chloro-1-((3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)(cyclopentyl)carbamate (**1e**) (2.06g, 4.04 mmol) and thioacetic acid (0.64 mL, 8.9 mmol). The mixture was then stirred overnight and slowly allowed to warm to rt. The clear mixture was quenched with triethylamine (0.3 mL) and concentrated. The residue was purified by flash (10-50%, EtOAc/hexanes, a gradient elution) to provide the title compound (**8a**) (2.9 g, 79% purity, 100% yield). m/z (ESI, +ve ion) = 568.2 $[M+H]^+$.

Step B. tert-Butyl (6-chloro-1-((3aR,4R,6S,6aS)-6-(mercaptomethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)(cyclopentyl)carbamate (8b)




[00369] To a flask containing **8a** (2.91 g, 4.04 mmol) was added methanol (57 mL) followed by triethylamine (8.0 mL, 57 mmol). To this mixture was added DL-dithiothreitol (778 mg, 5.04 mmol). After 2 h, the mixture was concentrated and purified by flash chromatography (0-30% EtOAc/hexanes, a gradient elution) to give the title compound (**8b**) (1.87g, 88.0% yield). m/z (ESI, +ve ion) = 526.2 $[M+H]^+$.

Step C. Ethyl 2-(((3aS,4S,6R,6aR)-6-(4-((tert-butoxycarbonyl)(cyclopentyl)amino)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methylthio)-2-(diethoxyphosphoryl)acetate (8c**)**



[00370] To an oven dried flask was added **8b** (515 mg, 0.98 mmol) followed by 1-[diazomethyl(ethoxy)phosphoryl]oxyethane ethyl acetate (274 mg, 1.03 mmol) and dirhodium tetraacetate (8.65 mg, 0.02 mmol). This mixture was dissolved in toluene (16 mL) and heated at 100°C overnight. More dirhodium tetraacetate (8.65 mg, 0.02 mmol) was added and the mixture was stirred at 100°C for another 2 h. The mixture was concentrated and purified by flash chromatography (0-80% EtOAc/hexanes, a gradient elution) to afford the title compound (**8c**) (483 mg, 66.0% yield) as a mixture of two diastereomers. m/z (ESI, +ve ion) = 748.3 $[M+H]^+$.


Step D. tert-Butyl (6-chloro-1-(((3aR,4R,6S,6aS)-6-(((2-(diethoxyphosphoryl)-1-hydroxypropan-2-yl)thio)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)(cyclopentyl)carbamate (8d**)**



[00371] To an oven dried flask was added **8c** (600 mg, 0.8 mmol) followed by DMF (8 mL) and cesium carbonate (549 mg, 1.68 mmol). To this mixture was added methyl iodide (0.1 mL, 1.7 mmol). After the solution was stirred overnight, it was cooled to rt and partitioned between water and EtOAc. The aqueous layer was extracted an additional time with EtOAc. The combined organic layers were dried with


MgSO₄, filtered, and concentrated. The resulting residue was purified by flash column chromatography (0-40% EtOAc/hexanes, a gradient elution) to give the crude product. To the crude product (377 mg, 0.490 mmol) and THF (4.8 mL) was added lithium borohydride (10.8 mg, 0.49 mmol). After 30 min, the reaction was quenched (sat. NH₄Cl) and was extracted (EtOAc). The combined organic layers were dried with MgSO₄, filtered, and concentrated. The resulting residue was purified by flash chromatography (0-100% EtOAc/hexanes, a gradient elution) to provide the title compound (**8d**) (139 mg, 39.0% yield) as a mixture of two diastereomers. *m/z* (ESI, +ve ion)= 720.2 [M+H]⁺.

Step E. tert-Butyl (6-chloro-1-((3aR,4R,6S,6aS)-6-(((2-(diethoxyphosphoryl)-1-hydroxypropan-2-yl)sulfonyl)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)(cyclopentyl)carbamate (8e**)**



[00372] To a vial was added **8d** (139 mg, 0.190 mmol) and DCM (7 mL) followed by *m*CPBA (88.8 mg, 0.39 mmol). The reaction mixture was stirred for 1 h and then quenched with sat NaHCO₃. The aqueous layer was extracted with DCM. The combined organic layers were dried with MgSO₄, filtered, and concentrated. The resulting residue was purified by flash chromatography (0-100% EtOAc/hexanes, a gradient elution) to give the title compound (**8e**) (128 mg, 88.2% yield) as a mixture of two diastereomers. *m/z* (ESI, +ve ion)= 752.2 [M+H]⁺.

Step F. (2-(((2S,3S,4R,5R)-5-(6-chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)sulfonyl)-1-hydroxypropan-2-yl)phosphonic acid (8**)**




[00373] To a vial was added **8e** (127 mg, 0.170 mmol) followed by MeCN (2.8 mL). To this solution was added bromo(trimethyl)silane (0.15 mL, 1.2 mmol) and the mixture was allowed to stir. After 4 h, another lot of bromo(trimethyl)silane (0.15 mL, 1.2 mmol) was added. After one additional hour, water (0.40 mL) was added and the mixture was allowed to stir overnight. The following morning, more water (0.40 mL) was added and the reaction was complete after 1 h. The mixture was quenched with aqueous NH₄OH (0.5 mL) and concentrated. The resulting residue was purified by reverse preparative HPLC (0-50% ACN/H₂O with 0.1% TFA) to give the title compound (**8**) (73.4 mg, 64.9% yield) as a mixture of two diastereomers. *m/z* (ESI, +ve ion)= 556.1 [M+H]⁺.

Examples 9-14: Examples 9-14 were synthesized as described in examples 1-8.


Ex	MS Data	Ex	MS Data
9	602.1 [M + H] ⁺	12	508.1 [M + H] ⁺
10	602 [M + H] ⁺	13	493.9 [M + H] ⁺
11	508.1 [M + H] ⁺	14	492 [M + H] ⁺

Example 15. (2-(((2R,3S,4R,5R)-5-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid (15)




[00374] The title compound was prepared from **1e** by procedures similar to these described in Example 8, Steps C, D, and F. *m/z* (ESI, +ve ion) = 508.1 [M+H]⁺.

Example 16. (((((2S,3S,4R,5R)-5-(5-Chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)sulfonyl)methyl)phosphonic acid (16)




Step 1. ((3aR,4R,6R,6aR)-6-(5-Chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol (16a)




[00375] The title compound was prepared from 5,7-dichloro-3H-[1,2,3]triazolo[4,5-b]pyridine by procedures similar to these described in Example 1, Steps A, B, D, and E, substituting 5,7-dichloro-3H-[1,2,3]triazolo[4,5-b]pyridine for 4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine in Step A.

Step B. (((((2S,3S,4R,5R)-5-(5-Chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)sulfonyl)methyl)phosphonic acid (16)



[00376] The title compound was prepared from **16a** similar to these described in Example 6, Steps A-E, and G. m/z (ESI, +ve ion) = 512.3 $[M+H]^+$.

Example 17. (((((2R,3S,4R,5R)-5-(5-Chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonic acid (**17**)




[00377] The title compound was prepared from **16a** by procedures similar to these described in Example 6, Steps C and G, substituting **16a** for **6b** in Step C. m/z (ESI, +ve ion) = 463.8 $[M+H]^+$.


Examples 18-54: Examples 18-54 were synthesized as described in examples 1-8 and 15-17.

Ex.	MS Data	Ex.	MS Data
18	540.3 $[M+H]^+$	37	582.4 $[M+H]^+$
19	540.3 $[M+H]^+$	38	542 $[M+H]^+$
20	463.9 $[M+H]^+$	39	541.9 $[M+H]^+$
21	450.1 $[M+H]^+$	40	478.3 $[M+H]^+$
22	520.1 $[M+H]^+$	41	566 $[M-H]^-$
23	447.9 $[M-H]^-$	42	507.98 $[M+H]^+$
24	464 $[M+H]^+$	43	496.1 $[M+H]^+$
25	498.1 $[M+H]^+$	44	522.2 $[M+H]^+$
26	518.1 $[M-H]^-$	45	522.1 $[M+H]^+$
27	568.1 $[M+H]^+$	46	508.3 $[M+H]^+$
28	508.1 $[M+H]^+$	47	563.2 $[M+H]^+$
29	440.4 $[M+H]^+$	48	599.2 $[M+H]^+$
30	480.1 $[M+H]^+$	49	557 $[M+H]^+$
31	508.12 $[M+H]^+$	50	557 $[M+H]^+$
32	477.9 $[M+H]^+$	51	520.1 $[M+H]^+$
33	478.2 $[M+H]^+$	52	537.2 $[M+H]^+$
34	556.1 $[M+H]^+$	53	527.8 $[M+H]^+$
35	532.1 $[M+H]^+$	54	542.0 $[M+H]^+$
36	538.1 $[M+H]^+$		

Example 55. (2-(((2R,3S,4R,5R)-5-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-(methylthio)propan-2-yl)phosphonic acid (**55**)




Step A. S-(2-(((3aR,4R,6R,6aR)-6-(4-((tert-Butoxycarbonyl)(cyclopentyl)amino)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)-2-(diethoxyphosphoryl)propyl) ethanethioate (**55a**)




[00378] A dried flask was charged with triphenylphosphine (685 mg, 2.61 mmol) and THF (12 mL). After the solution was cooled to 0 °C, DIAD (0.51 mL, 2.6 mmol) was added dropwise. The resulting mixture was stirred for 10 min and a white precipitate formed. In a separate flask, tert-butyl N-[1-[(3aR,4R,6R,6aR)-6-[(1-diethoxyphosphoryl-2-hydroxy-1-methyl-ethoxy)methyl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]-6-chloro-pyrazolo[3,4-d]pyrimidin-4-yl]-N-cyclopentyl-carbamate (ether analog of **8d**) (800 mg, 1.14 mmol) was dissolved in THF (2 mL). This THF solution was added into the first flask, followed by thioacetic acid (0.19 mL, 2.6 mmol). The mixture was stirred and slowly warmed to rt overnight. The reaction was quenched with Et₃N (0.3 mL), concentrated and partitioned between water and EtOAc. The organic layer was washed with brine, dried with MgSO₄, filtered and concentrated. The crude oil was purified by flash chromatography (0-70% EtOAc/hexanes, a gradient elution) to give the title compound (**55a**) (400 mg, 0.53 mmol, 46% yield). m/z (ESI, +ve ion)= 762.2 [M+H]⁺.

Step B. tert-Butyl (6-chloro-1-((3aR,4R,6R,6aR)-6-(((2-(diethoxyphosphoryl)-1-mercaptopropan-2-yl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)(cyclopentyl)carbamate (55b**)**




[00379] To a flask containing **55a** (400 mg, 0.52 mmol) was added methanol (7 mL) followed by triethylamine (1.04 mL, 7.45 mmol). To this mixture was added DL-dithiothreitol (101 mg, 0.660 mmol). After the mixture was stirred at rt for 2 h, it was concentrated and the residue was purified by flash chromatography (0-100% EtOAc/hexanes, a gradient elution) to afford the title compound (**55b**) (245 mg, 0.340 mmol, 65% yield). m/z (ESI, +ve ion)= 720.2 [M+H]⁺.

Step C. tert-Butyl (6-chloro-1-((3aR,4R,6R,6aR)-6-(((2-(diethoxyphosphoryl)-1-(methylthio)propan-2-yl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)(cyclopentyl)carbamate (55c**)**




[00380] To an oven dried vial was added potassium carbonate (14.4 mg, 0.1 mmol) followed by addition of a solution of **55b** (35 mg, 0.046 mmol) in acetone (0.5 mL). To this mixture was added methyl iodide (0.01 mL, 0.1 mmol). After the mixture was stirred at rt for 30 min, it was partitioned between sat. NaHCO_3 and EtOAc. The organic layer was washed with brine, dried with MgSO_4 , filtered and concentrated. The resulting residue was purified by flash chromatography (20-100% EtOAc/hexanes, a gradient elution) to give the title compound (**55c**) (30 mg, 0.041 mmol, 84% yield). m/z (ESI, +ve ion) = 734.2 $[\text{M}+\text{H}]^+$.

Step D. (2-(((2R,3S,4R,5R)-5-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-(methylthio)propan-2-yl)phosphonic acid (55**)**




[00381] To a vial was added **55c** (30 mg, 0.04 mmol) followed by MeCN (0.75 mL). To this solution was added bromo(trimethyl)silane (0.04 mL, 0.28 mmol) and the mixture was allowed to stir at rt. After 4 h, water (0.15 mL) was added and the mixture was allowed to stir for another 2 h. The mixture was quenched with concentrated NH_4OH (0.3 mL) and the resulting solution was concentrated. The residue was purified by reverse preparative HPLC (0-65% ACN/ H_2O containing 0.1% TFA) to give the title compound (**55**) (7.5 mg, 0.012 mmol, 28% yield) as a TFA salt. m/z (ESI, +ve ion) = 538.1 $[\text{M}+\text{H}]^+$.

Example 56. (2-(((2R,3S,4R,5R)-5-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-4-hydroxybutan-2-yl)phosphonic acid (56**)**




Step A. 2-(((3aR,4R,6R,6aR)-6-(4-((tert-Butoxycarbonyl)(cyclopentyl)amino)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)-2-(diethoxyphosphoryl)propanoic acid (56a**)**




[00382] A flask was charged a solution of α -methyl substituted **1f** (642 mg, 0.86 mmol) in THF (10 mL). Lithium hydroxide monohydrate (72.2 mg, 1.72 mmol) was weighed in a vial and then added water (0.9 mL). The freshly prepared lithium hydroxide solution was added to the starting material solution. After the mixture was stirred at rt overnight, it was cooled in an ice-bath and the pH was adjusted to 6 with 1M HCl. The nearly neutral solution was extracted with EtOAc. The combined organics were washed with brine, dried with MgSO_4 , filtered and concentrated to provide the title compound (**56a**) (572 mg, 0.8 mmol, 93% yield). m/z (ESI, +ve ion) = 718.3 $[\text{M}+\text{H}]^+$.

Step B. Ethyl 3-(((3aR,4R,6R,6aR)-6-(4-((tert-butoxycarbonyl)(cyclopentyl)amino)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)-3-(diethoxyphosphoryl)butanoate (56b**)**




[00383] To an oven dried flask was added (**56a**) (413 mg, 0.58 mmol) followed by DCM (4.1 mL) under N_2 . After the solution was cooled to 0°C , two drops of DMF were added followed by oxalyl chloride (0.29 mL, 0.58 mmol). The reaction mixture was warmed to rt and stirred for 1 h, and then concentrated. The residue was dissolved in 1:1 THF:MeCN (8 mL), the resulting solution was cooled to 0°C and trimethylsilyldiazomethane (2M solution, 0.43 mL, 0.86 mmol) was added dropwise. After the mixture was warmed to rt and stirred for 1 h, it was quenched with sat. NaHCO_3 , extracted with EtOAc. The combined organics were washed with brine, dried with MgSO_4 , filtered and concentrated. The residue was azeotroped with toluene and dissolved in EtOH (4 mL). The solution was cooled to 0°C and silver benzoate (131 mg, 0.58 mmol) was added. After the mixture was slowly warmed to rt and stirred overnight, the brown mixture was filtered through celite. The solution was extracted with EtOAc, dried with MgSO_4 , filtered, and concentrated. The residue was purified by flash chromatography (35-70% EtOAc/hexanes, a gradient elution) to give the title compound (**56b**) (42 mg, 0.055 mmol, 9.6% yield). m/z (ESI, +ve ion) = 760.3 $[\text{M}+\text{H}]^+$.

Step C. *tert*-Butyl (6-Chloro-1-((3aR,4R,6R,6aR)-6-(((2-(diethoxyphosphoryl)-4-hydroxybutan-2-yl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)(cyclopentyl)carbamate (**56c**)




[00384] To a flask containing (**56b**) (62 mg, 0.08 mmol) was added ethanol (1 mL). The solution was then cooled to 0 °C and calcium dichloride (18 mg, 0.16 mmol) was added to the solution, followed by sodium borohydride (6.2 mg, 0.16 mmol) in a single portion. The mixture was removed from the ice bath and allowed to stir at rt overnight. The mixture was quenched with sat. NH_4Cl , extracted with EtOAc. The combined organics were dried, filtered, and concentrated. The residue was purified by flash chromatography (0-100% EtOAc/hexanes followed by 0-10% MeOH/DCM, a gradient elution) to afford the title compound (**56c**) (11 mg, 0.015 mmol, 19% yield) as an oil. m/z (ESI, +ve ion) = 718.3 $[\text{M}+\text{H}]^+$.

Step D. (2-(((2R,3S,4R,5R)-5-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-4-hydroxybutan-2-yl)phosphonic acid (**56**)




[00385] To a vial was added (**56c**) (11 mg, 0.02 mmol) followed by MeCN (0.25 mL). To this solution was added bromo(trimethyl)silane (0.01 mL, 0.1 mmol) and the mixture was allowed to stir at rt. After 4 h, water (0.05 mL) was added and the mixture was allowed to stir for 2 h. The mixture was quenched with concentrated NH_4OH (0.1 mL) and concentrated. The residue was purified by reverse preparative HPLC (0-65% ACN/ H_2O containing 0.1% TFA, a gradient elution) to afford the title compound (**56**) (3.3 mg, 0.0052 mmol, 34% yield) as a TFA salt. m/z (ESI, +ve ion) = 522.2 $[\text{M}+\text{H}]^+$.

Example 57. (1-(((2R,3S,4R,5R)-5-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid (**57**)




Step A. (2R,3R,4S,5R)-2-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (**57a**)




[00386] A pressure-sealed tube was charged with [(2R,3R,4R,5R)-3,4-diacetoxy-5-(4,6-dichloropyrazolo[3,4-b]pyridin-1-yl)tetrahydrofuran-2-yl]methyl acetate (0.64g, 1.44 mmol) followed by ethanol (7 mL). To this solution was added trimethylamine (0.3 mL, 2.16 mmol) and cyclopentylamine (0.17 mL, 1.73 mmol) successively. The mixture was sealed and allowed to stir and heat at 110 °C overnight. The reaction was cooled to rt and was transferred to a round-bottom flask and concentrated under vacuum to afford a brown oil. The crude oil was transferred to a pressure sealed vial. Solvent was removed from the vial and degassed with Ar. Then ammonia solution (7 M NH₃ in THF, 5 mL, 34.5 mmol) was added to the vial and the solution was allowed to stir overnight. The reaction solution was concentrated and purified by silica gel chromatography (0-8% MeOH/CH₂Cl₂, a gradient elution) to give the title compound (**57a**) (250 mg, 47% yield) as an off-white solid. *m/z* (ESI, +ve ion) = 369.1 [M+H]⁺.

Step B. *tert*-Butyl (1-((3aR,4R,6R,6aR)-6-(((*tert*-butyldimethylsilyl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-6-chloro-1H-pyrazolo[3,4-b]pyridin-4-yl)(cyclopentyl)carbamate (**57b**)




[00387] A round bottom flask was charged with **57a** (290 mg, 0.55 mmol) was azeotroped with toluene, flushed with Ar and added 5 mL of THF. LiHMDS solution (1 M in THF, 1.3 mL, 1.3 mmol) was added dropwise at rt and the solution was allowed to stir for 15 min. Then a solution of Boc₂O (375 mg, 1.72 mmol) was added dropwise. After the reaction was allowed to stir under Ar for 2 h, the solvent was removed and the crude residue was partitioned between water (25 mL) and CH₂Cl₂ (25 mL). The organic layers were combined, washed with brine, dried with Na₂SO₄, filtered and concentrated under vacuum to give a crude oil. The oil was purified by silica gel chromatography (0-20% EtOAc/hexane) to afford the title compound (**57b**) (316 mg, 91% yield) as a white, foamy solid. *m/z* (ESI, +ve ion) = 623.3 [M+H]⁺.

Step C. *tert*-Butyl (6-chloro-1-((3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl)(cyclopentyl)carbamate (**57c**)




[00388] A round bottom flask was charged with **57b** (320 mg, 0.51 mmol), degassed with Ar, and added THF (10 mL). The solution was cooled to 0 °C, and tetra-*n*-butylammonium fluoride (1 M in THF, 0.53 mL, 0.53 mmol) was added dropwise. The reaction solution was allowed to warm to rt and was quenched with saturated NaHCO₃ and extracted with EtOAc. The organic layers were combined, washed with brine, dried with Na₂SO₄, filtered and concentrated under vacuum to give a crude oil. The oil was purified by silica gel chromatography (0-50% Acetone/hexane, a gradient elution) to afford the title compound (**57c**) (245 mg, 94% yield) as a white, foamy solid. *m/z* (ESI, +ve ion) = 509.2 [M+H]⁺.

Step D. (1-(((2R,3S,4R,5R)-5-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid (57**)**




[00389] The title compound was prepared from **57c** by procedures similar to those described in Example 1, Step F, followed by Steps A and C in Example 3. *m/z* (ESI, +ve ion) = 493.1 [M+H]⁺.

Example 58. (1-(((2R,3S,4R,5R)-5-(5-Chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid (58**)**




Step A. Ethyl 2-diazo-2-(diethoxyphosphoryl)acetate (58a**)**



[00390] To a mixture of ethyl 2-(diethoxyphosphoryl)acetate (187 g, 0.833 mol) and Cs₂CO₃ (339 g, 1.04 mol) in THF (1.5 L) was added 4-acetamidobenzenesulfonyl azide (100 g, 0.416 mol) in portions at 0 °C. The mixture was stirred at rt for 2 h and then diluted with EtOAc/water (1:1, 0.8 L). After the solution was acidified to a pH of 2 with 1 M HCl, the aqueous layer was extracted with EtOAc. The combined organic layers were dried and concentrated *in vacuo*. The residue was purified by flash chromatography


(Petroleum ether/EtOAc= 1:1) to give the title compound (**58a**) (86 g, 83% yield) as a yellow liquid. m/z (ESI, +ve ion)= 250.89 $[M+H]^+$.

Step B. Ethyl 2-(diethoxyphosphoryl)-2-(((3aR,4R,6R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)acetate (58b**)**




[00391] To a solution of ((3aR,4R,6R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol (100 g, 0.49 mol) and **58a** (100 g, 0.4 mol) in toluene (1L) was added rhodium acetate dimer (10.8 g). The reaction mixture was degassed and heated at 95-100°C for 1.5 h under N₂. The mixture was cooled to rt and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography (Petroleum ether/ethyl acetate: = 5:1) to afford the title compound (**58b**) (86.3 g, 41% yield) as an oil. m/z (ESI, +ve ion)= 448.9 $[M+Na]^+$.

Step C. Diethyl (2-hydroxy-1-(((3aR,4R,6R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)ethyl)phosphonate (58c**)**




[00392] LiBH₄ (2 M in THF, 14 ml, 28 mmol) was added dropwise to a solution of **58b** (3.0 g, 7 mmol) in THF (60 mL) at 0 °C and the resulting mixture was stirred at 0°C for 2 h. The mixture was quenched with water, extracted with EtOAc. The combined organic layers were washed with water, brine, and concentrated. The residue was purified by flash chromatography (Petroleum ether/ethyl acetate = 10:1 to 5:1) to give the title compound (**58c**) (2.7 g, 67% yield). m/z (ESI, +ve ion)= 384.7 $[M+H]^+$.

Step D. Diethyl (2-hydroxy-1-(((2R,3S,4R,5R)-3,4,5-trihydroxytetrahydrofuran-2-yl)methoxy)ethyl)phosphonate (58d**)**




[00393] To a solution of **58c** (2.5 g, 6.5 mmol) was added 70% acetic acid (25 mL) and the mixture was heated at 90 °C overnight. After the mixture was cooled to rt, it was concentrated and the crude residue (1.6 g) was directly used for next step without further purification.

Step E. (2S,3R,4R,5R)-5-((2-Acetoxy-1-(diethoxyphosphoryl)ethoxy)methyl)tetrahydrofuran-2,3,4-triyl triacetate (58e**)**




[00394] To a solution of **58d** (5.2 g, 15.7 mmol) and triethylamine (12.73 g, 126 mmol) in dry DCM (15 mL) was added dropwise acetic anhydride (12.86 g, 126 mmol) at 0 °C. After the mixture was stirred at rt overnight, water (30 mL) was added and the solution was extracted with DCM. The combined organic layers were washed with brine, dried, concentrated. The residue was purified by flash chromatography (Petroleum ether/EtOAc= 10:1) to afford the title compound (**58e**) (4.0 g, 51% yield for the two steps).

Step F. 2,6-Dichloro-5-nitropyrimidin-4-amine (58f)




[00395] To a solution of 2,4,6-trichloro-5-nitropyrimidine (9.0 g, 39.4 mmol) in THF (540 mL) was added an ammonia solution (10.8 mL, 10 N in EtOH, 78.8 mmol) dropwise at -70 °C. After the reaction was stirred at -70 °C for 30 min, it was acidified with AcOH (pH 4~5) and concentrated. The residue was diluted with EtOAc and the resulting mixture was stirred for 30 min and filtered. The solids were washed with EtOAc and the organics were combined and concentrated to afford the title compound (**58f**) (8.0 g, 97%), which was directly used for the next step without further purification.

Step G. 2,6-Dichloropyrimidine-4,5-diamine (58g)



[00396] A mixture of iron powder (10.7g, 191 mmol), acetic acid (24 ml) and ethanol (30 mL) was heated at 55 °C for 0.5 h. A solution of **58f** (8.0 g, 38.3 mmol) in ethanol (50 ml) was added dropwise. After the mixture was stirred at 55 °C for 20 min, it was cooled to rt and filtered. The filtrate was concentrated, the residue was diluted with water and the solution extracted with EtOAc. The combined organics were washed with water and brine, dried and concentrated. The residue was purified by column chromatography (petroleum ether/ethyl acetate: from 5:1 to 3:1) to give the title compound (**58g**) (4.4 g, 60.4%) as a white solid.


Step H. 5,7-Dichloro-3H-[1,2,3]triazolo[4,5-d]pyrimidine (58h)



[00397] A suspension of 2,6-dichloropyrimidine-4,5-diamine (**58g**) (4.4 g, 24.58 mmol) in water (47 ml) was heated and the solid was dissolved. The solution was cooled to 0 °C and acetic acid (94 ml) was


added, followed by addition of a solution of sodium nitrite (3.05 g, 44.3 mmol) in water (47 mL) during a period of 15 min. The reaction mixture was stirred at 0 °C for another 20 min and then was extracted with EtOAc. The organics were neutralized, dried and concentrated, the crude product was purified by column chromatography (petroleum ether/ethyl acetate: from 3:1 to 2:1) to provide the title compound (**58h**) (3.4 g, 72.8%) as a yellow solid.

Step I. (2R,3R,4R,5R)-2-((2-Acetoxy-1-(diethoxyphosphoryl)ethoxy)methyl)-5-(5,7-dichloro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)tetrahydrofuran-3,4-diyl diacetate (58i**)**




[00398] A flask charged with **58e** (4.0 g, 0.8 mmol) was heated at 90 °C for 10 min, **56h** (1.52 g, 0.8 mmol) and SnCl₄ (40 mg, 1%) was added successively. After the mixture was heated at 130 °C for 15 min under reduced pressure distillation, it was cooled to rt, quenched with water, extracted with EtOAc. The combined organic layers were washed with water and brine, dried and concentrated. The residue was purified by flash chromatography (Petroleum ether/EtOAc = 10:1 to 5:1) to give the crude product (**58i**) (3.1 g, 62 % yield) as a yellow solid. m/z (ESI, +ve ion)= 628.0 [M+H]⁺.

Step J. (2R,3R,4R,5R)-2-((2-Acetoxy-1-(diethoxyphosphoryl)ethoxy)methyl)-5-(5-chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)tetrahydrofuran-3,4-diyl diacetate (58j**)**




[00399] A mixture of **58i** (2.2 g, 3.5 mmol), cyclopentanamine (446 mg, 5.25 mmol) and triethylamine (530 mg, 5.25 mmol) in ethanol (40 mL) was stirred at rt for 1 h. The mixture was concentrated *in vacuo* and the residue was purified by flash chromatography (Petroleum ether/EtOAc = 8:1 to 3:1, a gradient elution) to give the title compound (**58j**) (2.2 g, 93 % yield) as a yellow solid. m/z (ESI, +ve ion)= 677.1 [M+H]⁺.

Step K. Diethyl (1-(((2R,3S,4R,5R)-5-(5-chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonate (58k**)**



[00400] A mixture of **58j** (1.1 g, 1.62 mmol), K_2CO_3 (673 mg, 4.88 mmol) in MeOH (11 mL) was stirred at 0 °C for 15 min, then acetic acid (585 mg) was added. The mixture was concentrated and the residue was extracted with EtOAc. The organics were washed with brine and concentrated to afford the title compound (**58k**) (450 mg, 47.4% yield for the two steps) as a white solid. m/z (ESI, +ve ion) = 551.0 $[M+H]^+$.

Step L. (1-(((2R,3S,4R,5R)-5-(5-Chloro-7-(cyclopentylamino)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-2-hydroxyethyl)phosphonic acid (**58**)




[00401] Triethylamine (3.23 g, 31.9 mmol) was added dropwise to a solution of **58k** (440 mg, 0.789 mmol) in anhydrous acetonitrile (20 ml). After the mixture was stirred at rt for 5 min, TMSBr (3.66 g, 23.9 mmol) was added dropwise. The mixture was stirred at rt for 2 h and then concentrated. The residue was directly purified by reverse preparative HPLC (30-90% ACN/H₂O containing 0.1% TFA) to give the title compound (**58**) (150 mg, TFA salt, 31% yield) as an off- yellow solid. m/z (ESI, +ve ion) = 495.0 $[M+H]^+$.


Examples 59-83: Examples 59-83 were synthesized as described in examples 1-8, 15-17, and 55-58.

Ex	MS Data	Ex	MS Data
59	425.8 $[M+H]^+$	72	538.1 $[M+H]^+$
60	493.8 $[M+H]^+$	73	570.1 $[M+H]^+$
61	556.4 $[M+H]^+$	74	570.1 $[M+H]^+$
62	508.0 $[M+H]^+$	75	494.1 $[M+H]^+$
63	508.0 $[M+H]^+$	76	508.1 $[M+H]^+$
64	508.0 $[M+H]^+$	77	570.0 $[M+H]^+$
65	522.1 $[M+H]^+$	78	556.8 $[M+H]^+$
66	508.0 $[M+H]^+$	79	508.0 $[M+H]^+$
67	509.1 $[M+H]^+$	80	532.1 $[M+H]^+$
68	531.9 $[M-H]^-$	81	535.2 $[M+H]^+$
69	522.04 $[M+H]^+$	82	523.1 $[M+H]^+$
70	506.09 $[M+H]^+$	83	560.1 $[M+H]^+$
71	577.3 $[M+H]^+$		

Example 84. (2-(((2R,3S,4R,5R)-5-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(2H-tetrazol-5-yl)propan-2-yl)phosphonic acid (**84**)




Step A. Ethyl 2-((2-(trimethylsilyl)ethoxy)methyl)-2H-tetrazole-5-carboxylate (84a-1**) and ethyl 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-tetrazole-5-carboxylate (**84a-2**)**




[00402] To a stirred solution of ethyl tetrazole-5-carboxylate (2.0 g, 14.1 mmol) in THF (60 mL) was added sodium hydride (60% in mineral oil, 647 mg, 16.2 mmol) in one portion at 0 °C. The mixture was allowed to warm to rt and stirred for 15 min. The mixture was then cooled back to 0 °C and 2-((trimethylsilyl)ethoxymethyl) chloride (2.84 mL, 16.2 mmol) was added dropwise. The resulting mixture was allowed to warm to rt and stirred for 3 h. Water was added into the reaction mixture and the solution was extracted (3 × EtOAc). The combined organic layers were washed (brine), dried (Na₂SO₄), and concentrated under reduced pressure. Purification of the residue by silica gel column chromatography (87g SiO₂, 5% to 40% EtOAc/hexanes, a gradient elution) provided a mixture of **84a-1** and **84a-2** (60:40 measured by ¹H NMR, 2.88 g, 73%) as a colorless oil.

Step B. (2-((2-(Trimethylsilyl)ethoxy)methyl)-2H-tetrazol-5-yl)methanol (84b**)**



[00403] To a stirred solution of ethyl 2-((2-(trimethylsilyl)ethoxy)methyl)-2H-tetrazole-5-carboxylate (**84a-1**) and ethyl 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-tetrazole-5-carboxylate (**84a-2**) (1.5 g, 5.51 mmol) in MeOH (15 mL) was added NaBH₄ (417 mg, 11.0 mmol) at rt. The reaction mixture was heated at 60 °C for 1 h. After the reaction mixture was cooled to rt, it was quenched with water and extracted (3 × EtOAc) and the combined organic layer was washed (brine), dried (Na₂SO₄), and concentrated under reduced pressure. Purification of the residue by silica gel column chromatography (120g SiO₂, 5% to 60% EtOAc/hexanes, a gradient elution) provided the title compound (**84b**) (1.06 g, 84%) as a colorless oil. The mixture of **84a-1** and **84a-2** was reduced with NaBH₄ to produce only one regioisomer and the structure of **84b** was arbitrarily assigned.


Step C. 5-(Bromomethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-tetrazole (84c**)**



[00404] To a stirred solution of **84b** (1.06 g, 4.60 mmol) and triphenylphosphine (2.41 g, 9.20 mmol) in DCM at -40 °C was added N-bromosuccinimide (1.64 g, 9.20 mmol) in one portion. After the mixture was stirred at the same temperature for 2 h, it was quenched with sat. NaHCO₃ and the resulting mixture was warmed to rt. The solution was extracted (3 × DCM) and the combined organic layer was washed (brine), dried (Na₂SO₄), and concentrated under reduced pressure. Purification of the residue by


silica gel column chromatography (87g SiO₂, 0% to 20% EtOAc/hexanes, a gradient elution) provided the title compound (**84c**) (1.22 g, 90%) as a colorless oil.

Step D. Ethyl 2-(((3aR,4R,6R,6aR)-6-(4-((tert-butoxycarbonyl)(cyclopentyl)amino)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)-2-(diethoxyphosphoryl)-3-(2-((2-(trimethylsilyl)ethoxy)methyl)-2H-tetrazol-5-yl)propanoate (84d**)**




[00405] To stirred solution of ethyl 2-(((3aR,4R,6R,6aR)-6-(4-((tert-butoxycarbonyl)(cyclopentyl)amino)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)-2-(diethoxyphosphoryl)acetate (**1f**) (1.16 g, 1.58 mmol) in THF (27 mL) at -15 °C was added dropwise sodium bis(trimethylsilyl)amide (1.0 M in THF, 2.06 mL, 2.06 mmol). After the reaction mixture was stirred at the same temperature for 25 min, tetrabutylammonium iodide (293 mg, 0.86 mmol) was added, followed by dropwise addition of 5-(bromomethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-tetrazole (**84c**) (1.16 g, 3.96 mmol) solution in THF (3 mL) at -15 °C. The mixture was stirred at the same temperature for another 3 h and then quenched with sat. NH₄Cl. The solution was diluted with EtOAc and water, extracted with EtOAc. The combined organic layer was washed (brine), dried (Na₂SO₄), and concentrated under reduced pressure. Purification of the residue by silica gel column chromatography (120g SiO₂, 5% to 40% acetone/hexanes, a gradient elution) provided the title compound (**84d**) (1.07 g, 72%) as a colorless gum. m/z (ESI, +ve ion) = 944.2 [M+H]⁺.

Step E. tert-Butyl (6-chloro-1-((3aR,4R,6R,6aR)-6-(((2-(diethoxyphosphoryl)-1-hydroxy-3-(2-((2-(trimethylsilyl)ethoxy)methyl)-2H-tetrazol-5-yl)propan-2-yl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)(cyclopentyl)carbamate (84e**)**




[00406] To a stirred solution of **84d** (960 mg, 1.02 mmol) in EtOH (15 mL) was added calcium dichloride (395 mg, 3.56 mmol), followed by addition of NaBH₄ (135 mg, 3.56 mmol) in a single portion at 0 °C. After the reaction was stirred at rt for 3 h, the mixture was quenched with 1H HCl, diluted with EtOAc and water. The solution was extracted (3 × EtOAc) and the combined organic layer was washed (brine), dried (Na₂SO₄), and concentrated under reduced pressure. Purification of the residue by silica gel column chromatography (120g SiO₂, 1% to 5% MeOH/DCM, a gradient elution) provided the title compound (**84e**) (658 mg, 72%) as a white foamy solid. m/z (ESI, +ve ion) = 902.2 [M+H]⁺.

Step F. (2-(((2R,3S,4R,5R)-5-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxy-3-(2H-tetrazol-5-yl)propan-2-yl)phosphonic acid (84)




[00407] To a solution of **84e** (49 mg, 0.054 mmol) in MeCN (1.0 mL) was added bromotrimethylsilane (0.071 mL, 0.54 mmol). The mixture was stirred at rt for 3 h and then water (0.2 mL) was added. After the mixture was stirred at rt overnight, the solution was purified by reverse preparative HPLC to give the TFA salt of the title compound as a mixture of two diastereomers (**84**) (60:40 measured by ^1H NMR, 4.2 mg, 11% yield) as a white solid. ^1H NMR of the major diastereomer (400 MHz, CD_3OD) δ 8.10 (1H, d, $J = 0.8$ Hz), 6.31 (1H, d, $J = 4.0$ Hz), 4.75 (1H, t, $J = 4.6$ Hz), 4.56-4.52 (m, 2H), 4.35-4.31 (1H, m), 4.13-4.03 (3H, m), 3.89 (1H, dd, $J = 6.2, 12.6$ Hz), 3.62-3.53 (1H, dd, $J = 15.8, 17.6$ Hz), 3.42 (1H, dd, $J = 7.2, 15.6$ Hz), 2.13-2.06 (2H, m), 1.89-1.56 (6H, m); ^1H NMR of the minor diastereomer (400 MHz, CD_3OD) δ 8.12 (1H, d, $J = 0.8$ Hz), 6.28 (1H, d, $J = 4.0$ Hz), 4.70 (1H, t, $J = 6.0$ Hz), 4.59 (1H, t, $J = 5.2$ Hz), 4.57-4.45 (1H, m), 4.27 (1H, dd, $J = 5.2, 9.6$ Hz), 4.17 (1H, dd, $J = 5.2, 9.6$ Hz), 4.06 (1H, dd, $J = 4.2, 9.8$ Hz), 3.96 (1H, dd, $J = 7.6, 12.4$ Hz), 3.84 (1H, dd, $J = 6.6, 12.6$ Hz), 3.57 (1H, dd, $J = 12.8, 15.6$ Hz), 3.47 (1H, dd, $J = 8.8, 15.6$ Hz), 2.11-2.06 (2H, m), 1.89-1.57 (6H, m). m/z (ESI, +ve ion) = 576.1 $[\text{M}+\text{H}]^+$.

Example 85. (2-(((2R,3S,4R,5R)-5-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-(2-hydroxyethoxy)propan-2-yl)phosphonic acid (85)




Step A. Ethyl 2-(2-(((3aR,4R,6R,6aR)-6-(4-((tert-butoxycarbonyl)(cyclopentyl)amino)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)-2-(diethoxyphosphoryl)propoxy)acetate (85a)



[00408] To a solution of tert-butyl (6-chloro-1-((3aR,4R,6R,6aR)-6-(((2-(diethoxyphosphoryl)-1-hydroxypropan-2-yl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-1H-pyrazolo[3,4-


d]pyrimidin-4-yl)(cyclopentyl)carbamate (ether analog of **8d**) (500 mg, 0.71 mmol) in DMF (15 mL) was added ethyl bromoacetate (0.39 mL, 3.6 mmol) at 0°C. To this solution was added NaH (60% mineral oil, 85.2 mg, 2.13 mmol) in one portion. After the mixture was stirred at 0°C for 4 h, it was quenched with sat. NH₄Cl. The solution was extracted with EtOAc and the combined organics were washed with brine and dried with Na₂SO₄. The slurry was filtered and concentrated. The resulting residue was purified by flash chromatography (0-100% EtOAc/hexanes, a gradient elution) to afford the title compound (**85a**) (337 mg, 0.43 mmol, 60% yield) as a foaming solid. *m/z* (ESI, +ve ion) = 860.3 [M+H]⁺.

Step B. tert-Butyl (6-chloro-1-((3aR,4R,6R,6aR)-6-(((2-(diethoxyphosphoryl)-1-(2-hydroxyethoxy)propan-2-yl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)(cyclopentyl)carbamate (85b**)**



[00409] To an oven-dried flask containing **85a** (337 mg, 0.43 mmol) was added ethanol (6.5 mL). To the mixture was added calcium dichloride (146 mg, 1.28 mmol), followed by sodium borohydride (48.4 mg, 1.28 mmol) at 0°C. After the mixture was warmed to rt and stirred for 1.5 h, it was cooled to 0°C and quenched with sat. NH₄Cl. The resulting solution was extracted with EtOAc and the combined organic layers were washed with brine, dried with MgSO₄, filtered and concentrated. The resulting residue was purified by flash chromatography (60-100% EtOAc/hexanes, a gradient elution) to afford the title compound (**85b**) (230 mg, 0.31 mmol, 72% yield) as a white foamy solid. *m/z* (ESI, +ve ion) = 748.2 [M+H]⁺.


Step C. (2-(((2R,3S,4R,5R)-5-(6-Chloro-4-(cyclopentylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-(2-hydroxyethoxy)propan-2-yl)phosphonic acid (85**)**




[00410] To a vial was added **85b** (130 mg, 0.17 mmol) followed by addition of MeCN (2.7 mL). To this solution was added bromo(trimethyl)silane (0.16 mL, 1.2 mmol) and the mixture was allowed to stir for 4 h. Water (0.54 mL) was then added and the mixture was allowed to stir overnight. The mixture was concentrated to remove the MeCN and diluted with MeOH (1.5 mL). The solution was purified by prep HPLC (20-40% ACN/H₂O with 0.1% TFA, a gradient elution) to provide the TFA salt of title compound (**85**) (24 mg, 0.036 mmol, 21% yield) as a mixture of diastereomers. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.19 - 1.32 (m, 3H) 1.48 - 1.86 (m, 6H) 1.94 - 2.09 (m, 2H) 3.38 - 3.47 (m, 4H) 3.49 - 3.56 (m, 1H) 3.57 - 3.71

(m, 2H) 3.73 - 3.90 (m, 1H) 3.90 - 3.98 (m, 1H) 4.15 - 4.22 (m, 1H) 4.38 - 4.48 (m, 1H) 4.52 - 4.61 (m, 1H) 5.93 - 6.19 (m, 1H), 8.19 - 8.31 (m, 1H) 8.65 - 8.85 (m, 1H). m/z (ESI, +ve ion) = 552.2 $[M+H]^+$.

Example 86. [1-[(2R,3S,4R,5R)-5-[6-Chloro-4-(cyclopentylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy]-2-hydroxy-1-(hydroxymethyl)ethyl]phosphonic acid (**86**)




Step A. Ethyl 2-[[[(3aR,4R,6R,6aR)-4-[4-[tert-butoxycarbonyl(cyclopentyl)amino]-6-chloro-pyrazolo[3,4-d]pyrimidin-1-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methoxy]-2-diethoxyphosphoryl-3-(2-trimethylsilylethoxy)propanoate (**86a**)




[00411] To a solution of ethyl 2-[[[(3aR,4R,6R,6aR)-4-[4-[tert-butoxycarbonyl(cyclopentyl)amino]-6-chloro-pyrazolo[3,4-d]pyrimidin-1-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methoxy]-2-diethoxyphosphoryl-acetate (**1f**) (1.6 g, 2.19 mmol) in THF (44 mL) was added dropwise sodium bis(trimethylsilyl)amide (2.84 mL, 2.84 mmol) at -15°C. After stirring at -15°C for 25 min, tetra-*n*-butylammonium iodide (403.6 mg, 1.09 mmol) was added, immediately followed by the dropwise addition of 2-(chloromethoxy)ethyl[(trimethyl)silane] (1.18 mL, 6.56 mmol). After the solution was allowed to stir for 75 min at this temperature, it was quenched with sat. aq. NH_4Cl and subsequently diluted with EtOAc. The mixture was allowed to stir at rt for 5 min. To the mixture was added deionized water to dissolve some salts and the layers were separated. The organic layer was washed with additional sat. aq. NH_4Cl and the combined aqueous layers were then extracted with EtOAc (3X). The combined organic layers were washed with brine, dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The crude residue was purified by flash column chromatography (0-75% EtOAc/Hexanes, a gradient elution) to afford the title compound (**86a**) (1.454 g, 84%) as a light yellow oil.

Step B. tert-Butyl N-[1-[(3aR,4R,6R,6aR)-6-[[1-diethoxyphosphoryl-1-(hydroxymethyl)-2-(2-trimethylsilylethoxy)ethoxy]methyl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]-6-chloro-pyrazolo[3,4-d]pyrimidin-4-yl]-N-cyclopentyl-carbamate (**86b**)




[00412] To a solution of **86a** (1.45 g, 1.68 mmol) in ethanol (30 mL) was added calcium dichloride (769.45 mg, 6.73 mmol) at 0°C followed by sodium borohydride (254.42 mg, 6.73 mmol). The mixture was warmed to rt and stirred for 4.5 h before being placed back into an ice bath. Once cooled, the reaction was quenched with 1 N HCl (35 mL), and then diluted with EtOAc (30 mL). The flask was allowed to stir at rt for 5 min and the organic layer was washed with additional 1 N HCl. The combined aqueous layers were extracted with EtOAc (2X) and the combined organic layers were then washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting crude residue was purified by flash column chromatography (0-100% EtOAc/Hexanes, a gradient elution) to afford the title compound (**86b**) (1.11g, 88%). m/z (ESI, +ve ion) = 890.3 [M+H]⁺.

Step C. 2-[[[(3aR,4R,6R,6aR)-4-[6-Chloro-4-(cyclopentylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methoxy]-2-diethoxyphosphoryl-propane-1,3-diol (**86c**)




[00413] To a solution of **86b** (920 mg, 1.12 mmol) in DCM (56 mL) was added dropwise boron trifluoride diethyl etherate (0.74 mL, 2.8 mmol) at 0 °C. The reaction was allowed to warm to rt. After stirring for 75 min the reaction was quenched with triethylamine (20 mL). The solution was diluted with EtOAc (100 mL), and sat. aq. NaHCO₃ (100 mL) was added. Following separation of the layers, the aqueous layer was extracted with EtOAc (3X). The combined organic layers were then washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The resulting crude residue was purified by flash column chromatography (0-75% EtOAc/Hexanes, a gradient elution and then 0-10% MeOH/DCM) to afford the title compound (**86c**) (469 mg, 67%) as an off-white foam. m/z (ESI, +ve ion) = 620.2 [M+H]⁺.

Step D. [1-[[[(2R,3S,4R,5R)-5-[6-Chloro-4-(cyclopentylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy]-2-hydroxy-1-(hydroxymethyl)ethyl]phosphonic acid (**86**)




[00414] To a solution of **86c** (460 mg, 0.74 mmol) in MeCN (37 mL) was added triethylamine (2.07 mL, 14.84 mmol). Bromo(trimethyl)silane (1.51 mL, 11.13 mmol) was then added dropwise to this mixture at rt. After stirring for 5 h, the mixture was concentrated under reduced pressure. The resulting residue was suspended in deionized water (12 mL), to which trifluoroacetic acid (4 mL) was added. After stirring at rt for 75 min, the solution was concentrated under reduced pressure to remove all volatile organics. The remaining aqueous solution was diluted with MeOH, and the resulting solution was then purified by reverse phase HPLC (15-40% ACN/H₂O with 0.1% TFA, a gradient elution) to provide the TFA salt of the title compound (**86**) (229.5 mg, 48%) as an off-white powder. ¹H NMR (400 MHz, CD₃OD) δ 8.14 (s, 1 H), 6.23 (d, J = 4.8 Hz, 1 H), 4.86 (t, J = 5.0 Hz, 1 H), 4.61–4.45 (m, 2 H), 4.22 (q, J = 4.0 Hz, 1 H), 4.05 (dd, J = 10.0, 3.2 Hz, 1 H), 3.99 (dd, J = 10.0, 4.8 Hz, 1 H), 3.96–3.84 (m, 4H), 2.19–2.01 (m, 2H), 1.88–1.74 (m, 2H), 1.74–1.50 (m, 4H). m/z (ESI, +ve ion) = 524.1 [M+H]⁺.

Example 87. 1-[[[(2R,3S,4R,5R)-5-[6-Chloro-4-(cyclopentylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy]-2-methoxy-1-(methoxymethyl)ethyl]phosphonic acid (87**)**




Step A. Ethyl 2-(((3aR,4R,6R,6aR)-6-(4-((tert-butoxycarbonyl)(cyclopentyl)amino)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)-2-(diethoxyphosphoryl)-3-methoxypropanoate (87a**)**



[00415] To a solution of ethyl 2-[[[(3aR,4R,6R,6aR)-4-[4-[tert-butoxycarbonyl(cyclopentyl)amino]-6-chloro-pyrazolo[3,4-d]pyrimidin-1-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methoxy]-2-diethoxyphosphoryl-acetate (**1f**) (2.9 g, 3.96 mmol) in THF (75 mL) was added dropwise sodium bis(trimethylsilyl)amide (5.15 mL, 5.15 mmol) at -15°. After stirring at -15°C for 25 min, tetra-*n*-butylammonium iodide (731.52 mg, 1.98 mmol) was added, immediately followed by the dropwise addition of chloromethyl methyl ether (1.12 mL, 13.86 mmol). The solution was allowed to stir for 65 min at this


temperature. The reaction was then quenched with sat. aq. NH_4Cl , and subsequently diluted with EtOAc. The mixture was allowed to stir at rt for 5 min. To the mixture was added deionized water to dissolve some salts and the layers were then separated. The organic layer was washed with additional sat. aq. NH_4Cl and the combined aqueous layers were extracted with EtOAc (3X). The combined organic layers were then washed with brine, dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The crude residue was purified by flash column chromatography (0-75% EtOAc/Hexanes, a gradient elution) to afford the title compound (**87a**) (2.8558 g, 91%) as a yellow syrup. m/z (ESI, +ve ion) = 846.3 $[\text{M}+\text{H}]^+$.

Step B. tert-Butyl N-[1-[(3aR,4R,6R,6aR)-6-[[1-diethoxyphosphoryl-1-(hydroxymethyl)-2-methoxyethoxy]methyl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]-6-chloro-pyrazolo[3,4-d]pyrimidin-4-yl]-N-cyclopentyl-carbamate (87b**)**



[00416] To a solution of **87a** (1.61 g, 2.07 mmol) in ethanol (34 mL) that had been cooled to 0 °C using an ice bath, was added calcium dichloride (0.71g, 6.22 mmol) followed by sodium borohydride (235.4 mg, 6.22 mmol). The mixture was warmed to rt, where it was stirred for 5 h before being placed back into an ice bath. Once cooled, the reaction was quenched with 1 N HCl (30 mL), and then diluted with EtOAc (30 mL). The flask was removed from the bath and allowed to stir at rt for 20 min. The organic layer was washed with additional 1 N HCl and the combined aqueous layers were extracted with EtOAc (2X). The combined organic layers were then washed with brine, dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The resulting crude residue was purified by flash column chromatography (0-100% EtOAc/Hex and then 0-10% MeOH/DCM, gradient elution) to yield the title compound (**87b**) (1.23 g, 87%) as a white foam. m/z (ESI, +ve ion) = 734.2 $[\text{M}+\text{H}]^+$.


Step C. Butyl N-[1-[(3aR,4R,6R,6aR)-6-[[1-diethoxyphosphoryl-2-methoxy-1-(methoxymethyl)ethoxy]methyl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]-6-chloro-pyrazolo[3,4-d]pyrimidin-4-yl]-N-cyclopentyl-carbamate (87c**)**



[00417] To a round bottom flask containing activated 4 Å MS was added a solution of **87b** (1.1 g, 1.5 mmol) in DCM (40 mL). To this stirring solution was added 1,8-bis(dimethylamino)naphthalene (2.01 g, 9.36 mmol), followed by the addition of trimethyloxonium tetrafluoroborate (1.22 g, 7.84 mmol). After stirring at rt for 7 h, the reaction was quenched with sat. aq. NaHCO_3 (20 mL). The biphasic solution was


filtered to remove the MS, and the MS were washed with deionized water and DCM. After separating the two layers, the organic layer was washed with additional sat. aq. NaHCO_3 (20 mL). The combined aqueous layers were extracted with DCM (2X) and the combined organic layers were then washed with 1 N HCl (2X). The aqueous layers were combined and extracted with DCM (2X) again and the combined organic layers were washed with brine, dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The resulting crude residue was purified via flash column chromatography (silica gel, 0-100% EtOAc/Hexanes, a gradient elution) to give the title compound (**87c**) (588.4 mg, 52%) as a clear colorless oil. m/z (ESI, +ve ion) = 748.3 $[\text{M}+\text{H}]^+$.

Step D. [1-[(2R,3S,4R,5R)-5-[6-Chloro-4-(cyclopentylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy]-2-methoxy-1-(methoxymethyl)ethyl]phosphonic acid (87**)**




The title compound was prepared from **87c** by procedures similar to those described in Example 86, Step D. ^1H NMR (400 MHz, CD_3OD) δ 8.14 (s, 1 H), 6.20 (d, J = 4.4 Hz, 1 H), 4.86 (t, J = 4.8 Hz, 1 H), 4.54 (p, J = 6.9 Hz, 1 H), 4.47 (t, J = 4.6 Hz, 1 H), 4.16 (q, J = 4.9 Hz, 1 H), 3.99 (dd, J = 10.0, 4.8 Hz, 1 H), 3.87 (dd, J = 10.2, 5.8 Hz, 1 H), 3.86–3.64 (m, 4 H), 3.33 (s, 3H), 3.31 (s, 3H), 2.19–2.03 (m, 2H), 1.89–1.74 (m, 2H), 1.74–1.53 (m, 4H). m/z (ESI, +ve ion) = 552.1 $[\text{M}+\text{H}]^+$.

Example 88. (2-(((2R,3S,4R,5R)-5-(4-(Cyclopentylamino)-6-(3-hydroxypropyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid (88**)**




Step A. Ethyl (E)-3-(4-((tert-butoxycarbonyl)(cyclopentyl)amino)-1-((3aR,4R,6R,6aR)-6-(((2-(diethoxyphosphoryl)-1-ethoxy-1-oxopropan-2-yl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)acrylate (88a**)**



[00418] To a solution of ethyl 2-(((3aR,4R,6R,6aR)-6-(4-((tert-butoxycarbonyl)(cyclopentyl)amino)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)-2-


(diethoxyphosphoryl)propanoate (alpha-methyl substituted **1f**) (930 mg, 1.25 mmol) in dioxane (50 mL) was added (E)-ethyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)acrylate (565 mg, 2.5 mmol), Na₂CO₃ (400 mg, 3.75 mmol) and water (15 mL). After the mixture was degassed by N₂ three times, Pd(PPh₃)₄ (200 mg) was added and the resulting mixture was degassed for another 5 min. The mixture was stirred at 90 °C for 6 h, cooled to rt. quenched with water, and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography to afford the title compound (**88a**) (600 mg, 59% yield) as a yellow oil. m/z (ESI, +ve ion) = 879.36 [M+H]⁺.

Step B. Ethyl 2-(((3aR,4R,6R,6aR)-6-(4-((tert-butoxycarbonyl)(cyclopentyl)amino)-6-(3-ethoxy-3-oxopropyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)-2-(diethoxyphosphoryl)propanoate (88b**)**




[00419] To a solution of **88a** (500 mg, 0.62 mmol) in MeOH (70 mL) was added 10% Pd-C (0.1 g). After the mixture was stirred under 1 atm of H₂ at rt for 3 h, it was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to afford the title compound (**88b**) (360 mg, 0.44 mmol, 72% yield) as a yellow oil.

Step C. tert-Butyl cyclopentyl(1-(((3aR,4R,6R,6aR)-6-(((2-(diethoxyphosphoryl)-1-hydroxypropan-2-yl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-6-(3-hydroxypropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)carbamate (88c**)**




[00420] To a solution of **88b** (360 mg, 0.44 mmol) in THF (10 mL) was added LiBH₄ (1.8 mL, 2.0M in THF) at 0 °C. The mixture was stirred at rt for 2 h and then quenched with sat. NH₄Cl (5 mL). The solution was extracted with EtOAc and the combined organic layer was washed with brine, dried with Na₂SO₄, filtered, concentrated. The crude oil was purified by column chromatography to provide the title compound (**88c**) (110 mg, 34% yield) as a yellow oil. m/z (ESI, +ve ion) = 727.36 [M+H]⁺.

Step D. 2-(((2R,3S,4R,5R)-5-(4-(Cyclopentylamino)-6-(3-hydroxypropyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-ylphosphonic acid (88**)**




[00421] The title compound was prepared from **88c** by procedures similar to those described in Example **86**, Step D. ^1H NMR (400 MHz, D_2O) δ 8.34-8.26 (m, 1H), 6.22 (m, 1H), 4.88 (m, 1H), 4.44 (m, 1H), 4.30 (m, 1H), 4.18 (m, 1H), 3.74-3.70 (m, 3H), 3.63-3.51 (m, 3H), 2.95 (t, $J=7.6$ Hz, 1H), 2.84 (t, $J=7.6$ Hz, 1H), 2.04-1.92 (m, 4H), 1.65-1.56 (m, 6H), 1.20 (d, $J=13.2$ Hz, 3H). m/z (ESI, +ve ion) = 531.27 $[\text{M}+\text{H}]^+$.

Example 89. (2-(((2R,3S,4R,5R)-5-(4-(Cyclopentylamino)-6-(3-hydroxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid (**89**)




Step A. tert-Butyl (1-((3aR,4R,6R,6aR)-6-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-4-yl)(cyclopentyl)carbamate (**89a**)




[00422] To a solution of **1e** (2.25 g, 4.42 mmol) in DCM (25 mL) was added TBDPSCl (2.06 g, 7.5 mmol), Et_3N (1.01 g, 10 mmol) and DMAP (53.7 mg, 0.44 mmol). After the mixture was stirred at rt overnight, it was washed with water (15 mL), saturated aqueous NaHCO_3 (15 mL) and brine (15 mL). The organic phase was dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The residue was purified by column chromatography to provide the title compound (**89a**) (3.0 g, 89% yield) as a white solid. m/z (ESI, +ve ion) = 748.24 $[\text{M}+\text{H}]^+$.

Step B. tert-Butyl (6-amino-1-((3aR,4R,6R,6aR)-6-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)(cyclopentyl)carbamate (**89b**)




[00423] To a high pressure reactor was added **89a** (3.0 g, 40.1 mmol), dioxane (90 mL) and NH_3 (300 mL, 5.0 N in methanol). The reaction mixture was stirred at 87°C overnight and concentrated. The residue was purified by column chromatography to afford the title compound (**89b**) (1.6 g, 55% yield) as a white solid. m/z (ESI, +ve ion) = 729.17 $[\text{M}+\text{H}]^+$.

Step C. tert-Butyl (1-((3aR,4R,6R,6aR)-6-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-6-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)(cyclopentyl)carbamate (89c**)**



[00424] To a solution of **89b** (5.9 g, 8.1 mmol) in THF (70 mL) was added CuI (2.0 g, 10.5 mmol), I_2 (2.67 g, 10.5 mmol) and CH_2Cl_2 (2.89 g, 10.5 mmol). The mixture was degassed by N_2 three times, subsequently, tert-butyl nitrite (3.34 g, 32.4 mmol) was added and the resulting mixture was degassed for another 5 min. The mixture was stirred at reflux for 2 h and then cooled to rt. The mixture was filtered and the filtrate was extracted with EtOAc. The organic layers was washed with brine, dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The residue was purified by column chromatography to afford the title compound (**89c**) (2.3 g, 34% yield) as a yellow solid. m/z (ESI, +ve ion) = 909.26 $[\text{M}+\text{H}]^+$.


Step D. tert-Butyl (1-((3aR,4R,6R,6aR)-6-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-6-(3-(((tetrahydro-2H-pyran-2-yl)oxy)prop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)(cyclopentyl)carbamate (89d**)**



[00425] To a solution of **89c** (1.5 g, 1.8 mmol) in dioxane (20 mL) was added CuI (20 mg), 2-(prop-2-ynyloxy)tetrahydro-2H-pyran (0.326 g, 2.5 mmol) and TEA (10 mL). After the mixture was degassed by N_2 three times, $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$ (38 mg, 0.03 eq) was added and the resulting mixture was degassed for 5 min. The mixture was stirred at 40°C for 1 h and then cooled to rt. The mixture was added water and extracted


with EtOAc. The organic layers was washed with brine, dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The residue was purified by column chromatography to afford the title compound (**89d**) (1.3 g, 85% yield) as a yellow solid. m/z (ESI, +ve ion) = 851.43 $[\text{M}+\text{H}]^+$.

Step E. tert-Butyl cyclopentyl(1-((3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-6-(3-(((tetrahydro-2H-pyran-2-yl)oxy)prop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)carbamate (89e**)**




[00426] To a solution of **89d** (1.3 g, 1.5 mmol) in THF (20 mL) at 0 °C was added TBAF (0.75 g, 2.4 mmol). After the mixture was stirred at 25 °C for 1 h, it was quenched with saturated NaHCO_3 and extracted with EtOAc. The organic layers were washed with brine, dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The residue was purified by column chromatography to afford the title compound (**89e**) (0.69 g, 73% yield) as a purple solid. m/z (ESI, +ve ion) = 613.31 $[\text{M}+\text{H}]^+$.

Step F. (2-(((2R,3S,4R,5R)-5-(4-(Cyclopentylamino)-6-(3-hydroxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid (89**)**




[00427] The title compound was prepared from **89e** by procedures similar to these described in Example 8, Steps C, D, and F. ^1H NMR (400 MHz, D_2O) δ 8.31-8.19 (m, 1H), 6.13 (m, 1H), 4.85 (m, 1H), 4.43-4.40 (m, 3H), 4.34-4.17 (m, 2H), 3.80-3.60 (m, 3H), 3.52-3.47 (m, 1H), 1.96 (m, 2H), 1.65-1.55 (m, 6H), 1.18 (d, $J=14$ Hz, 3H). m/z (ESI, +ve ion) = 527.18 $[\text{M}+\text{H}]^+$.

Example 90. (2-(((2R,3S,4R,5R)-5-(4-(Cyclopentylamino)-6-(hydroxymethyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxypropan-2-yl)phosphonic acid (90**)**




Step A. ((3aR,4R,6R,6aR)-6-(4-((tert-Butoxycarbonyl)(cyclopentyl)amino)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl benzoate (90a**)**




[00428] To a solution of **1e** (5.0 g, 9.8 mmol), triethylamine (2.98 g, 29.5 mmol) and DMAP (300 mg, 2.5 mmol) in DCM (100 mL) was added dropwise BzCl (2.07 g, 14.7 mmol) at 0 °C over 10 min. The mixture was allowed to warm to rt and stirred overnight. The mixture was washed with aq. NaHCO₃. The organic layer was dried and concentrated in vacuo. The residue was purified by column chromatography to afford the title compound (**90a**) (5.2 g, 87% yield).

Step B. ((3aR,4R,6R,6aR)-6-(4-((tert-Butoxycarbonyl)(cyclopentyl)amino)-6-((E)-styryl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl benzoate (90b**)**



[00429] Pd(PPh₃)₄ (987 mg, 0.85 mmol) was added to a mixture of **90a** (5.2 g, 8.48 mmol), (E)-styrylboronic acid (1.88 g, 12.7 mmol), and Na₂CO₃ (2.7 g, 25.4 mmol) in THF (120 mL) and water (40 mL). The reaction mixture was refluxed under nitrogen overnight. After the mixture was cooled to rt, it was diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated in vacuo. The residue was purified by column chromatography to give the title compound (**90b**) (5 g, 86% yield). m/z (ESI, +ve ion) = 688.8 [M+H]⁺.


Step C. ((3aR,4R,6R,6aR)-6-(4-((tert-Butoxycarbonyl)(cyclopentyl)amino)-6-formyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl benzoate (90c**)**



[00430] To a solution of **90b** (5 g, 7.34 mmol) and 2,6-lutidine (1.57 g, 14.7 mmol) in THF (200 mL) and water (100 mL) was added NaIO₄ (9.43 g, 44.1 mmol) followed by addition of K₂OsO₄·2H₂O (67 mg, 0.2 mmol). The mixture was stirred at rt overnight and then diluted with water and extracted with EtOAc. The organic layer was washed with sat. Na₂S₂O₃, brine, dried and concentrated in vacuo. The residue


was purified by column chromatography to afford the title compound (**90c**) (4 g, 90% yield). m/z (ESI, +ve ion) = 629.9 $[M+Na]^+$.

Step D. ((3aR,4R,6R,6aR)-6-(4-((tert-Butoxycarbonyl)(cyclopentyl)amino)-6-(hydroxymethyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl benzoate (**90d**)




[00431] $NaBH_4$ (375 mg, 9.88 mmol) was added to a solution of **90c** (4 g, 6.59 mmol) in methanol (100 mL). After the mixture was stirred at rt for 1 h, it was concentrated in vacuo and purified by column chromatography to provide the title compound (**90d**) (3.8 g, 95% yield). m/z (ESI, +ve ion) = 610.0 $[M+H]^+$.

Step E. ((3aR,4R,6R,6aR)-6-(4-((tert-Butoxycarbonyl)(cyclopentyl)amino)-6-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl benzoate (**90e**)



[00432] PPTS (470 mg, 1.87 mmol) was added to a solution of **90d** (3.8 g, 6.2 mmol) and 3,4-dihydro-2H-pyran (5.2 g, 62 mmol) in DCM (120 mL). After the mixture was stirred at rt overnight, it was washed with sat. $NaHCO_3$. The organic layer was washed with brine, dried and concentrated. The residue was purified by column chromatography to afford the title compound (**90e**) (4 g, 92% yield). m/z (ESI, +ve ion) = 694.6 $[M+H]^+$.


Step F. tert-butyl Cyclopentyl(1-((3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-6-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)carbamate (**90f**)



[00433] K_2CO_3 (1.19 g, 8.66 mmol) was added to a solution of **90e** (4 g, 5.84 mmol) in methanol (150 mL). After the mixture was stirred at rt for 1 h, it was poured into brine and extracted with EtOAc. The


organic layer was dried, concentrated and purified by column chromatography to give the title compound **90f** (3 g, 88% yield). m/z (ESI, +ve ion) = 590.2 $[M+H]^+$.

Step G. (2-(((2R,3S,4R,5R)-5-(4-(Cyclopentylamino)-6-(hydroxymethyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-methoxypropan-2-yl)phosphonic acid (90)




[00434] The title compound was prepared from **90f** by procedures similar to those described in Example 8, Steps C and D, followed by Steps C and D in Example 87. ^1H NMR (D_2O , 400 MHz) δ 8.24-8.48 (m, 1H), 6.23 (m, 1H), 4.79-4.74 (m, 3H), 4.43 (m, 2H), 4.16 (m, 1H), 3.78 (m, 2H), 3.52-3.46 (m, 2H), 3.18 (s, 3H), 2.04 (m, 2H), 1.65 (m, 6H), 1.22-1.16 (dd, $J=14.8$ Hz, 6.4 Hz, 3H). m/z (ESI, +ve ion) = 517.8.0 $[M+H]^+$.

Example 91. (2-(((2R,3S,4R,5R)-5-(2-Chloro-4-(cyclopentylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid (91)




Step A. 2-Chloro-N-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (91a)



[00435] A mixture of 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine (5 g, 26.74 mmol), cyclopentanamine (3.41 g, 40.11 mmol) and triethylamine (5.4 g, 53.48 mmol) in ethanol (50 mL) was refluxed overnight. The mixture was concentrated to dryness, the residue was treated with water (50 mL) and the mixture was stirred for 1 h. The solid was filtered and dried under vacuum to afford the title compound (**91a**) (6 g, 95% yield). m/z (ESI, +ve ion) = 237.0 $[M+H]^+$.


Step B. (3aR,6R,6aR)-6-(Hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-ol (91b)



[00436] Concentrated sulfuric acid (0.3 mL) was added to a suspension of D-ribose (12.5 g, 90 mmol) in acetone (125 mL). The reaction mixture was stirred at rt for 90 min to obtain a clear solution


which was then neutralized with saturated aqueous sodium carbonate. The mixture was filtered over celite and the filtrate was concentrated in vacuo to afford the title compound (**91b**) (16 g), which was used in next step without purification.

Step C. ((3aR,4R,6aR)-6-Hydroxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl benzoate (84c)




[00437] To a solution of **91b** (16 g, 90 mmol) in pyridine (60 mL) was added dropwise BzCl (12.9 g, 91 mmol) at 0 °C. After the mixture was stirred at rt overnight, it was concentrated in vacuo. The residue was treated with EtOAc and the solution was washed with 5% aq. citric acid. The organic layer was dried and concentrated in vacuo and the residue was purified by column chromatography (20% EtOAc/Petroleum) to afford the title compound (**91c**) (12 g, 49% yield over two steps). m/z (ESI, +ve ion) = 316.4 $[M+Na]^+$

Step D. ((3aR,4R,6aR)-6-Bromo-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl benzoate (91d)




[00438] To a solution of **91c** (3.3 g, 11.22 mmol) in dry DCM (60 mL) was added dropwise TMSBr (5.15 g, 33.66 mmol) at 0 °C. After the mixture was allowed to warm to rt and stirred for 2 h, it was concentrated in vacuo at rt. The residue was used in next step immediately.

Step E. ((3aR,4R,6R,6aR)-6-(2-Chloro-4-(cyclopentylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl benzoate (91e)




[00439] To a suspension of **91a** (608 mg, 2.58 mmol) in dry MeCN (20 mL) was added NaH (60% in mineral oil, 155 mg, 3.86 mmol). After the mixture was stirred at rt for 0.5 h, a solution of **91d** (1.1 g, 3.09 mmol) in dry MeCN (10 mL) was added to the solution above. The reaction mixture was stirred at rt overnight and then poured into sat. NH_4Cl . The solution was extracted with EtOAc and the organic layer was washed with brine, dried and concentrated in vacuo. The residue was purified by column chromatography to give the title compound (**91e**) (1 g, 76% yield). m/z (ESI, +ve ion) = 535.1 $[M+Na]^+$.

Step F. ((3aR,4R,6R,6aR)-6-(2-Chloro-4-(cyclopentylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol (91f)




[00440] K_2CO_3 (248 mg, 1.85 mmol) was added to a solution of **91e** (460 mg, 0.90 mmol) in MeOH (10 mL). After the mixture was stirred at rt for 0.5 h, it was quenched with acetic acid and concentrated to dryness. The residues was purified by column chromatography to provide the tile compound (**91f**) (350 mg, 95% yield). m/z (ESI, +ve ion) = 430.7 $[M+Na]^+$.

Step G. 7-((3aR,4R,6R,6aR)-6-(((tert-Butyldiphenylsilyl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-2-chloro-N-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (91g**)**




[00441] TBDPSCl (405 mg, 1.47 mmol) was added dropwise to a solution of **91f** (400 mg, 0.98 mmol) and imidazole (200 mg, 2.94 mmol) in DMF (10 mL) at 0 °C. The mixture was allowed to warm to rt and stirred overnight. The reaction mixture was poured into water and the solution was extracted with EtOAc. The organic layer was washed with brine, dried and concentrated. The residue was purified by column chromatography to afford the title compound (**91g**) (500 mg, 86% yield). m/z (ESI, +ve ion) = 646.54 $[M+H]^+$.

Step H. tert-Butyl (7-((3aR,4R,6R,6aR)-6-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-2-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)(cyclopentyl)carbamate (91h**)**




[00442] Boc_2O (506.2 mg, 2.32 mmol) was added to a solution of **91g** (500 mg, 0.84 mmol), triethylamine (258 mg, 2.55 mmol) and DMAP (19 mg, 0.15 mmol) in DMF (10 mL). After the mixture was stirred at rt for 2 days, it was poured into water and the solution was extracted with EtOAc. The organic layer was washed with brine, dried and concentrated. The residue was purified by column chromatography to afford the title compound (**91h**) (140 mg, 24% yield).

Step I. tert-Butyl (2-chloro-7-((3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)(cyclopentyl)carbamate (91i**)**



[00443] TBAF (98 mg, 0.38 mmol) was added to a solution of **91h** (140 mg, 0.19 mmol) in THF (10 mL). After the mixture was stirred at rt overnight, it was poured into water and the solution was extracted with EtOAc. The organic layer was washed with brine, dried and concentrated. The residue was purified by column chromatography to afford the title compound (**91i**) (90 mg, 95% yield). m/z (ESI, +ve ion) = 508.7[M+H]⁺.

Step J. (2-(((2R,3S,4R,5R)-5-(2-Chloro-4-(cyclopentylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)-1-hydroxypropan-2-yl)phosphonic acid (91**)**



[00444] The title compound was prepared from **91i** by procedures similar to those described in Example 8, Steps C, D, and F. ¹H NMR(D₂O, 400 MHz) δ 7.31-7.30 (d, J=3.2 Hz, 1H), 6.55 (d, J=2.8 Hz, 1H), 6.27 (d, J=4.8 Hz, 1H), 4.56 (m, 1H), 4.30 (m, 2H), 4.18 (m, 1H), 3.88-3.58 (m, 4H), 1.92 (m, 2H), 1.61-1.51 (m, 6H), 1.30-1.26 (d, J=14.4 Hz, 3H). m/z (ESI, +ve ion) = 506.91 [M+H]⁺.

Examples 92-248: Examples 92-248 were synthesized as described in examples 1-8, 15-17, 55-58, and 84-91.

Ex	MS Data	Ex	MS Data	Ex	MS Data
92	575.0 [M+H] ⁺	144	493.94 [M+H] ⁺	196	562.2 [M+H] ⁺
93	585.3 [M+H] ⁺	145	547.9 [M+H] ⁺	197	562.2 [M+H] ⁺
94	588.1 [M+H] ⁺	146	562.2 [M+H] ⁺	198	582.1 [M+H] ⁺
95	606.1 [M+H] ⁺	147	534.3 [M+H] ⁺	199	528.0 [M+H] ⁺
96	590.2 [M+H] ⁺	148	521.97 [M+H] ⁺	200	523.2 [M+H] ⁺
97	546.2 [M+H] ⁺	149	494.2 [M+H] ⁺	201	580.0 [M+H] ⁺
98	546.1 [M+H] ⁺	150	538.1 [M+H] ⁺	202	506.2 [M+H] ⁺
99	574.0 [M+H] ⁺	151	538.1 [M+H] ⁺	203	580.0 [M+H] ⁺
100	598.2 [M+H] ⁺	152	507.2 [M+H] ⁺	204	550.2 [M+H] ⁺
101	494.3 [M+H] ⁺	153	561.9 [M+H] ⁺	205	528.0 [M+H] ⁺
102	494.3 [M+H] ⁺	154	571.1 [M+H] ⁺	206	592.2 [M+H] ⁺
103	576.1 [M+H] ⁺	155	571.1 [M+H] ⁺	207	606.1 [M+H] ⁺
104	576.2 [M+H] ⁺	156	535.9 [M+H] ⁺	208	606.1 [M+H] ⁺
105	522.1 [M+H] ⁺	157	507.9 [M+H] ⁺	209	590.2 [M+H] ⁺
106	522.1 [M+H] ⁺	158	522.1 [M+H] ⁺	210	566.2 [M+H] ⁺
107	586.1 [M+H] ⁺	159	507.9 [M+H] ⁺	211	537.9 [M+H] ⁺
108	574.2 [M+H] ⁺	160	508.1 [M+H] ⁺	212	590.2 [M+H] ⁺
109	523.0 [M+H] ⁺	161	507.9 [M+H] ⁺	213	562.2 [M+H] ⁺
110	523.2 [M+H] ⁺	162	511.0 [M+H] ⁺	214	562.2 [M+H] ⁺
111	521.1 [M+H] ⁺	163	578.2 [M+H] ⁺	215	567.1 [M+H] ⁺

Ex	MS Data	Ex	MS Data	Ex	MS Data
112	552.1 [M+H] ⁺	164	564.0 [M+H] ⁺	216	567.1 [M+H] ⁺
113	572.0 [M+H] ⁺	165	547.8 [M+H] ⁺	217	572.2 [M+H] ⁺
114	566.2 [M+H] ⁺	166	538.1 [M+H] ⁺	218	572.2 [M+H] ⁺
115	566.2 [M+H] ⁺	167	564.1 [M+H] ⁺	219	575.2 [M+H] ⁺
116	510.1 [M+H] ⁺	168	586.1 [M+H] ⁺	220	552.1 [M+H] ⁺
117	493.0 [M+H] ⁺	169	552.1 [M+H] ⁺	221	552.1 [M+H] ⁺
118	566.2 [M+H] ⁺	170	578.2 [M+H] ⁺	222	578.1 [M+H] ⁺
119	560.0 [M+H] ⁺	171	578.2 [M+H] ⁺	223	576.3 [M+H] ⁺
120	560.0 [M+H] ⁺	172	568.2 [M+H] ⁺	224	572.0 [M+H] ⁺
121	574.2 [M+H] ⁺	173	547.9 [M+H] ⁺	225	576.2 [M+H] ⁺
122	574.2 [M+H] ⁺	174	537.8 [M+H] ⁺	226	606.1 [M+H] ⁺
123	534.1 [M+H] ⁺	175	578.2 [M+H] ⁺	227	657.9 [M+H] ⁺
124	552.1 [M+H] ⁺	176	590.0 [M+H] ⁺	228	537.8 [M+H] ⁺
125	538.3 [M+H] ⁺	177	626.1 [M+H] ⁺	229	629.2 [M+H] ⁺
126	534.1 [M+H] ⁺	178	567.1 [M+H] ⁺	230	615.3 [M+H] ⁺
127	503.9 [M+H] ⁺	179	614.2 [M+H] ⁺	231	643.2 [M+H] ⁺
128	503.9 [M+H] ⁺	180	614.1 [M+H] ⁺	232	566.2 [M+H] ⁺
129	505.9 [M+H] ⁺	181	564.0 [M+H] ⁺	233	566.2 [M+H] ⁺
130	494.3 [M+H] ⁺	182	547.9 [M+H] ⁺	234	590.2 [M+H] ⁺
131	507.9 [M+H] ⁺	183	561.7 [M+H] ⁺	235	586.2 [M+H] ⁺
132	509.8 [M+H] ⁺	184	562.0 [M+H] ⁺	236	580.2 [M+H] ⁺
133	548.1 [M+H] ⁺	185	580.2 [M+H] ⁺	237	524.1 [M+H] ⁺
134	534.1 [M+H] ⁺	186	534.1 [M+H] ⁺	238	524.2 [M+H] ⁺
135	534.1 [M+H] ⁺	187	628.0 [M+H] ⁺	239	550.1 [M+H] ⁺
136	534.1 [M+H] ⁺	188	628.2 [M+H] ⁺	240	562.2 [M+H] ⁺
137	584.1 [M+H] ⁺	189	586.2 [M+H] ⁺	241	562.2 [M+H] ⁺
138	584.1 [M+H] ⁺	190	628.2 [M+H] ⁺	242	538.1 [M+H] ⁺
139	507.9 [M+H] ⁺	191	564.0 [M+H] ⁺	243	610.2 [M+H] ⁺
140	507.8 [M+H] ⁺	192	556.1 [M+H] ⁺	244	610.2 [M+H] ⁺
141	548.1 [M+H] ⁺	193	506.9 [M+H] ⁺	245	582.3 [M+H] ⁺
142	509.1 [M+H] ⁺	194	506.8 [M+H] ⁺	246	582.1 [M+H] ⁺
143	521.92 [M+H] ⁺	195	591.1 [M+H] ⁺	247	538.2 [M+H] ⁺
				248	566.2 [M+H] ⁺

II. Biological Evaluation

Example A1: Biochemical Assay

Assay Reaction Conditions

- Assay Volume: 70 µl
- Reaction Volume: 50 µl
- CD73 : 0.3208 nM
- AMP: 15 µM
- Assay Buffer: 2 5mM Tris-HCL, pH 7.4, 0.01% Brij-35, 0.01% BSA, 5 mM MgCl₂

Assay Procedure:

[00445] Used 384 clear plate.

[00446] Made dose titration of testing compounds in assay buffer, 10 points 1/2 log titrations in duplicates starting at 100 µM.

- [00447] Added 25 μ l of CD73 to each well for a final concentration of 320 pM.
- [00448] Incubated at RT for 15 min.
- [00449] Added 25 μ l of AMP to each well for a final concentration of 15 μ M.
- [00450] Incubated at RT for 10 min.
- [00451] Added 10 μ l of Malachite Green Reagent A, incubate at RT for 10 min.
- [00452] Added 10 μ l of Malachite Green Reagent B, incubate at RT for 45 min.
- [00453] Read the Absorbance on Envision plate reader using excitation filter: Cy5 620 nM.
- [00454] The ability of the compounds disclosed herein to inhibit CD73 activity was quantified and the respective IC₅₀ values were determined. Table 2 provides the biochemical IC₅₀ values of compounds disclosed herein.

TABLE 2

Ex	Biochemical IC ₅₀	Ex	Biochemical IC ₅₀	Ex	Biochemical IC ₅₀
1	A	84	A	154	A
2	B	85	A	155	A
3	A	86	A	156	A
4	A	87	A	157	A
5	A	88	A	158	A
6	A	89	A	159	A
7	A	90	A	160	A
8	A	91	A	161	A
9	B	92	A	162	A
10	A	93	A	163	A
11	A	94	B	164	A
12	A	95	A	165	A
13	A	96	A	166	A
14	A	97	A	167	A
15	A	98	A	168	A
16	A	99	A	169	A
17	B	100	A	170	A
20	B	101	A	171	A
21	A	102	A	172	A
22	A	103	A	173	A
23	A	104	A	174	A
24	A	105	A	175	A
25	A	106	A	176	A
26	A	107	A	177	A
27	A	108	A	178	A
28	A	109	A	179	A
29	A	110	A	180	A
30	A	111	A	181	A
31	A	112	B	182	A
32	A	113	A	183	A
33	A	114	A	184	A
34	B	115	A	185	A
35	A	116	A	186	A
36	A	117	A	187	B
37	A	118	A	188	B
38	B	119	A	189	A

Ex	Biochemical IC ₅₀	Ex	Biochemical IC ₅₀	Ex	Biochemical IC ₅₀
39	A	120	A	190	A
40	A	121	A	191	A
41	B	122	A	192	A
42	A	123	A	193	A
53	A	124	A	194	A
54	A	125	A	195	A
55	A	126	A	196	A
56	A	127	A	197	A
57	A	128	A	198	A
58	A	129	A	199	A
59	B	130	A	200	A
60	A	131	A	201	A
61	A	132	A	202	A
62	A	133	A	203	A
63	A	134	A	204	A
64	A	135	A	205	A
65	A	136	A	206	A
66	A	137	A	207	A
67	A	138	A	208	A
68	A	139	A	209	A
69	A	140	A	210	A
70	B	141	A	211	A
71	C	142	A	212	A
72	A	143	A	213	A
73	A	144	A	214	A
74	A	145	A	215	A
75	A	146	A	216	A
76	A	147	A	217	A
77	A	148	A	218	A
78	A	149	A	219	A
79	A	150	A	220	B
80	B	151	A	221	A
81	C	152	A	222	A
82	A	153	A	224	A
83	A			227	A
				228	A

A: IC₅₀ ≤ 100 nM;

B: 100 nM < IC₅₀ ≤ 1 μM

C: 1 μM < IC₅₀


NT: Not Tested

[00455] The examples and embodiments described herein are for illustrative purposes only and in some embodiments, various modifications or changes are to be included within the purview of disclosure and scope of the appended claims.

CLAIMS

WHAT IS CLAIMED IS:

1. A compound of Formula (II), or a pharmaceutically acceptable salt, solvate, stereoisomer, or an isotopic variant thereof:



Formula (II);

wherein:



Ring A is ;

Q^1 is N and Q^2 is CW or Q^1 is N and Q^2 is N;

Q^3 and Q^4 are independently N or CW; provided that at least one of Q^3 or Q^4 is N;

each W is independently hydrogen, halogen, -CN, -OR^b, NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

A is -O-;

X is -S- or -O-;

R¹ and R² are independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a},

or R¹ and R² are taken together with the nitrogen atom to which they are attached to form a

heterocycloalkyl optionally substituted with one, two, or three R^{1b};

each R^{1a} and R^{1b} is independently oxo (when feasible) halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -

NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -

OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b,

C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl,

heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆

alkyl(heterocycloalkyl);

R³ is hydrogen, halogen, -CN, -OR^b, -SR^b, -NR^cR^d, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{3a} ;

each R^{3a} is independently oxo (when feasible) halogen, $-CN$, $-OR^b$, $-NR^cR^d$, $-C(=O)R^a$, $-C(=O)OR^b$, $-C(=O)NR^cR^d$, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^4 and R^7 are independently hydrogen, halogen, $-OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^5 and R^6 are independently hydrogen, halogen, $-OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^8 is hydrogen, halogen, $-OR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

R^9 and R^{10} are independently hydrogen, halogen, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

R^{11} is halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} ;

R^{12} is hydrogen, halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{12a} ;

or R^{11} and R^{12} are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b} ;

each R^{11a} , R^{11b} , and R^{12a} is independently oxo (when feasible), halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} ;

each R^{11c} is independently oxo (when feasible), halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_1 -

C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

each R¹³ is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a};

each R¹⁴ is independently C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{14a};

each R¹⁵ and R¹⁶ is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{15a};

or R¹⁵ and R¹⁶ are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b};

each R^{13a}, R^{14a}, R^{15a}, and R^{15b} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -CN, -OR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl;

R²¹ and R²² are independently hydrogen, C₁-C₂₀ alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a};

or R²¹ and R²² are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b};

each R^{21a} and R^{21b} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

each R^a is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

each R^b is independently hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl; and

each R^c and R^d is independently hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.

2. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
Q¹ is N; and
Q² is CW.
3. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
Q¹ is N; and
Q² is N.
4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
Q³ is N and Q⁴ is CW.
5. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
Q⁴ is N and Q³ is CW.
6. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
Q³ is N and Q⁴ is N.
7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
each W is independently hydrogen, halogen, or C₁-C₆ alkyl.
8. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:

each W is hydrogen.

9. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
 R^3 is halogen, $-OR^b$, C_1-C_6 alkyl, C_2-C_6 alkynyl, C_1-C_6 haloalkyl, C_1-C_6 hydroxyalkyl, or C_1-C_6 heteroalkyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{3a} .
10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
 R^3 is halogen, $-OR^b$, C_2-C_6 alkynyl, or C_1-C_6 hydroxyalkyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{3a} .
11. The compound of any one of claims 1-10, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
 R^3 is halogen.
12. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
 R^1 is C_1-C_6 alkyl, C_1-C_6 haloalkyl, cycloalkyl, heterocycloalkyl, C_1-C_6 alkyl(aryl), C_1-C_6 alkyl(heteroaryl), C_1-C_6 alkyl(cycloalkyl), or C_1-C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a} .
13. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
 R^1 is C_1-C_6 alkyl, cycloalkyl, C_1-C_6 alkyl(aryl), or C_1-C_6 alkyl(cycloalkyl); wherein each alkyl, cycloalkyl, and aryl is independently optionally substituted with one, two, or three R^{1a} .
14. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
 R^1 is cycloalkyl optionally substituted with one, two, or three R^{1a} .
15. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
each R^{1a} is independently oxo (when feasible) halogen, $-CN$, $-OR^b$, C_1-C_6 alkyl, or C_1-C_6 fluoroalkyl.
16. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
each R^{1a} is independently halogen or C_1-C_6 alkyl.
17. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
 R^2 is hydrogen or C_1-C_6 alkyl.
18. The compound of any one of claims 1-17, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:

R² is hydrogen.

19. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁸ is hydrogen or C₁-C₆ alkyl.
20. The compound of any one of claims 1-19, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁸ is hydrogen.
21. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁹ and R¹⁰ are independently hydrogen or C₁-C₆ alkyl.
22. The compound of any one of claims 1-21, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁹ and R¹⁰ are hydrogen.
23. The compound of any one of claims 1-22, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
A is -O-.
24. The compound of any one of claims 1-22, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
X is -O-.
25. The compound of any one of claims 1-24, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁵ and R⁶ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.
26. The compound of any one of claims 1-25, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁵ and R⁶ are hydrogen.
27. The compound of any one of claims 1-26, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁴ and R⁷ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.
28. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁴ and R⁷ are independently hydrogen, halogen, or -OH.
29. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁴ and R⁷ are independently halogen or -OH.
30. The compound of any one of claims 1-29, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁴ and R⁷ are independently hydrogen or -OH.

31. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁴ and R⁷ are -OH.
32. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R²¹ and R²² are hydrogen.
33. The compound of any one of claims 1-32, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R¹² is hydrogen, halogen, -OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkynyl, or C₁-C₆ heteroalkyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{12a}.
34. The compound of any one of claims 1-33, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R¹² is hydrogen, C₁-C₆ alkyl, C₁-C₆ hydroxyalkyl, or C₂-C₆ alkynyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{12a}.
35. The compound of any one of claims 1-34, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R¹² is hydrogen.
36. The compound of any one of claims 1-35, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R¹¹ is halogen, -CN, -OR¹³, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a}.
37. The compound of any one of claims 1-36, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R¹¹ is -CN, -S(=O)₂R¹⁴, -C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkynyl, or heteroaryl; wherein each alkyl, alkynyl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a}.
38. The compound of any one of claims 1-37, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R¹¹ is -CN, -S(=O)₂R¹⁴, -C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, or heteroaryl; wherein each alkyl and heteroaryl is independently optionally substituted with one, two, or three R^{11a}.
39. The compound of any one of claims 1-38, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R¹¹ is C₁-C₆ alkyl optionally substituted with one, two, or three R^{11a}.

40. The compound of any one of claims 1-39, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
 R^{11} is C_1 - C_6 alkyl substituted with one R^{11a} .
41. The compound of any one of claims 1-40, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
each R^{11a} is oxo (when feasible), halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} .
42. The compound of any one of claims 1-41, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
each R^{11a} is independently oxo (when feasible), halogen, $-OR^{13}$, $-SR^{13}$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)OR^{13}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, heterocycloalkyl, aryl, or heteroaryl; wherein each heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} .
43. The compound of any one of claims 1-42, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
each R^{11a} is independently $-OR^{13}$.
44. The compound of any one of claims 1-43, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
 R^{11} and R^{12} are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b} .
45. The compound of any one of claims 1-44, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
each R^{13} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a} .
46. The compound of any one of claims 1-45, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
each R^{13} is independently C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, or cycloalkyl; wherein each alkyl and cycloalkyl is independently optionally substituted with one, two, or three R^{13a} .
47. The compound of any one of claims 1-45, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
each R^{13} is independently C_1 - C_6 alkyl.
48. The compound of any one of claims 1-47, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:

each R^{14} is independently C_1 - C_6 alkyl.


49. The compound of any one of claims 1-48, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:

each R^{15} and R^{16} is independently hydrogen or C_1 - C_6 alkyl.

50. The compound of any one of claims 1-49, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:

R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl.

51. A compound of Formula (IV), or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof:



Formula (IV);

wherein:



Ring A is ;

Q^2 is N or CW;

Q^3 is N and Q^4 is CW;

or Q^3 is CW and Q^4 is N;

each W is independently hydrogen, halogen, -CN, -OR^b, NR^cR^d, C_1 - C_6 alkyl, or C_1 - C_6 haloalkyl;

A is -O- or -CH₂-;

X is -O-, -S-, -S(=O)₂-, -NR¹⁷-, or -C(R¹⁸)₂-;

R^1 and R^2 are independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a} ,

or R^1 and R^2 are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{1b} ;

each R^{1a} and R^{1b} is independently oxo (when feasible) halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b,

C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

R³ is hydrogen, halogen, -CN, -OR^b, -SR^b, -NR^cR^d, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{3a};

each R^{3a} is independently oxo (when feasible) halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁴ and R⁷ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁵ and R⁶ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁸ is hydrogen, halogen, -OR^b, -NR^cR^d, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

R⁹ and R¹⁰ are independently hydrogen, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

R¹¹ is hydrogen, halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -OC(=O)NR¹⁵R¹⁶, -NR¹³C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, -NR¹³C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a};

R¹² is hydrogen, halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -OC(=O)NR¹⁵R¹⁶, -NR¹³C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, -NR¹³C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{12a};

or R¹¹ and R¹² are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b};

each R^{11a}, R^{11b}, and R^{12a} is independently oxo (when feasible), halogen, -CN, -OR¹³, -SR¹³, -S(=O)R¹⁴, -NO₂, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -NR¹³S(=O)₂R¹⁴, -S(=O)₂NR¹⁵R¹⁶, -C(=O)R¹⁴, -OC(=O)R¹⁴, -C(=O)OR¹³, -OC(=O)OR¹³, -C(=O)NR¹⁵R¹⁶, -OC(=O)NR¹⁵R¹⁶, -NR¹³C(=O)NR¹⁵R¹⁶, -NR¹³C(=O)R¹⁴, -NR¹³C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆

hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c};

each R^{11c} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

each R¹³ is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a};

each R¹⁴ is independently C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{14a};

each R¹⁵ and R¹⁶ is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{15a};

or R¹⁵ and R¹⁶ are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b};

each R^{13a}, R^{14a}, R^{15a}, and R^{15b} is independently oxo (when feasible), halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NHS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, -CN, -OR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl;

R¹⁷ is hydrogen, -CN, -OR^b, -S(=O)₂R^a, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

each R¹⁸ is independently hydrogen, halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NHS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -

$\text{OC(=O)NR}^c\text{R}^d$, $-\text{NR}^b\text{C(=O)NR}^c\text{R}^d$, $-\text{NR}^b\text{C(=O)R}^a$, $-\text{NR}^b\text{C(=O)OR}^b$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ haloalkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, $\text{C}_1\text{-C}_6$ alkyl(aryl), $\text{C}_1\text{-C}_6$ alkyl(heteroaryl), $\text{C}_1\text{-C}_6$ alkyl(cycloalkyl), or $\text{C}_1\text{-C}_6$ alkyl(heterocycloalkyl);

R^{21} and R^{22} are independently hydrogen, $\text{C}_1\text{-C}_{20}$ alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, $\text{C}_1\text{-C}_6$ alkyl(aryl), $\text{C}_1\text{-C}_6$ alkyl(heteroaryl), $\text{C}_1\text{-C}_6$ alkyl(cycloalkyl), $\text{C}_1\text{-C}_6$ alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a} ,

or R^{21} and R^{22} are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b} ;

each R^{21a} and R^{21b} is independently oxo (when feasible), halogen, $-\text{CN}$, $-\text{OR}^b$, $-\text{SR}^b$, $-\text{S(=O)R}^a$, $-\text{NO}_2$, $-\text{NR}^c\text{R}^d$, $-\text{S(=O)}_2\text{R}^a$, $-\text{NHS(=O)}_2\text{R}^a$, $-\text{S(=O)}_2\text{NR}^c\text{R}^d$, $-\text{C(=O)R}^a$, $-\text{OC(=O)R}^a$, $-\text{C(=O)OR}^b$, $-\text{OC(=O)OR}^b$, $-\text{C(=O)NR}^c\text{R}^d$, $-\text{OC(=O)NR}^c\text{R}^d$, $-\text{NR}^b\text{C(=O)NR}^c\text{R}^d$, $-\text{NR}^b\text{C(=O)R}^a$, $-\text{NR}^b\text{C(=O)OR}^b$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, $\text{C}_1\text{-C}_6$ alkyl(aryl), $\text{C}_1\text{-C}_6$ alkyl(heteroaryl), $\text{C}_1\text{-C}_6$ alkyl(cycloalkyl), or $\text{C}_1\text{-C}_6$ alkyl(heterocycloalkyl);

each R^a is independently $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-\text{OH}$, $\text{C}_1\text{-C}_6$ alkyl, or $\text{C}_1\text{-C}_6$ haloalkyl;

each R^b is independently hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-\text{OH}$, $\text{C}_1\text{-C}_6$ alkyl, or $\text{C}_1\text{-C}_6$ haloalkyl; and

each R^c and R^d is independently hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $\text{C}_1\text{-C}_6$ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo (when feasible), halogen, $-\text{OH}$, $\text{C}_1\text{-C}_6$ alkyl, or $\text{C}_1\text{-C}_6$ haloalkyl;

or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, $\text{C}_1\text{-C}_6$ alkyl, or $\text{C}_1\text{-C}_6$ haloalkyl.

52. The compound of claim 51, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
 Q^2 is CW.
53. The compound of claim 51, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
 Q^2 is N.
54. The compound of any one of claims 51-53, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:

Q^3 is N and Q^4 is CW.

55. The compound of any one of claims 51-54, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:

Q^4 is N and Q^3 is CW.

56. The compound of any one of claims 51-55, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:

each W is independently hydrogen, halogen, or C_1 - C_6 alkyl.

57. The compound of any one of claims 51-56, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:

each W is hydrogen.

58. The compound of any one of claims 51-57, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:

R^3 is halogen, $-OR^b$, C_1 - C_6 alkyl, C_2 - C_6 alkynyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, or C_1 - C_6 heteroalkyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{3a} .

59. The compound of any one of claims 51-58, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:

R^3 is halogen, $-OR^b$, C_2 - C_6 alkynyl, or C_1 - C_6 hydroxyalkyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{3a} .

60. The compound of any one of claims 51-59, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:

R^3 is halogen.

61. The compound of any one of claims 51-60, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:

R^1 is C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, cycloalkyl, heterocycloalkyl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a} .

62. The compound of any one of claims 51-61, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:

R^1 is C_1 - C_6 alkyl, cycloalkyl, C_1 - C_6 alkyl(aryl), or C_1 - C_6 alkyl(cycloalkyl); wherein each alkyl, cycloalkyl, and aryl is independently optionally substituted with one, two, or three R^{1a} .

63. The compound of any one of claims 51-62, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:

R^1 is cycloalkyl optionally substituted with one, two, or three R^{1a} .

64. The compound of any one of claims 51-63, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:

- each R^{1a} is independently oxo (when feasible) halogen, -CN, -OR^b, C₁-C₆ alkyl, or C₁-C₆ fluoroalkyl.
65. The compound of any one of claims 51-64, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
each R^{1a} is independently halogen or C₁-C₆ alkyl.
66. The compound of any one of claims 51-65, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R² is hydrogen or C₁-C₆ alkyl.
67. The compound of any one of claims 51-66, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R² is hydrogen.
68. The compound of any one of claims 51-67, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁸ is hydrogen or C₁-C₆ alkyl.
69. The compound of any one of claims 51-68, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁸ is hydrogen.
70. The compound of any one of claims 51-69, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁹ and R¹⁰ are independently hydrogen or C₁-C₆ alkyl.
71. The compound of any one of claims 51-70, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁹ and R¹⁰ are hydrogen.
72. The compound of any one of claims 51-71, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
A is -O-.
73. The compound of any one of claims 51-72, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
A is -CH₂-.
74. The compound of any one of claims 51-73, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁵ and R⁶ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.
75. The compound of any one of claims 51-74, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁵ and R⁶ are hydrogen.
76. The compound of any one of claims 51-75, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁴ and R⁷ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.

77. The compound of any one of claims 51-76, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁴ and R⁷ are independently hydrogen, halogen, or -OH.
78. The compound of any one of claims 51-77, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁴ and R⁷ are independently halogen or -OH.
79. The compound of any one of claims 51-78, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁴ and R⁷ are independently hydrogen or -OH.
80. The compound of any one of claims 51-79, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁴ and R⁷ are -OH.
81. The compound of any one of claims 51-80, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R²¹ and R²² are hydrogen.
82. The compound of any one of claims 51-81, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R¹² is hydrogen, halogen, -OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkynyl, or C₁-C₆ heteroalkyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{12a}.
83. The compound of any one of claims 51-82, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R¹² is hydrogen, C₁-C₆ alkyl, C₁-C₆ hydroxyalkyl, or C₂-C₆ alkynyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{12a}.
84. The compound of any one of claims 51-83, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R¹² is hydrogen.
85. The compound of any one of claims 51-84, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R¹¹ is halogen, -CN, -OR¹³, -NR¹⁵R¹⁶, -S(=O)₂R¹⁴, -C(=O)OR¹³, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a}.
86. The compound of any one of claims 51-85, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:

- R^{11} is -CN, -S(=O) $_2R^{14}$, -C(=O)OR ^{13} , C $_1$ -C $_6$ alkyl, C $_1$ -C $_6$ haloalkyl, C $_1$ -C $_6$ hydroxyalkyl, C $_2$ -C $_6$ alkynyl, or heteroaryl; wherein each alkyl, alkynyl, and heteroaryl is independently optionally substituted with one, two, or three R^{11a} .
87. The compound of any one of claims 51-86, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
 R^{11} is C $_1$ -C $_6$ alkyl optionally substituted with one, two, or three R^{11a} .
88. The compound of any one of claims 51-87, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
 R^{11} is C $_1$ -C $_6$ alkyl substituted with one R^{11a} .
89. The compound of any one of claims 51-88, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
each R^{11a} is oxo (when feasible), halogen, -CN, -OR ^{13} , -SR ^{13} , -S(=O)R ^{14} , -NR $^{15}R^{16}$, -S(=O) $_2R^{14}$, -NR $^{13}S(=O)_2R^{14}$, -S(=O) $_2NR^{15}R^{16}$, -C(=O)R ^{14} , -C(=O)OR ^{13} , -C(=O)NR $^{15}R^{16}$, -OC(=O)NR $^{15}R^{16}$, -NR $^{13}C(=O)R^{14}$, C $_1$ -C $_6$ alkyl, C $_1$ -C $_6$ haloalkyl, C $_1$ -C $_6$ hydroxyalkyl, C $_1$ -C $_6$ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} .
90. The compound of any one of claims 51-89, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
each R^{11a} is independently oxo (when feasible), halogen, -OR ^{13} , -SR ^{13} , -NR $^{15}R^{16}$, -S(=O) $_2R^{14}$, -NR $^{13}S(=O)_2R^{14}$, -S(=O) $_2NR^{15}R^{16}$, -C(=O)OR ^{13} , -OC(=O)NR $^{15}R^{16}$, -NR $^{13}C(=O)R^{14}$, heterocycloalkyl, aryl, or heteroaryl; wherein each heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{11c} .
91. The compound of any one of claims 51-90, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
each R^{11a} is independently -OR ^{13} .
92. The compound of any one of claims 51-91, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
 R^{11} and R^{12} are taken together to form a cycloalkyl or heterocycloalkyl each optionally substituted with one, two, or three R^{11b} .
93. The compound of any one of claims 51-92, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
each R^{13} is independently hydrogen, C $_1$ -C $_6$ alkyl, C $_1$ -C $_6$ haloalkyl, C $_1$ -C $_6$ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a} .
94. The compound of any one of claims 51-93, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:

each R¹³ is independently C₁-C₆ alkyl, C₁-C₆ haloalkyl, or cycloalkyl; wherein each alkyl and cycloalkyl is independently optionally substituted with one, two, or three R^{13a}.

95. The compound of any one of claims 51-94, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:

each R¹³ is independently C₁-C₆ alkyl.

96. The compound of any one of claims 51-95, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:

each R¹⁴ is independently C₁-C₆ alkyl.


97. The compound of any one of claims 51-96, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:


each R¹⁵ and R¹⁶ is independently hydrogen or C₁-C₆ alkyl.

98. The compound of any one of claims 51-97, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:


R¹⁵ and R¹⁶ are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl.


99. A compound selected from the group consisting of:





























100. A pharmaceutical composition comprising a compound of any one of claims 1-99, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and a pharmaceutically acceptable excipient.
101. A method of inhibiting CD73 comprising contacting CD73 with a compound of any one of claims 1-99, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
102. A method of treating cancer in a subject, comprising administering to the subject a compound of any one of claims 1-99, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
103. A method of treating cancer in a subject, comprising administering to the subject a pharmaceutical composition of claim 100.
104. The method of either of claims 102 or 103, wherein the cancer is lung cancer, melanoma, breast cancer, ovarian cancer, colorectal cancer, gastric cancer, gallbladder cancer, prostate cancer, renal cancer, or a lymphoma.

105. The method of any one of claims 102-104, further comprising administering a second therapeutic agent.
106. The method of claim 105, wherein the second therapeutic agent is a chemotherapeutic agent or an immunotherapy agent.
107. A method of treating an infection in a subject, comprising administering to the subject a compound of any one of claims 1-99, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
108. A method of treating an infection in a subject, comprising administering to the subject a pharmaceutical composition of claim 100.
109. The method of either of claims 107 or 108, wherein the infection is a viral infection.
110. The method of either of claims 107 or 108, wherein the infection is a parasitic infection.
111. A method of treating a neurodegenerative disease in a subject, comprising administering to the subject a compound of any one of claims 1-99, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
112. A method of treating a neurodegenerative disease in a subject, comprising administering to the subject a pharmaceutical composition of claim 100.
113. The method of either of claims 111 or 112, wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, or autism.